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THE GROWING PROBLEM OF BACTERIAL RESISTANCE TO ANTIBIOTICS 
 
Bacterial multi-drug resistance (MDR) is defined as acquisition of non-
susceptibility to at least one agent in three categories of antibacterials by pathogenic 
bacteria 
1
. MDR is a growing problem worldwide 
2
. The World Health Organisation 
(WHO) has identified antibacterial resistance and the antibiotics crisis as ´´bigger than 
AIDS´´ The so-called “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, 
Enterobacter spp.) are the main cause of hospital infections and are resistant to 
virtually all the currently marketed antibiotics
3, 4
.
.
Infections due to resistant bacteria 
have 1.3 – 2 fold higher associated healthcare costs than susceptible bacteria due to 
increased mortality, morbidity and treatment costs 
5
. The aging population and 
growing number of immunocompromised patients due to HIV, cancer therapy or 
transplantation are making the need for novel antibacterials even more acute.  
 
CLASSICAL AND POST-GENOMIC ANTIBACTERIAL DRUG DISCOVERY 
 
All currently used antibiotic classes have been discovered by screening natural 
products  from various sources or synthetic compounds for antibacterial activities 
against a spectrum of different bacteria 
6, 2, 7
. Over the past decade the large number of 
available sequenced genomes from multiple strains of pathogenic bacterial stimulated 
a change in the screening approaches for antibacterials 
8
. Rather than screening for 
whole-cell antibacterial activity, efforts shifted to screening for inhibitors of rationally 
preselected targets, otherwise known as target-based drug discovery 
6
.  
 
CLASSICAL PHENOTYPIC SCREENING 
Phenotypic screening for inhibition of bacterial growth with libraries of chemical 
compounds, including natural products from soil or marine ecosystems, fungi or 
plants, and bacterial secondary metabolites, has to date been the most successful way 
of discovering novel antibacterials 
9
. Typically, inhibition of bacterial growth in the 
pre-clinical screening stage is followed up by isolation and purification of the active 
compound and evaluation of its toxicity. Promising hits are then optimized by 
synthesizing a series of similar compounds to investigate their structure-activity 
relationship and identify a lead compound. Ultimately, the mode of action of the lead 
and its antibacterial spectrum are determined. Nearly all antibacterials on the market 
are based on antibiotics produced by Streptomyces and their chemically modified 
derivatives 
10, 11
. However, since the 1950s the number of novel classes of antibiotics 
discovered by phenotypic screenings has dwindled and novel strategies have been 
investigated to overcome the raising problem of bacterial multi-drug resistance and the 
lack of novel antibacterials
12
. 
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TARGET-BASED ANTIBACTERIALS DRUG DISCOVERY  
In the genomic era, more potential antibacterial targets were identified and 
rational target-based antibacterial drug design gained popularity as an approach 
13
. 
This approach is based on the assumption that some targets, proteins or whole 
biological pathways, are essential or conditionally essential for bacterial survival. 
Therefore, blocking them will lead to bacterial death 
14
. In target-based drug 
discovery, selected targets are purified and used in in vitro screenings of compound 
libraries for inhibitors of the target activity. Typically, screenings are performed in a 
high-throughput manner (i.e. high-throughput screening, HTS) and libraries of 
hundreds of thousands of compounds are screened. 
Recent advances in computational biology and chemistry made it became possible 
to screen compound libraries for putative target ligands in silico commonly referred to 
as virtual screening 
15, 16, 17
. This reduced the number of hits that have to be evaluated 
in vitro for the desired biochemical activity. Target-based screening in silico (or 
structure-based virtual screening) utilizes a three-dimensional structure of the target 
protein obtained experimentally by X-ray crystallography or NMR or a homology 
model based on the structure of homologous proteins. Then, large virtual libraries of 
chemical compounds are screened in silico to identify ligands predicted to bind to the 
target site on the protein. The most promising hits with biochemical activity against 
the target are optimized by iterative rounds of structure-based drug design 
18, 19
. 
Another approach combining the principles behind high-throughput in vitro 
screening and structure-based drug design is fragment-based drug discovery (FBDD). 
In FBDD a library of few thousands fragment-like compounds 
20, 21, 22
 is screened for 
ligands of a selected drug target in vitro. Ideally, hits are confirmed by elucidating the 
target-fragment structure by X-ray crystallography or NMR. The obtained structural 
information is used to guide structure-based design of more complex inhibitors with 
enhanced selectivity and potency by chemically linking fragment hits binding to 
different regions of the target site.  
 
TWO-COMPONENT SYSTEMS AS ANTIBACTERIAL DRUG TARGETS 
 
Signaling by two-component systems (TCS) is one of the promising 
antibacterial targets to be proposed since the genomics revolution (Figure 1) 23, 24, 
25. 
TCS are the primary regulators used by bacteria to respond and adapt to a large 
variety of environmental and intracellular signals 
26
. Prototypical TCS consist of two 
proteins, a sensor histidine kinase (HK) and an effector response regulator (RR) 
(Figure 1, 2, and 3).  
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Figure 1. Two-component systems signalling and inhibition. A prototypical two-
component system (TCSs) consists of a membrane-bound histidine kinase (HK) and a 
cognate response regulator (RR). HKs sense environmental stimuli via an extracellular 
sensor domain (pink) and this triggers HK autophosphorylation at conserved His residues 
in the dimerization and phosphotransfer (DHp) domain (orange). ATP accommodated in 
the ATP-binding and catalytic (CA) domain (blue) serves as a phosphodonor. Phosphoryl 
group is transferred from the bound ATP in the CA domain to the His residue of the DHp 
domain (autophosphorylation) and then from the DHp domain to Asp residue of the RR 
(phosphotransfer). RR phosphorylation induces changes of the expression of target genes. 
RR phosphorylation levels are regulated via dephosphorylation mediated by the 
phosphatase RR intrinsic or HK-induced phosphatase activity or by ancillary proteins. TCS 
inhibition can be targeted at different steps of the TCS signalling (indicated A to G) and the 
most promising and exploited so far is autophosphorylation inhibition. 
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Figure 2. Promising TCS 
antibacterial drug targets A) 
WalKR is highly conserved 
among Gram-positive 
bacteria, conditionally 
essential for bacterial growth 
and involved in the 
regulation of variety of 
processes including virulence 
32. B) QseCB is present in a 
number of Gram-negative 
bacteria and is involved in 
the response to host-
adrenergic signals and AI-2 
mediated quorum sensing. 
QseC inhibitors were shown 
to inhibit virulence of 
susceptible Gram-negatives 
in vitro and in vivo 33 C) 
PhoPQ is involved in 
response to changes in Mg2+ 
levels and in the regulation 
of virulence. PhoPQ 
inhibitors with antibacterial 
and antivirulence effect have 
been discovered following 
structure-based screenings 
for PhoQ or PhoP inhibitors 
44, 51. D) PhoRB is involved 
in responses to inorganic 
phosphate and is implicated to the regulation of virulence and pathogenesis of Gram-negative 
bacteria 76, 86. 
 
The sensor HK is membrane-bound and signal recognition alters the 
phosphorylation state of a cognate response regulator (RR). HK sensing of specific 
signals occurs via a variable domain, which is commonly exposed to the extracellular 
milieu, whereas the remaining protein domains are generally conserved, cytoplasmic 
and required for signal transduction. RRs are usually transcription factors of which the 
DNA-binding capacity and consequently, gene transcription is determined by their 
phosphorylation state. TCS may directly or indirectly control numerous genes, 
including those involved in the regulation of metabolism, cell physiology, virulence 
and res istance to antibiotics or antimicrobial peptides 
27, 28, 29, 30
. TCS represent an 
attractive target for novel antibacterial agents as they are pervasive in microorganisms 
but absent in mammals. Furthermore, some TCS are essential or conditionally 
essential for viability in several important bacterial pathogens 
27, 31, 32
. Many TCS play
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Figure 3. Structural information on TCS has facilitated the discovery of TCS inhibitors 
using structure-based discovery and rational structure-based design. A) Structure of S. 
mutans WalK (PDB:4I5S). S. mutans WalK is a long-rod dimer anchoring a HAMP signal-
transducer domain (light green) and a PAS sensor domain (dark green) directly connected 
to the catalytic DHp (orange) and CA (blue) domains. High-resolution structures of full-
length HKs will shed light on how the different domains interact with each other and how 
this can be used for inhibitor design B) Structure of the CA domain of B. subtilis WalK 
(PDB:3SL2). CA is the most exploited domain in structure-based TCS inhibitors discovery 
so far because of its well defined and generally conserved ATP-binding site (shown as 
yellow surface) C) Structure of the T. maritima HK853-RR468 (PDB:3DGE) reveals the 
interaction between the catalytic DHp (orange) and CA (blue) domains of the HK with the 
response receiver (REC) domain of the cognate RR (magenta). TCS catalytic domains, 
especially the CA domain, are highly conserved and suitable for the development of broad-
spectrum inhibitors. Narrow –spectrum inhibitors can be designed/ discovered by 
targeting the interaction of a HK and its cognate RR. For this high-resolution structures of 
TCS complexes are needed Putative ligand binding sites were calculated with PyMol and 
are shown as yellow surface (detection radius and detection cut-off is 5 solvent radii). 
Ligands are shown as sticks. 
 
role in bacterial adaption to environmental stresses and the regulation of virulence 
factor production. Thus drugs inhibiting TCS function are expected to attenuate 
pathogen virulence and/ or compromise pathogen growth under a range 
ofphysiological stresses 
23, 33, 34
. Moreover, HKs and RRs possess a high degree of 
homology in their active sites, suggesting that it might be possible to identify 
inhibitors targeting multiple TCS 
35, 36
. Developing resistance to a drug with multiple 
targets is expected to be slower than to a drug with a single target 
19
.  
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TWO-COMPONENT SYSTEM SIGNALLING  
Upon sensing of a ligand or physiological stimulus TCS signal transduction is 
initiated by autophosphorylation of a conserved histidine (His) residue in the 
dimerization and phosphotransfer (DHp) domain 
37
. Autophosphorylation involves the 
helical DHp domain hosting the conserved His and the C-terminal catalytic and ATP-
binding (CA) domain that binds ATP and phosphorylates the His (Figure 1 and 3). The 
phosphoryl group from the phosphorylated His in the DHp domain is then transferred 
to an exposed Asp that belongs to the response receiver (REC) domain of the cognate 
RR. Phosphotransfer, i.e. phosphorylation of the RR, triggers changes in the 
conformation of the RR, modulating the affinity of the effector domain for its targets, 
typically DNA binding motifs in specific gene promoters 
38, 26
. In some cases the RR 
lacks the effector domain and the REC domain takes over the effector role. The 
phosphorylation levels of the RR are tightly regulated by the phosphatase activity of 
the HK; the RR itself or a partner protein 
26, 39, 40, 41
. The DHp, CA, and REC domains 
are always present in all TCS and relatively well conserved in amino-acid sequence 
(Figure 4), compared to the sensor domains of HKs (the periplasmic domain, HAMP, 
PAS and GAF domains) or the effector domains of RRs. The presence or absence and 
the variability of the sensor and effector domains is determined by the wide range of 
specific signals or targets to be recognized by the different TCS 
38, 26
. Therefore, 
inhibitors of the catalytic activity of the highly conserved DHp, CA and REC domain 
are expected to possess broad-spectrum antibacterial activity. 
 
DISCOVERY OF TWO-COMPONENT SYSTEM INHIBITORS  
There are several publications describing the discovery of TCS inhibitors which 
have been reviewed elsewhere 
34, 36, 42
 and some aspects are discussed in more detail in 
the following sections. The target TCS include among others, S. pneumoniae and S. 
epidermidis WalKR 
43, 43
, E. coli QseCB 
43
, S. flexnerii and S. eneterica PhoQP 
44, 45, 45
. 
The identified TCS inhibitors were from libraries of natural products 
46
, small 
molecules 
34
 and antibacterial peptides 
47
 (Figure 5). Different approaches have been 
employed to discover TCS inhibitors, including high-throughput target-based 
screening 
48, 33, 49
 and virtual structure-based screening 
43, 50, 51, 44, 35
.  
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Figure 4. Conservation of the different domains of TCS A) S. mutans WalK (PDB:4I5S) the 
catalytic domains (DHp and CA) are relatively more conserved than the sensor domains 
(HAMP and PAS). Furthermore DHp and CA domains are always present in all HK, whereas 
the sensor domains vary. B) REC domain of B. subitilis WalR is relatively more conserved 
than C) the DNA-binding effector domain of B. subtilis WalR. The variability of the HK 
sensor domains and the RR effector domains are determined by the variety of input signals 
and adaptation responses TCS are involved in. Targeting the relatively more conserved 
DHp, CA and REC domain might facilitate the development of broad-spectrum 
antibacterials with low potential of resistance development. 
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Figure 4 Published two-component systems inhibitors can be used as starting point for 
the design of more potent inhibitors following structure-based drug design approaches A) 
Led209 inhibits the binding of adrenergic signals to the periplasmic domain of E. coli QseC, 
preventing its autophosphorylation and consequently inhibiting QseC-mediated activation 
of virulence gene expression 33. B) Compound 5 was identified in a structure-based 
screening for ligands of the CA domain of S. epidermidis WalK 43. Compound 5 inhibited S. 
epidermidis WalK autophosphorylation with IC50 = 14 µM and showed antibacterial effect 
against Gram-positive bacteria with minimal inhibitory concentrations (MICs) in the range 
of 2 – 6 µM. C) NSC48630 inhibited the formation of S. enterica PhoP-DNA complex with 
IC50 = 3.6 µM. NSC4836 was identified as putative PhoP ligand in a structure-based 
screening for ligands of the activated response regulator PhoP (PDB: 2PL1) 51. Compound 
5 and NSC48630 and other TCS inhibitors identified by structure-based virtual screenings 
indicate the potential of structure-based approaches to discover promising TCS inhibitors 
with antibacterial and therapeutic effect 43, 50, 44, 51, 35.  
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PROMISING TWO-COMPONENT SYSTEM TARGETS 
WalKR 
WalKR (aka YycF/G, MicA/B, VicK/R) is highly conserved and has been 
identified in the genomes of the major group of Gram-positive bacteria with a low 
genomic GC-content (Figure 2A) 
52, 53, 54, 55, 32, 30
. This includes pathogenic species 
belonging to the genus Staphylococcus, Streptococcus, Enterococcus, Clostridium, and 
Listeria. In the important pathogens S. aureus, S. pneumoniae, and Enterococcus 
faecalis WalKR has been shown to be essential for viability in rich laboratory growth 
medium 
52, 30, 56
. WalKR regulates genes responsible for cell wall metabolism and cell 
wall homeostasis 
55, 57, 53
 but the specific genes and pathways regulated by WalKR may 
differ from species to species. Additionally, walKR regulates genes involved in 
metabolism, stress response, virulence, host-microbe interactions, transport and 
regulatory pathways depending on the species 
27, 58
.  
Of all the TCS WalKR is considered one of the most attractive targets for 
antibacterial drugs due to its essentiality, links to virulence and antibiotic resistance. 
Imidazole and zerumbone derivatives were the first inhibitors of WalK to be identified 
59, 46
. Following this pioneering discovery, Utsumi´s group developed biochemical and 
genetic high-throughput screening methods to search for WalK and WalR inhibitors. 
This led to the discovery of WalK inhibitors such as aranorosinol, walkmycin B, 
waldiomycin, signermycin B and the WalR inhibitors, walrycin A and B 
48, 49
.
 
Later, 
some of these inhibitors were not proven to be selective to WalKR and other 
mechanisms such as membrane damage and adverse effects on macromolecules 
biosynthesis most likely account for the observed antibacterial effects.  
Elucidation of the structure of HK catalytic domains opened up the possibility for 
structure-based virtual screening (SBVS) for WalK inhibitors 
60, 61, 43, 43
. The catalytic 
ATP-binding domain (CA domain) appeared to be the most promising target for this 
approach as this domain contains a well-defined and partially conserved pocket where 
ATP is accommodated (Figure 3B). Before the elucidation of WalK structure (PDB: 
3SL2 and PDB:4I5S), homology models of the CA domains of S. pneumoniae and S. 
epidermidis WalK based on the three-dimensional structures of Thermotoga maritima 
HK853 (PDB: 2C2A) and E. coli EnvZ (PDB: 1BXD) HKs were used for SBVS of 
drug-lead compound libraries. These screenings yielded WalK autophosphorylation 
inhibitors belonging to different classes of chemical structures, such as imidazole 
analogues and derivatives of furan, thiophene, thiazolidinone, benzamide and 
pyrimidinone (Figure 4).
 
The SBVS hits inhibited the growth of S. pneumoniae and S. 
epidermidis and showed bactericidal effects towards both planktonic and biofilm cells 
62, 63
. Furthermore, some of these inhibitors decreased the mortality of mice infected 
with S. pneumoniae in an in vivo sepsis model, demonstrating that SBVS is a valuable 
tool for the identification of WalK inhibitors with therapeutic effect 
43
. Nevertheless, 
Chapter 1 
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the design of potent ATP-competitive inhibitors specific for WalK is challenging, even 
more so when structural homology models are used instead of experimental (e.g. X-
ray) data. This issue is crucial when attempting to generate a WalK inhibitor with 
higher specificity and affinity in the hit-to-lead optimization phase. Although the 
overall fold of the CA domain as well as the catalytic residues is generally conserved, 
there are large variations in size and sequence in the ATP-lid, a HK distinctive flexible 
loop that covers the ATP-binding pocket and is crucially involved in ATP binding and 
in HK catalytic reactions 
26, 64, 65
. The recently published WalK structures of the entire 
intracellular portion from Streptococcus mutans (PDB: 4I5S) (Figure 3A) and the CA 
domain from Bacillus subtilis (PDB: 3SL2, Figure 3B) might provide the key to 
design of improved WalK inhibitors 
66, 67
. These structures have not only revealed 
specific characteristics of the WalK CA domain but also insights into the molecular 
mechanism of WalK autokinase activation and clues how it can be effectively 
inhibited by exploring HK domains for structure-based drug design 
25
. 
 
QseCB 
Targeting microbial virulence without inhibiting growth has been proposed as 
promising strategy in antibacterial drug discovery as it was proposed that antivirulence 
drugs present less selective pressure for resistance development 
33, 24, 51
. QseCB is a 
TCS involved in recognizing the host-derived adrenergic signals and the bacterial 
aromatic signal autoinducer-3 AI-3 (epinephrine, norepinephrine) to trigger expression 
of virulence genes (Figure 2B) 
68
. Homologues of QseC are present in at least 25 
important human and plant pathogens, therefore, a QseC inhibitor is expected to be a 
promising drug for antivirulence therapy against a wide range of pathogenic bacteria 
33
. 
Adrenergic signals, as well as, AI-3 are recognized by QseC periplasmic domain 
68
. Drugs targeting QseC periplasmic domain have an advantage compared to drugs 
with intracellular targets of Gram-negative bacteria as they only need to pass the outer 
membrane to reach the target.  
High-throughput screening to search for a compound that inhibits the activation of 
QseC by AI-3 has been reported 
33
. LED209 (Figure 4) was identified as inhibitor of 
the binding of the signaling molecules to QseC from different Gram-negative 
pathogenic bacteria. LED209 inhibited QseC autophosphorylation, bacterial 
pathogenicity in vitro and in vivo, but did not inhibit cell growth. The discovery of 
LED209 demonstrates that targeting microbial virulence without inhibiting growth is a 
promising strategy to identify antibacterials with therapeutic effect 
33
.  
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PhoPQ 
The PhoQ/PhoP two-component regulatory system is a major regulator of 
virulence in the enteric pathogen Salmonella enterica serovar Typhimurium 
69, 70
 and is 
present in a range of Gram-negative bacteria. It also controls the adaptation to low 
Mg
2+
 environments by governing the expression and/or activity of Mg
2+
 transporters 
and of enzymes modifying the Mg
2+
-binding sites on the bacterial cell surface (Figure 
2C). The RR PhoP modifies expression of about 3% of the Salmonella genes in 
response to the periplasmic Mg
2+
 concentration detected by the HK PhoQ 
71
. Genes 
that are directly controlled by PhoP often differ in their promoter structures, resulting 
in distinct expression levels and kinetics in response to the low Mg
2+
 inducing signal. 
PhoP regulates a large number of genes indirectly via other transcription factors and 
TCS that form a panoply of regulatory networks. These regulatory networks include 
transcriptional cascades, feed-forward loops and the use of connector proteins to 
modify the activity of RRs 
72
. These networks confer distinct expression properties 
that may be important contributors to the lifestyle of Salmonella. 
The structure of the catalytic domain of PhoQ has been well studied 
73
. PhoQ has 
also been co-crystallized with the inhibitor radicicol 
45
. The available structural 
information has been exploited in structure-based screening for PhoQ inhibitors that 
attenuate the virulence of S. flexneri in vitro and in vivo 
44
. PhoP inhibitors have also 
been discovered via structure-based screenings and shown to inhibit PhoP-DNA 
complex formation (Figure 4) 
51
. Taken together these findings highlight good 
potential to develop novel antibacterials against PhoPQ using structure-based 
screening and design. 
 
PhoRB 
PhoRB is a two-component system sensing the extracellular concentration of 
phosphate (Figure 2D) 
74
. It consists of the HK PhoR and its cognate RR PhoB. 
PhoRB responds to phosphate limitation, when the extracellular concentration of 
phosphate falls below 4 µM. In phosphate-limiting conditions, PhoR phosphorylates 
PhoB, which then binds to specific DNA sequences, known as Pho boxes. PhoB 
binding either induces or represses the genes belonging to the Pho (phosphate) 
regulon, which includes genes involved in acquisition and metabolism of different 
phosphates. 
The Pho regulon in E. coli K12 comprises of 31 genes, and it is not only involved 
in phosphate homeostasis, but it is also related to bacterial virulence as the induction 
of Pho regulon results in attenuated pathogenesis 
75, 76
. Examples of virulence 
attributes altered by induction of the Pho regulon are a significant reduction in the 
amount of capsular antigen at the cell surface, resistance to the bactericidal effect of 
serum, to cationic antimicrobial peptides, and to acid and oxidative stress, as well as 
the production of type 1 fimbriae 
75, 76
. Therefore, PhoRB presents a promising target 
for antibacterials that inhibit bacterial virulence.  
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ANTIMICROBIAL PEPTIDES INHIBITING TCS SIGNALING  
 
Antimicrobial peptides (AMPs) have been proposed as promising strategy to 
address the growing problem of MDR 
77, 78
. Eukaryotic cationic AMPs are produced at 
sites of infection or inflammation in many different organisms 
79, 80
. Typically they are 
peptides of 12 to 45 amino acids with a net positive charge and a high proportion of 
hydrophobic amino acids 
81
. Bovine lactoferricin (LfcinB; Figure 6) is a typical 
cationic antibacterial peptide generated by proteolytic cleavage of lactoferrin that has a 
broad-spectrum antibacterial activity 
82, 83, 84, 82
. 
Figure 5. LactoferricinB is an 
antimicrobial peptide identified as a 
TCS inhibitor. LactoferricinB was 
shown to inhibit the phosphorylation 
activity of E. coli BasR-BasS and the 
ability of CreC to recognize CreB 47. 
 
 
 
 
 
 
 
 
 
It has been shown that LfcinB derived peptides (LfcinB17-41, LfcinB17-31 and D-
LfcinB17-31) enter the cytoplasm of E. coli and S. aureus 
85
. In a recent study aimed at 
elucidation of the intracellular targets of LfcinB, the TCS BasSR and CreCB were 
among the 16 proteins shown to specifically interact with LfcinB 
47
. This discovery 
suggested that LfcinB-derived peptides were a promising starting point for the 
development of AMP-based TCS inhibitors.  
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THESIS OUTLINE AND AIMS  
The main aims of the current thesis were: 
1. To discover hits that can be further developed to broad-spectrum TCS inhibitors 
following a multidisciplinary approach. 
 2. To provide structural-knowledge on TCS inhibition to facilitate the 
optimization of the identified TCS inhibitors using structure-based drug design. 
 3. To evaluate the identified hits for their biochemical, antibacterial and cytotoxic 
effects in vitro 
4. To explore ways to improve hit compound permeability of the Gram-negative 
bacteria outer membrane using nanoparticles and AMPs 
In Chapter 2, we describe the discovery of histidine kinase (HK) 
autophosphorylation inhibitors targeted at the ATP-binding and catalytic (CA) domain 
of multiple HKs using combined structure-based and ligand-based virtual screening 
approaches. 
In Chapter 3, we describe the application of fragment-based screenings by 
differential scanning fluorimetry and ligand-based similarity searches to discover 
fragment-like HK autophosphorylation inhibitors targeted at the CA domain of 
multiple HKs.  
Due to the weak or absent antibacterial effect of identified HK inhibitors (Chapter 
2 and 3) against Gram-negative bacteria, nanoparticles were investigated as potential 
drug delivery vehicles. Silica-based mesoporous nanoparticles capped with ε-poly-L-
lysine were loaded with HK autophosphorylation inhibitors and their antibacterial 
effect, cytotoxicity and immunotoxicity were studied and described in Chapter 4.  
In Chapter 5 we used computer-aided approaches in an attempt to discover 
improved HK inhibitors. 
As lactoferricinB-derived peptides seemed to present a promising starting point 
for the development of antimicrobial-peptides-based TCS inhibitors, in Chapter 6 we 
investigated the possibility to use T. maritima HK853-RR468 and E. coli PhoRB for 
structural studies of TCS inhibition by LactoferricinB – derived peptides.  
In Chapter 7 the (co-)crystallization and preliminary X-ray diffraction analysis of 
the T. maritima CheA-inhibitors co-crystals and CopM periplasmic domain are 
described.  
In Chapter 8 the potential of targeting WalK for developing antibacterial drugs 
with low potential of resistance development is discussed in the light of current 
literature and results.  
Chapter 9 is a concluding discussion on the results described in the thesis and 
their implications for antibacterial drug discovery and development.  
2014 
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ABSTRACT 
 
The emergence of multi-drug resistant bacteria is an overwhelming world-wide 
public health problem. Two-component systems, consisting of a sensor histidine 
kinase (HK) and an effector response regulator, are the main signaling devices in 
bacteria and have been proposed as promising targets for the development of novel 
broad-spectrum antibacterials. Rational design of competitive inhibitors for the 
nucleotide-binding site of HKs that inhibit the autophosphorylation activity is 
considered a promising strategy to generate a novel class of antibacterials. To discover 
HK inhibitors we employed a virtual screening approach, including structure-based 
virtual screening (SBVS) and a ligand-based similarity search (LBSS). Two of the hits 
identified using SBVS inhibited the autophosphorylation activity of multiple HKs in 
vitro and had a weak antibacterial activity against several Gram-positive bacteria 
species. Using the two hits as query molecules for LBSS, three compounds were 
identified with greater autophosphorylation inhibitory capacity (IC50 ≥16 µg/m for the 
best hit, B13) and stronger antibacterial activity against different Gram-positive 
laboratory strains and clinical isolates of Staphyloccus epidermidis and methicillin- 
resistant Staphylococcus aureus (MRSA). One of these compounds, B14, inhibits the 
growth of multi-drug resistant clinical isolates of both Gram-positive and Gram-
negative bacteria. Analysis of the predicted binding modes of the reported inhibitors 
suggests different modes of interaction with the ATP-binding site of HKs and thus can 
be used as a starting point for designing inhibitors with higher affinity and selectivity 
for HKs. 
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INTRODUCTION 
 
There is an urgent need to discover new antibacterials to combat the growing 
problem of antibiotic resistance world-wide 
1, 2
. Two-component systems (TCS) have 
been proposed for almost two decades as promising antibacterial drug-targets 
3, 4, 5
. 
TCS are highly pervasive in bacteria and used for signal transduction but are not 
present in mammals, making them attractive antibacterial drug targets 
6
. Moreover, 
TCS are involved in the regulation of a variety of processes related to bacterial 
pathogenicity 
7
, including virulence 
8
, biofilm formation 
9, 10
, antibiotic resistance 
11
, 
and bacterial persistence 
12
. Some TCS are essential or conditionally essential for 
bacterial growth 
13
. Furthermore, the high degree of conservation among TCS active 
sites and the existence of multiple TCS in each bacterium suggest that it should be 
possible to identify an inhibitor of multiple TCS regulatory networks with a broad-
spectrum activity. Overall, targeting TCS is expected to effectively incapacitate the 
ability of bacteria to adapt to environmental and physiological changes. 
A prototypical TCS consists of a membrane-bound histidine kinase (HK) and a 
cognate response regulator (RR) with transcription activity 
14
. Upon sensing 
environmental stimuli, the HK is autophosphorylated at conserved histidine residues. 
Subsequently, the phosphoryl groups attached to His are transferred to conserved 
aspartic acid residues in the receiver domains (RECs) of the cognate RRs. For some 
RRs, phosphorylation has been shown to alter affinity of binding to the operator sites 
and alter gene transcription due to conformational changes and protein dimerization 
14
. 
HK autophosphorylation involves two well-conserved domains, a dimerization and 
histidine phosphotransfer domain (DHp) containing the phospho-accepting His and a 
C-terminal catalytic ATP-binding (CA) domain that phosphorylates His through ATP 
hydrolysis. The structure and amino acid sequence of the ATP-binding domain is well 
conserved so inhibitors targeted at ATP -binding would be expected to inhibit multiple 
TCS. Here we describe the identification of HK autophosphorylation inhibitors 
(HKAIs) by combined virtual screening approach including structure-based virtual 
screening (SBVS), followed by ligand-based similarity search (LBSS) for homologues 
of the initial hits. The compounds were demonstrated to inhibit Escherichia coli and 
Staphylococcus aureus PhoR autophosphorylation and are expected to inhibit the 
autophosphorylation of other HKs. The HKAIs were also tested for their antibacterial 
activity against reference and multi-drug resistant bacterial strains, including MRSA.  
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MATERIALS AND METHODS 
 
STRUCTURE-BASED VIRTUAL SCREENING 
Target preparation 
The chosen molecular targets for molecular docking were the CA domains of 
Thermotoga maritima HK853 (PDB: 3DGE) 
15
, Geobacillus stearothermophillus 
KinB (PDB: 3D36) 
16
 and T. maritima CheA (PDB: I58B) 
17
. Residues corresponding 
to the CA domain of each A chain (320-480 for 3DGE, 270-415 for 3D36 and 354-540 
for I58B) were selected for each structure and additional atoms corresponding to water 
molecules, ions or ligands were removed. Hydrogen atoms were added in the absence 
of the cognate ligand using the GOLD program 
18
. 
Docking parameters 
All docking calculations were performed with the GOLD docking software 
(version 5.2) using ChemPLP as a scoring function 
19
. Binding sites were defined as 
being 10 Å around the geometric center of the cognate ligand.  
Library 
For the initial screening, a diversity set (600 000) of the Scopius – CSpace 
database (over 6 million commercially available drug-like compounds) 
20, 21
 was 
docked into each of the three HK structures. The search efficiency parameter was set 
to 30 % and 10 solutions were generated for each compound of which only the 
highest-scoring poses were saved.  
Post-processing of docking results 
Compounds with unwanted functional groups (in-house rules used by InhibOx) 
were removed and the resulting set of compounds was ranked in two lists: i) by the 
ChemPLP GOLD docking score (ChemPLP) and ii) by a ligand efficiency score (i.e.) 
which is ChemPLP divided by the number of non-hydrogen atoms in the compound 
22
. 
The top 3500 compounds in each list were used to extract the top 100 compounds 
docking to all three HK CA domain structures. This resulted in two final lists of 
compounds: one with respect to ChemPLP and one with respect to ligand efficiency. 
The top 100 compounds of each list were finally visually inspected and ten compounds 
were purchased for experimental testing.  
 
LIGAND-BASED SIMILARITY SEARCH 
The database from the Developmental Therapeutics program of the National 
Cancer Institute and the National Institute of Health (DTP) was searched for analogue 
structures of the initial hits A5 and A6. The similarity search with A5 or A6 as query 
molecules was performed using the Morgan fingerprint as implemented in RDKit 
23
, 
which is a variation of the “extended connectivity fingerprints” (ECFP) 24. The top 100 
hits of each similarity search were visually inspected of which in total 25 compounds 
were ordered and experimentally tested. 
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BINDING AND INTERACTION MODE PREDICTION 
Docking calculations to predict the binding mode of selected inhibitors were 
performed with the initial hits, A5 and A6, and the LBSS hits showing antibacterial 
effect, B7, B13 and B14, using the CA domain of T. maritima HK853 (PDB: 3DGE, 
chain A) and GOLD docking software. For each ligand 100 solutions were generated, 
of which the top 20 were visually inspected.  
 
CHEMICAL REAGENTS 
Compounds A1 to A10 from the initial SBVS screening were purchased from 
Ukrainian Organic Synthesis (Kiev, Ukraine). Compounds B1 to B25 from the ligand-
based similarity search (LBSS) were obtained from DTP. Compounds were dissolved 
in 100% DMSO and stored at 4ºC protected from direct light. [γ-32] ATP was 
purchased from Perkin Elmer.  
 
CLONING  
Streptococcus pneumoniae walK encoding the catalytic portion (DHp and CA 
domain) of WalK (amino acids from 208 to 449) was amplified by PCR from S. 
pneumoniae CDC3059-06 genomic DNA using the following primers: forward 5´-
aagttctgtttcagggcccgatggagcaggagaaggaagaacgc-3´ and reverse 5´-
atggtctagaaagctctagtcttctacttcatccac-3´. The PCR product was purified by PCR product 
purification kit (Macherey-Nagel) and cloned into a gel-purified pOpinF vector 
(kindly provided by Nick Berow, IRB, Spain) linearized with KpnI and HindIII 
(Fischer Scientific). The insert was cloned into the pOpinF vector with In-Fusion HD 
cloning system (Clontech). Positive clones were confirmed by colony PCR and DNA 
sequencing. 
 
PROTEIN EXPRESSION AND PURIFICATION 
The catalytic portions (DHp and CA domain) of T. maritima HK853 (HK853), E. 
coli PhoR (PhoR
E
) and S. aureus PhoR (PhoR
S
) were expressed and purified as 
previously described 
15, 25
. In brief, the proteins were expressed in E. coli RIL and 
purified by Ni-affinity (PhoR
E
 and PhoR
S
) or anion-exchange (HK853) and size-
exclusion chromatography. S. pneumoniae WalK (WalK) was expressed in E. coli 
RIL. Luria Broth (LB) media supplemented with 100 µg/ml ampicillin and 33 µg/ml 
chloramphenicol was inoculated with an overnight pre-culture (1/50 of the culture 
volume). At exponential phase (OD600 0.2 – 0.4) protein expression was induced by 
addition of 1 mM IPTG for 3 to 5 h at 37°C. The cells were harvested by 
centrifugation at 4000 g, 4 ° C for 25 min and the pellets were stored at -80°C until 
use. The cell pellets were resuspended in lysis buffer (100 mM Tris pH 8.0, 150 mM 
NaCl, 0.1 mM PMSF) and sonicated at 4°C for 5 min with pulses of 15 sec at intervals 
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of 1 minute. The cell debris and the supernatant were separated by centrifugation at 11 
000 g, 4°C for 60 min. The cell debris were resuspended in equilibration buffer (100 
mM Tris pH 8.0, 150 mM NaCl) containing 2M urea and incubated overnight at 4°C 
with rotation. After centrifugation at 11 000 g, the supernatant was injected into a Ni-
affinity chromatography column (GE Healthcare) equilibrated with equilibration 
buffer, washed with 5 volumes of equilibration buffer and eluted with equilibration 
buffer containing 0.5 M imidazole. WalK was concentrated with AmiconUltra 
(Millipore) centrifugal filters, aliquoted and stored at –80°C until use. The yield was ≤ 
0.5 mg/L culture.  
 
KINASE ASSAY  
Kinase assay was performed as previously described 
26
. When comparing the 
inhibitory capacity of ligands and measuring IC50, the final DMSO concentration in 
the assay was 10% (v/v). Controls lacking ligands and containing an equal 
concentration of DMSO were carried out in parallel. Inhibition of HK 
autophosphorylation was determined by incubating 0.12 mg/ml (≈4 µM HK) and up to 
20 mM compound in kinase buffer (50 mM Tris HCl, pH 8.5, 50 mM KCl, 5 mM 
MgCl2, 0.5 mM EDTA and 0.1 mM DTT). Autophosporylation reactions were 
initiated by addition of 0.1 µCi/µl [γ-32P] ATP containing from 0.03 to 0.06 µM ATP 
(final concentrations). Autophosphorylation was quenched with 2x SDS-PAGE sample 
buffer supplemented with 50 mM EDTA. Samples were applied without heating to 
15% (w/v) Tris-glycine SDS-polyacrylamide gels. After electrophoresis, the bottoms 
of the gels were removed to lower the background signal from the unincorporated 
radiolabeled ATP. Gels were dried without staining on a Bio-Rad Gel Air drying 
system and the phosphorylated protein was quantified by phosphor-imaging using a 
Fluoro Image Analyzer FLA-5000 (Fujifilm) and evaluated with the MultiGauge 
software (Fujifilm). IC50 is the concentration at which 50% residual enzyme activity 
was observed compared to the negative control, DMSO. Prism GraphPad v.4 was used 
for curve fitting and statistical analysis 
27
.  
 
AGGREGATION ANALYSIS BY NATIVE POLYACRYLAMIDE GEL 
ELECTROPHORESIS 
PhoR
E 
and PhoR
S
 (0.12 µg/ml, final concentration) were prepared in kinase 
buffer. Compounds were added to a final concentration of 5 mM or 2 mM for the 
initial SBVS or the secondary LBSS hits, respectively. DMSO in the assays was 
maintained to a final concentration 10% (v/v). After 30 min of incubation at room 
temperature Native polyacrylamide gel electrophoresis (Native-PAGE) loading buffer 
was added and samples loaded. Coomassie blue staining was used for protein 
visualization.  
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BACTERIAL STRAINS  
Bacterial strains used in this study for antibacterial susceptibility testing are listed 
in Table S3. The strains (Table S3) were propagated using standard microbiological 
procedures. 
 Uropathogenic Escherichia coli CFT 073, S. aureus DSM 20231 and S. 
epidermidis DSM 20044 were obtained from the German Collection of 
Microorganisms and Cell culture (DSMZ). S. aureus ATCC 25293, S. epidermidis 
RP62A and RP62A/1, E. coli ATCC 25276, Klebsiella pneumoniae ATCC 700603, 
Pseudomonas aeruoginosa ATCC 27853, and S. pneumoniae ATCC 49619 were 
obtained from the American Type Culture Collection (ATCC). Streptococcus suis 
3881/S10 was provided by the Central Veterinary Institute of Wageningen University 
and Research Centre (CVI, Lelystad, The Netherlands). 
Six clinical sporadic isolates of MRSA (127/08, 145/08, 274/08, V4180, S908, 
and T4/6) were obtained from wounds of patients admitted to Tawam hospital (Al Ain, 
UAE). Characterization of the MRSA strains by multilocus sequence typing (MLST), 
staphylococcal cassette chromosome (SCCmec) typing, accessory gene regulator (agr) 
typing, Staphylococcus protein A (spa) typing, and toxin gene carriage has been 
described previously [36]. The MRSA strains were resistant to all β-lactam antibiotics 
tested and to a range of non-β-lactam antibiotics 28. 
Three isolates of S. epidermidis (T7/3, T6/19, and T37/8) were obtained from 
wounds of patients admitted to Tawam hospital (Al Ain, UAE). The biofilm-producing 
Staphylococcus epidermidis RP62A strain produces polysaccharide intercellular 
adhesin that protects the bacteria against the components of the human innate immune 
system. Its full genome sequence is in the GenBank: NC002976. S. epidermidis 
RP62A/1 is a stable biofilm non-producer phase variant of RP62A 
29
 . 
Five independent well-characterized multidrug-resistant Acinetobacter baumanii 
strains (NM8, NM35, NM75, NM109, and NM124) and three Stenotrophomonas 
maltophilia strains (B32/1, B5/5, and B6/2) were included in the study. These strains 
were isolated at four different hospitals in Abu Dhabi Emirate, UAE and their clonal 
lineages and antibiotic susceptibilities have been previously described 
30, 31
. 
 
ANTIBACTERIAL SUSCEPTIBILITY TESTING 
For all microorganisms tested except S. pneumoniae, the minimal inhibitory 
concentrations (MICs) were determined as previously described following a standard 
double-dilution method 
32, 33, 34
. MICs were recorded as the lowest concentration of the 
compound where no visible growth was observed. After plating the dilutions around 
the MIC, MBC was recorded as the lowest concentration of the compound at which no 
colonies were formed after 24h of incubation at 37°C. For S. pneumoniae MICs were 
determined by adapting the standard double-dilution method of this microorganism 
(use of Todd Hewitt Yeast extract (THY) with 200U/mL of catalase and continuous 
monitoring of growth) to anaerobic conditions 
34
. MBCs for S. pneumoniae were 
determined by inoculation of 10 µl from each well that did not show visible bacterial 
growth on THY 0,5% 3% blood agar plates. After 24 h of incubation at 37°C 5% CO2, 
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the first dilution yielding three colonies or fewer was scored as the MBC, as described 
by the CLSI for starting inoculate of 1 x 10
5
 CFU/ml 
35
. 
 
HEMOLYSIS ASSAY  
Hemolytic activity against human erythrocytes taken from a healthy donor was 
measured as previously described 
36
. Erythrocytes were incubated with up to 500 
µg/ml compounds and the LC50 value was recorded as the mean concentration of 
compound producing 50% hemolysis in three independent incubations.  
 
CELL LINES AND MEDIUM 
Caco-2 BBE cells (CRL 2102) were purchased from the American Type Culture 
Center (Manassas, VA) and grown in DMEM (Invitrogen, Paisley, UK) containing 
Glutamax and supplemented with 10% fetal bovine serum (FBS; PAA Laboratories, 
Colbe, Germany) and 100 U/ml penicillin/100 μg streptomycin (Sigma, St. Louis, 
MO) in an atmosphere of 5% CO2-95% O2 at 37°C. Cells were trypsinized weekly. 
 
NEUTRAL RED UPTAKE ASSAY OF CELL VIABILITY 
Neutral red uptake assay of cell viability with Caco-2 cells was performed as 
previously described 
37
. Briefly, after overnight incubation (16 to 24 h) with 
concentration ranges of B7, B13 or B14, 10 µl of neutral red solution (33 µg/ml) was 
added to the wells. After 3 h of incubation at 37°C the medium was removed and cells 
were washed rapidly with PBS. Neutral red was extracted from the cells with 150 μl 
1% acetic acid-50% ethanol, shaken for 10 min at RT. The neutral red content was 
measured on a SpectraMax M5 microplate reader (Molecular Devices) at 540 nm. The 
readings were expressed as neutral-red uptake relative to the neutral-red uptake of the 
cells exposed to DMSO. IC50 is the concentration causing 50% reduction in neutral-red 
uptake. Prism GraphPad v.4 was used for curve fitting and statistical analysis 
27
. 
 
HUMAN PBMCS ISOLATION AND FLOW CYTOMETRY  
This study was approved by Wageningen University Ethical Committee and was 
performed according to the principles of the Declaration of Helsinki. Buffy coats from 
healthy blood donors were obtained from the Sanquin Blood bank in Nijmegen (The 
Netherlands). A written informed consent was obtained from each volunteer before 
sample collection. 
PBMCs were isolated from buffy coats of healthy donors using Ficoll Paque Plus 
density gradient (GE Healthcare, Diegem Belgium) according to the manufacturer’s 
protocol. After centrifugation, the mononuclear cells were collected, washed in IMDM 
+ glutamax (Invitrogen, Breda, The Netherlands) and resuspended in IMDM + 
glutamax supplemented with 10% foetal calf serum (FCS), 100 U/ml penicillin and 
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100 µg/ml streptomycin (Sigma, St. Louis, MO). PBMCs were seeded at 1 x 10
6
 cells/ 
well in 48-well plates and, treated with B7 and B13. After 24 hours, the cells were 
stained with annexin V and PI (BD Biosciences, Breda, The Netherlands) and 
analysed on a flow cytometer (FACS Canto II, BD).  
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RESULTS 
 
VIRTUAL SCREENING STRATEGY FOR POTENTIAL HISTIDINE-KINASE 
INHIBITORS 
The ATP-binding pocket of the CA domains of HKs is considered to be the most 
promising target for inhibition of TCS HKs and has been used previously in structure-
based virtual screenings 
38, 39, 40, 41
. To identify drug-like ligands of the ATP-binding 
sites of the HK CA domains with putative broad spectrum of inhibition, a diverse set 
of 600 000 compounds was screened via in silico docking calculation using as target 
receptors the ATP-binding sites of the CA domains of three different HKs: T. 
maritima HK853 (PDB: 3DGE) 
42
, T. maritima CheA (PDB: 1I58) 
17
 and G. 
stearothermophilus KinB (PDB: 3D36) 
16
. These three CA domains were selected 
because the structures were solved in the presence of a nucleotide and re-docking of 
the cognate ligand was successful (RMSD 1Å for 3DGE and 3D36, and 3 Å for 1I58). 
Virtual screening with the three structures that have some sequence variability at the 
ATP-binding site was expected to facilitate the identification of broad-spectrum 
histidine kinase autophosphorylation inhibitors (HKAI). The screened compounds 
were ranked based on the raw docking score, ChemPLP, as well as ligand efficiency. 
The top 100 docked compounds in common for the three HKs were ranked on both 
scoring schemes (i.e. ChemPLP and ligand efficiency) and then visually inspected to 
select 10 compounds, A1-A10 (Figure 1, Tables 1, S1 and S2), for experimental 
testing. 
 
INHIBITION OF HK AUTOPHOSPHORYLATION IN VITRO AND 
ANTIBACTERIAL SUSCEPTIBILITY TESTING REVEALED TWO HIT 
COMPOUNDS 
The inhibitory activity of the 10 selected compounds from the SBVS on HKs 
autophosphorylation was tested in vitro using four different HKs: T. maritima HK853 
(HK853), as a representative of the structures used in the docking assays, the highly 
extended HK PhoR from a Gram-negative (E. coli; PhoR
E
), and Gram-positive (S. 
aureus; PhoR
S
) representative and S. pneumoniae WalK (WalK) as a representative of 
the essential WalKR TCS ubiquitous among Gram-positive bacteria 
43
. As a fast way 
to compare the autophosphorylation inhibitory capacity of the 10 selected compounds 
the kinase assays were performed at a single and high (5 mM) compound 
concentration and at one time point (30 sec). Autophosphorylation activity of HK853 
was not or weakly (up to 30%) inhibited by the 10 compounds compared to the 
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Figure 1. Identification of antibacterial compounds form virtual screening. (A) Schematic 
representation of the screening workflow including structure-based virtual screening 
(SBVS; blue) followed by ligand-based similarity search (LBSS; green). In the SBVS a 
diversity set of the Scopius CSpace database was screened for putative ligands of the ATP-
binding site of the CA domain of three HK structures using GOLD. Out of the top 3500 hits 
for each HK the top 100 in common for the three HKs based on ChemPLP or ligand 
efficiency were visually inspected and 10 compounds (B) were selected for experimental 
testing. The results of the in vitro evaluation by kinase assay and antibacterial 
susceptibility testing of these 10 compounds are provided in Table 1. 
 
negative control (Fig S1A) and it was not possible to identify (a) more potent 
inhibitor(s) based on HK853 autophosphorylation inhibition. The kinase assays with 
WalK, PhoR
E 
and PhoR
S
 revealed that compounds A5 and A6 had a higher 
autophosphorylation inhibitory activity than the other selected compounds identified 
by SBVS and were general inhibitors of HK autophosphorylation (Figure 1B, Table 
1). A5 and A6 inhibit HK autophosphorylation activity in a dose-dependent manner, 
with IC50 in the high micromolar / milimolar range (Table 1, Figure S2). A5 inhibits 
PhoR
E
, PhoR
S
 and WalK with IC50 ≈ 1000 µM and it seems it is not soluble in kinase 
buffer in the presence of 10% DMSO at concentrations higher than 1.3 mM. 
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Table 1. Selected compounds from the SBVS and their corresponding IC50 and MICs 
Initial hits IC50 [mM] MIC µg/ml 
Name PhoRS PhoRE HK853 WalK S. aureus S. epidermidis 
E. coli 
          DSM 20231 DSM 20044 CFT 073 
A1 > 5 > 5 > 5 > 5 >500 >500 >500 
A2 > 5 > 5 > 5 > 5 >500 >500 >500 
A3 > 5 > 5 > 5 > 5 >500 >500 >500 
A4 > 5 > 5 > 5 > 5 >500 >500 >500 
A5 ≈ 1  ≈ 1  > 5 >1 >500 500# >500 
A6 1.14 0.37 > 5 >1 >500 500# 500# 
A7 < 5* > 5 > 5 > 5 >500 >500 >500 
A8 < 5* > 5 > 5 > 5 >500 >500 >500 
A9 > 5 > 5 > 5 > 5 >500 >500 >500 
A10 > 5 > 5 > 5 > 5 >500 >500 >500 
* % Inhibition at 5 mM ≥ 70%, i.e. IC50 < 5 mM 
#MBC > 500 µg/ml 
 
 A6 inhibits PhoR
E
, PhoR
S
 and WalK autophosphorylation with IC50 of 372 µM, 1141 
µM and > 1000 µM, respectively (Table 1, Figure S2). The inhibitory activity on HK 
autophosphorylation was most likely due to inhibition of ATP binding in the CA 
domain as neither inhibitor caused PhoR
E 
or PhoR
S 
protein aggregation when added in 
high concentrations (Figure S3). 
To evaluate the antibacterial effect of the 10 selected compounds from SBVS, 
their minimal inhibitory concentrations (MICs) and minimal bactericidal 
concentrations (MBCs) were determined for Gram-positive (S. aureus DSM 20231 
and S. epidermidis DSM 20044) and Gram-negative (E. coli UCF 073) bacteria. Only 
A5 and A6 were able to inhibit bacterial growth at high compound concentrations, 
which is in agreement with their inhibitory activity on HKs (Table 1). S. epidermidis 
DSM 20044 growth was inhibited by A5 and A6 while E. coli UCF 073 growth was 
only inhibited by A6, in all the cases with a modest MICs of 500 µg/ml that are in line 
with the low HK affinity suggested by the measured IC50 (Table 1 and Figure S1). 
Both compounds were bacteriostatic against the three bacterial strains in the tested 
concentration range (MBC > 500 µg/ml). On the basis of these results, A5 and A6 
were used for a ligand-based similarity search (LBSS) in order to identify more potent 
inhibitors with stronger antibacterial effect. 
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LIGAND-BASED SIMILARITY SEARCH 
It is a well-accepted assumption that similar compounds have similar activity; 
however, small structural changes in a compound can result in significant difference in 
potency (so called ‘activity cliffs’) 44. The latter is exemplified by A5 and A6 since the 
two compounds are structurally similar but they show different inhibitory capacity 
toward the HKs assayed (Figures 1B and S1, Table 1). Thus, to explore the chemical 
space around the scaffolds represented by the initial hits from the SBVS and to 
identify more potent HK inhibitors with stronger antibacterial effect, analogue 
compounds of A5 and A6 in the database from the Developmental Therapeutics 
Program of the National Cancer Institute and the National Institute of Health (DTP) 
were identified using LBSS (i.e. by circular topological fingerprints). The top 100 hits 
for the LBSS with A5 or A6 were visually investigated and 25 representative 
compounds, B1-B25 (Figure 2 and Table S1), were experimentally evaluated for their 
HK autophosphorylation inhibitory capacity and antibacterial effect in vitro. 
 
LBSS IDENTIFIED MORE POTENT HKS INHIBITORS WITH STRONGER 
ANTIBACTERIAL ACTIVITY AGAINST GRAM-POSITIVE BACTERIA 
To evaluate the 25 selected hits from LBSS, inhibition of autophosphorylation 
was measured at a single time point (30 sec) using one concentration of each putative 
inhibitor. PhoR
S
 and PhoR
E
 were used as targets as these HKs were more strongly 
inhibited by A5 and A6 than WalK and HK853. The concentration of putative 
inhibitors was reduced from 5 mM to 2 mM in order to identify inhibitors with higher 
potency than A5 and A6. B2, B11, B13 inhibit autophosphorylation activity of both 
PhoR
S
 and PhoR
E
 by more than 75%. B7, B14 and B15 inhibit PhoR
S
 and PhoR
E 
autophosphorylation by more than 75% and more than 40 % compared to the negative 
control, respectively (Figure S2). 
The antibacterial effect evaluation of the 25 compounds identified using LBSS 
showed that B7 was bacteriostatic for S. aureus DSM 20231 with a MIC of 250 µg/ml 
(Table 2). B13 was bactericidal for S. aureus DSM 20231 and S. epidermidis DSM 
20044 with MIC of 8 and 1 µg/ml, respectively, and MBCs of 33 and 8 µg/ml, 
respectively (Table 2). Additionally, B14 was bactericidal for S. aureus DSM 20231 
and S. epidermidis DSM 20044 at a MIC and MBC of 500 µg/ml (Table 2). The rest of 
the tested compounds did not inhibit the growth of S. aureus DSM 20231 or S. 
epidermidis DSM 20044 at the highest tested concentration of 500 µg/ml (MICs > 500 
µg/ml). None of the 25 tested LBSS hits inhibited the growth of E. coli CFT 073 at the 
highest tested concentration of 500 µg/ml (MICs > 500 µg/ml; Table 2). Compounds 
B7, B13 and B14, which had the highest inhibitory activity in the biochemical assays 
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Figure 2. Chemical structures of LBSS selected hits. The results of the in vitro evaluation 
by kinase assay and antibacterial susceptibility testing are presented in Table 2.  
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Table 2. LBSS hits and their corresponding IC50 and MICs 
Secondary hits IC50 [mM] MIC [µg/ml] 
Name PhoRS PhoRE S. aureus S. epidermidis E. coli 
      DSM 20231 DSM 20044 
CFT 
073 
B1 > 2 > 2 >500 >500 >500 
B2 <2 <2 >500 >500 >500 
B3 > 2 > 2 >500 >500 >500 
B4 > 2 > 2 >500 >500 >500 
B5 > 2 > 2 >500 >500 >500 
B6 > 2 > 2 >500 >500 >500 
B7 ≈ 1 ≈ 0.1 250# >500 >500 
B8 > 2 > 2 >500 >500 >500 
B9 > 2 > 2 >500 >500 >500 
B10 > 2 > 2 >500 >500 >500 
B11 <2 <2 >500 >500 >500 
B12 > 2 > 2 >500 >500 >500 
B13 0.212 0.016 8¥ 1¥ >500 
B14 1.48 > 2 500¶ 500¶ >500 
B15 <2 > 2 >500 >500 >500 
B16 > 2 > 2 >500 >500 >500 
B17 > 2 > 2 >500 >500 >500 
B18 > 2 > 2 >500 >500 >500 
B19 > 2 > 2 >500 >500 >500 
B20 > 2 > 2 >500 >500 >500 
B21 > 2 > 2 >500 >500 >500 
B22 > 2 > 2 >500 >500 >500 
B23 > 2 > 2 >500 >500 >500 
B24 > 2 > 2 >500 >500 >500 
B25 > 2 > 2 >500 >500 >500 
# A7 S. aureus MBC > 500 µg/ml 
¥ B13 MBC S. aureus DSM20231 31 µg/ml; B13 MBC S. epidermidis DSM20044 8 µg/ml 
¶ B14 MBC S. aureus DSM20231 and B14 MBC S. epidermidis DSM20044 500 µg/ml 
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and antibacterial activity were selected for further evaluation in vitro. First, their IC50 
against PhoR
E
 and PhoR
S 
was measured (Figure S2, Table 2). B7 inhibits PhoR
E
 
autophosphorylation with IC50 in the lower micromolar range (≥ 100 µM) and PhoR
S
 
in the higher micromolar/ milimolar range (IC50 PhoR
S
 ≥ 1000 µM). The IC50 curves 
indicated that B7 is not soluble in concentrations higher than 1000 µM in kinase buffer 
in the presence of 10% DMSO. B13 inhibits PhoR
E
 and PhoR
S
 with IC50 PhoR
E 
< 100 
µM and IC50 PhoR
S
 = 212 µM and possess good solubility in kinase buffer in the 
presence of 10% DMSO. B14 IC50 against PhoR
E
 and PhoR
S
 is higher than 2000 µM 
and higher than 1000 µM, respectively. The possibility of non-specific inhibition by 
aggregation was ruled out since none of the compounds caused protein aggregation of 
PhoR
S
 or PhoR
E
 at 2 mM in native PAGE (Figure S3). Another reported side effect of 
previously published TCS inhibitors is membrane damage. To exclude that the 
antibacterial activity of these compounds could be mediated by this mechanism, the 
hemolytic activity of B7, B13 and B14 was tested. B7 and B14 did not cause 
hemolysis at 500 µg/ml (i.e. LC50> 500 µg/ml). Hemolysis was observed with 
compound B13 at concentrations higher than the observed MICs (LC 50 277 µg/ml). 
 
CLINICAL ISOLATES OF MULTIDRUG RESISTANT BACTERIA ARE 
SUSCEPTIBLE TO SELECTED HKAIS IN VITRO 
The most promising LBSS hits B7, B13 and B14 (Figure 2) were tested for their 
ability to inhibit the growth of well-characterized methicillin resistant clinical isolates 
of S. aureus (MRSA) 
28
 and clinical isolates of S. epidermidis, as well as reference 
strains of S. pneumoniae and S. suis and additional reference strains of S. aureus and S. 
epidermidis. Since B7, B13 and B14 are expected to inhibit the autophosphorylation of 
multiple HKs, including HKs from Gram-negative bacteria, their antibacterial effect 
against multi-drug resistant clinical isolates of the important pathogens A. baumannii 
45
, 
46
 and S. maltophilia 
31
 and against reference strains from Klebsiella pneumoniae 
and Pseudomonas aeruoginosa were also tested (Table 3, Table S3). B7 inhibited the 
growth of two of the 6 MRSA strains in vitro with MICs ≥250 µg/ml, which was 
comparable to the MICs for the S. aureus reference strains 25293 and DSM 202231. 
The other four MRSA strains were not susceptible to B7. As expected from the results 
of the antibacterial susceptibility testing with S. epidermidis DSM 20044, compound 
B7 had no antibacterial effect on the clinical isolates of S. epidermidis. B7 inhibits the 
growth of all tested S. pneumoniae strains with MIC of 128 µg/ml, which was similar 
to the MICs for the reference strains of S. aureus. B7 did not inhibit the growth of the 
S. suis 3881/ S10 strain in the tested concentration range (≤ 500 µg/ml).  
B13 inhibited the growth of all tested MRSA stains with MICs between 8 and 16 
µg/ml, which was comparable to the MICs for the reference strains of S. aureus. B13 
also inhibited the growth of clinical isolates of S. epidermidis with MICs between 8 
and 16 µg/ml, which is similar to the MICs for, the biofilm forming S. epidermidis 
RP62A and non-biofilm forming S. epidermidis RP62A/1. Like B7, B13 inhibited the 
growth of the S. pneumoniae strains with MIC of 16 µg/ml.  
B14 inhibits growth of MRSA with MICs of 250 µg/ml, which was comparable to 
the MICs for the reference strains of S. aureus. B14 inhibited growth of all S. 
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epidermidis strains except S. epidermidis strain RP62A, with MICs in the range of 250 
to 500 µg/ml. B14 was not active against S. pneumoniae strains but inhibited growth 
of the S. suis S10 with MIC of 125 µg/ml. 
Even though the three selected HKAIs, B7, B13 and B14, inhibit PhoR
E
, 
homologues of which are present in many Gram-negative bacteria, only B14 inhibits 
the growth of the Gram-negative A. baumanii and S. maltohilia strains with MICs 
from 250 μg/ml to 500 μg/ml. None of the 3 selected inhibitors inhibit the growth of 
K. pneumoniae ATCC 700603 and P. aeruginosa ATCC 27853 at the highest tested 
concentration (MIC > 500 µg/ml).  
 
INCREASED ANTIBACTERIAL ACTIVITY IS NOT RELATED TO INCREASED 
CYTOTOXICITY TO MAMMALIAN CELLS  
To check the effect of the most promising inhibitors (B7, B13 and B14) on 
mammalian cell viability, cytotoxicity was evaluated i) with neutral-red uptake assays 
with Caco-2 cells (Figure 3) and ii) measurement of dead (propidium iodide positive) 
and apoptotic (annexin V positive) freshly isolated human peripheral blood 
mononuclear cells (PBMCs) by flow cytometry (Figure 4). After overnight incubation 
(16 to 20 h), B7, B13 and B14 inhibited neutral-red uptake with IC50 values of 105, 29 
and 3 µg/ml, respectively. B7 and B14 IC50 are lower than the observed MICs. 
However, B13 IC50 is from 1.8 to 29 times higher than the observed MICs for the 
panel of Gram-positive strains tested. PBMCs were incubated with 0.2, 1, 3, 13 and 50 
µg/ml B7 and B13 for 24 h. There was no significant difference in the number of dead 
cells in the control (DMSO treated) and B13 treated samples. However, the number of 
cells binding annexin V, a marker of early apoptosis, was significantly higher in cells 
incubated with 50 µg/ml of B13 than the control cells (DMSO). This is reflected in a 
reduction of viable (PI and annexin V negative) cells (Figure 4). Similar results were 
obtained for compound B7 (Figure 4C) suggesting that a concentration between 13 
and 50 µg/ ml induces apoptosis in a proportion of the PBMCs after 24 h incubation.  
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Table 3. Antibacterial effect of selected HK inhibitors against reference strains (marked 
with *) and (multi-drug resistant) clinical isolates  
 MIC (µg/ml) 
Strain B7 B13 B14 
Staphylococcus aureus 
DSM 20231* 250 8 500 
25293* 125 8 125 
274/08 250 16 250 
V4180 >500 8 250 
T4/6 250 8 250 
145/08 >500 8 250 
127/08 >500 16 250 
S908 >500 16 250 
 Staphylococcus epidermidis 
DSM 20044* >500 1 500 
RP62A* >500 8 >500 
RP62A/1* >500 8 500 
T7/3 >500 8 250 
T37/8 >500 16 500 
T6119 >500 8 500 
Streptococcus pneumoniae 
DP1004* 128 16 >500 
TIGR4* 128 16 >500 
ATCC 49619* 128 16  >500 
Streptococcus suis 
3881/ S10 > 500 8 125 
Acinetobacter baumanii 
NM109 >500  >500 250 
NM124 >500  >500 250 
NM8 >500 >500 500 
NM35 >500  >500 500 
NM75 >500 >500 500 
Stenotrophomonas maltophilia 
B5/5 >500 >500  500 
B6/2 >500  >500 500 
B32/1 >500 >500 500 
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Figure 4. Mammalian cell viability assessed by neutral-red uptake assays with Caco-2 cell 
line. The error bars represent the SEM of at least two independent experiments in 
duplicate. IC50 is the concentration at which 50% reduction of neutral-red uptake is 
observed compared to the negative control (DMSO). 
 
 
Figure 5. Dose effect of HKAIs on PBMCs viability (A) and apoptosis evaluated by 
propidioum iodide and annexin V (AV) staining. The highest tested concentration (50 
µg/ml) of both B7 (C) and B13 (B) induces expression of the early apoptotic marker AV 
which is reflected in reduction of the live cells with more than 50% compared to the 
control (DMSO-treated PBMCs). The error bars represent the SEM of three independent 
donors. 
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THE HKAIS ARE PREDICTED TO INTERACT WITH CONSERVED 
RESIDUES IN THE ATP-BINDING SITE OF THE HK CA DOMAIN  
To gain insights into the mechanism of inhibition at the atomic level, the binding 
modes of A5, A6, B7, B13 and B14 to T. maritima HK853 (PDB: 3DGE) were 
predicted with GOLD and visually investigated. All selected inhibitors were predicted 
to occupy the ATP-binding pocket and interact with key residues involved in binding 
of the natural substrate. A common feature for all the compounds was the presence of 
an aromatic ring that accommodates into the hydrophobic cavity occupied by the 
pyrimidine ring of adenine. (Figure 6) The aromatic ring forms π – π stacking 
interactions with Y384 on one side and van der Waals contacts with I416 on the other 
side of the ring. Similar hydrophobic interactions have been observed for the adenine 
in the structures of T. maritima HK853 and other HKs in complex with nucleotides 
26
, 
42
. Located at the bottom of the hydrophobic pocket is the conserved Asp (D411) in the 
G1 box that gives specificity for recognition of the N6 amino group in the pyrimidine 
ring of adenine (Figure  3). For B13, the most potent inhibitor, and B14, the hydroxyl 
group of the phenolic ring stacked in the adenine pocket is predicted to be hydrogen 
bonded to the conserved D411 residue (Figure 5). Similar mode of interaction was 
observed for the binding of the Hsp90 inhibitor radicicol to the ATP-binding domain 
of the HK PhoQ 
47
. In contrast, A5, A6 and B7 are predicted to exploit their common 
amide moieties to mediate polar interaction on the other part of the active site, which 
in HK structures with the native ligand is occupied by the nucleotide phosphates and 
the Mg
2+
 cation (Figure 5). In all the three compounds, A5, A6, and B7, the nitrogen 
of the amide moiety is predicted to be hydrogen bonded to the conserved N-box Mg
2+
 
chelating residue N380 whereas the oxygen is predicted to bind to the main-chain of 
the G2-Box residues G443, L444 and G445, mimicking in this way the interactions of 
the ATP γ-phosphate 48.  
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 Figure 6. Predicted binding modes of selected HK autophosphorylation inhibitors 
(HKAIs). All HKAIs (shown in blue as sticks) dock in the ATP-binding site of HK853 with a 
predicted binding mode resembling the experimental data (3DGE) for the natural 
substrate ADP (top left). They interact with key elements involved in ATP-binding and 
autophosphorylation, i.e the N-, G1-, G2-boxes (shown in orange, blue and yellow, 
respectively) and the ATP-lid (shown in red). 
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DISCUSSION 
 
The rapidly growing problem of multi-drug resistant bacteria requires urgent 
development of a pipeline of new classes of antibiotics. A new class of antibiotics 
ideally should be broad-spectrum, potent and the initial ´´hit´´ scaffold should be 
amenable to structural changes to allow for optimization of the potency, specificity, 
efficacy and the ADMET properties 
49
. Inhibitors targeting virulence factors including 
the ability of bacteria to form biofilms 
50, 51
 have been proposed as a useful approach. 
As TCS are involved in the regulation of bacterial pathogenesis, including virulence, 
and biofilm formation, they are absent in mammals and some TCS are essential or 
conditionally essential for bacterial growth, TCS in general, and HKs in particular, are 
recognized as promising antibacterial drug targets 
51
. The first attempts to discover 
TCS inhibitors resulted in hydrophobic compounds with non-specific activity, which 
inhibited HK autophosphorylation by indirect mechanisms such as protein aggregation 
and showed antibacterial effect due to decreasing membrane integrity 
52, 41, 53
. After the 
elucidation of HK structures 
54, 26, 42
 SBVS for ligands of the CA domain of HK were 
reported 
38, 39, 40, 41
 demonstrating that SBVS is a viable tool for discovery of HKAIs 
with antibacterial, antivirulence and therapeutic effect. 
 HK CA domains present a characteristic fold with highly conserved residues 
involved in nucleotide-cation selection and binding 
55
. Therefore, autophosphorylation 
inhibitors discovered using structures of one HK CA are expected to have broad 
activity against orthologous kinases. However, using one protein structure for SBVS 
does not take into account the highly flexible and catalytically competent ATP-lid 
which is variable in length and sequence 
6
 or the conformation and target plasticity 
56
. 
To address these and to increase the probability of identifying broad-spectrum HKAI, 
a SBVS by molecular docking using as receptors the ATP-binding site of three HK 
CA-domains: T. maritima HK853 (PDB: 3DGE), G. stearothermophilus KinB (PDB 
3D36) and T. maritima CheA (PDB: 1I58) was performed. The use of multiple 
structures in docking experiments increases the chance of finding broad-spectrum 
ligands because it implicitly considers the receptors plasticity, sequence and 
conformation variability in the docking approach. This approach mimics an ensemble 
based docking which has been shown to improve the overall performance of virtual 
screening experiments 
57
. The methodology was validated by “re-docking” 
experiments where experimental protein-ligand complexes were reproduced with low 
RMSD values using the computational approach followed in the reported SBVS 
58
. 
This provides some confidence that novel ligands can be found using the same 
protocol. Encouragingly, two of the selected hits from the SBVS, A5 and A6, inhibited 
the autophosphorylation of HKs different from the HKs used in the SBVS and showed 
modest antibacterial effect. It seems that the observed HK autophosphorylation 
inhibition could be specifically mediated via the binding to the CA domain since A5 
and A6 did not cause protein aggregation which is a common non-specific mechanism 
of action of previously reported HK inhibitors 
41
. Furthermore, there was a good 
correlation between the in vitro biochemical activity and the antibacterial effects of A5 
and A6.  
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To identify other possible inhibitors with stronger antibacterial effect, A5 and A6 
were successfully used as query molecules in a ligand-based similarity search (LBSS). 
Among the LBSS hits, the most potent inhibitor was B13 (IC50 PhoR
E
 = 16 µM, IC50 
PhoR
S 
= 212 µM), which inhibited the growth of clinical isolates of MRSA and S. 
epidermidis with MICs ≤ 16 µg/ml. The MICs against multi-drug resistant clinical 
isolates are comparable with the MICs against reference strains. This suggests that the 
putative mechanism of action of B13 differs from the known antibiotics and/or the 
mechanisms of resistance of the tested strains to known antibiotics are not functional 
against B13. Furthermore, B13 is amenable for chemical modification and further 
optimization. Encouragingly, the stronger antibacterial effect of B13 was not related to 
higher cytotoxicity. B13 inhibited neutral-red uptake by Caco-2 cells with IC50 of 29 
µg/ml, which is higher than the observed MICs for Gram-positive strains. 
Furthermore, even 24 h incubation of PBMCs with up to 50 µg/ml of B13 and B7 did 
not increase proportion of dead cells. However, the highest B13 concentration tested 
(50 µg/ml) increased the proportion cells expressing an early marker of apoptosis. 
Together these results suggest that B13 is a good lead candidate for the development 
of antibacterials for Gram-positive bacteria. Even though B13 is the most potent 
PhoR
E
 inhibitor among the once here reported it did not inhibit the growth of any of 
the tested Gram-negative strains at the highest tested concentration (500 µg/ml). The 
cell envelope of Gram-negative bacteria is well known to be more effective barrier to 
penetration of drugs than that of Gram-positive bacteria but ultimately the compound 
may be modified to promote uptake or penetrate prokaryotic membranes according to 
experience with other antibacterials entering into Gram-negatives or by applying 
nanotechnology approaches 
59, 60, 49
.  
The predicted binding mode of B14 exploits similar features to B13 as well as 
polar interaction with the conserved G1-box Asp residue, inhibits Gram-positive (S. 
aureus reference strains and MRSA, S. epidermidis strains and S. suis 3881/S10) and 
Gram-negative (A. baumannii and S. maltophilia) strains with MICs in the range of 
125 to 500 µg/ml. The MICs range is higher that the observed for B13 in close 
agreement with B14 higher than B13 IC50 for PhoR
E
 and PhoR
S
 autophosphorylation 
inhibition. Therefore, B13 and B14 could represent a promising scaffold to re-design 
new compounds that could be expected to inhibit a broad spectrum of HKs. 
Furthermore, B14 scaffold seems to possess good safety profile since the screening of 
B14 with 60-cell lines 
61
 showed that except for HL-60(TB) and UO-31, the compound 
was not cytotoxic (cell growth > 90%).  
On the other hand, the relatively weaker than B13 HKAI B7 (IC50 PhoR
E
 ≈ 
100µM, IC50 PhoR
S ≥ 1000 µM) inhibits the growth of the two reference S. aureus 
strains and 2 of 6 tested MRSA strains. B7 inhibited the growth of S. pneumoniae with 
MICs in the same range as the MICs for the S. aureus strains. However, B7 was not 
active against S. epidermidis or any of the Gram-negative bacteria tested. This strain 
specificity of B7 correlated with the quite different IC50 observed for PhoR
E
 and 
PhoR
S
 HKs. A tentative explanation for this fact can arise from the predicted binding 
mode of B7 that suggests a main interaction mediated by its amide group with the 
variable part of the ATP-binding site, the ATP lid. All together these indicate that B7 
would inhibit autophosphorylation of different HKs with affinity affected by sequence 
variability. B7 did not cause protein aggregation or hemolysis and seems to possess 
good toxicity properties as intraperitoneal injection on mice leukemia model L1210 
62
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with up to 400 mg/kg of B7 led to from 93 to 98% survival of the treated animals, 
showing B7 was nontoxic in vivo. All together these data 
62
, indicate B7 as a good hit 
candidate for development of an antibacterial drug. Furthermore, the effect of B7 on 
PBMCs was similar to that of B13 and B7 (Fig 5). As B7 has been shown to be 
nontoxic in vivo it could be expected that B13 would also be nontoxic in vivo. 
Except of the number of rotatable bonds, the reported inhibitors B7, B13 and B14 
are fragment-like, i.e. they follow the so called ¨rule of 3¨ (MW < 300 DA, hydrogen 
bond donors (HBD) < 3, hydrogen bond acceptors (HBA) < 3). Therefore, they present 
a promising starting point for the rational re-design of more potent and/ or specific 
HKAIs. The predicted binding modes of these candidates point to different ways of 
compound binding to the HK active site that could be exploited in the re-design 
process. In this way, the interaction with the conserved Asp in the G1 box mediated by 
the phenolic ring predicted for B13, the most potent inhibitor, and B14 could be 
combined with the amide group of B7 that could interact with the ATP-lid at the other 
side of the active center. This new generation of structure-based re-designed 
compounds could increases potency following the features of B13 and/or specificity 
exploiting the sequence and structural differences between HKs, mainly located at the 
ATP-lid, to generate general or strain-specific HK inhibitors. 
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SUPPLEMENTARY MATERIAL CHAPTER 2 
 
Figure S1. Autophosphorylation inhibitory activity of the initial hits from the SBVS. (A) 
One-time (30 sec) one-concentration (5 mM) kinase assay with the SBVS hits and PhoRS, 
PhoRE, WalK and HK853 distinguished A5 and A6 as relatively stronger multiple HKs 
autophosphorylation inhibitors. The IC50 for PhoRS, PhoRE and WalK in presence of A5 (B) 
and A6 (C) were calculated from the autophosphorylation reaction assays at different 
concentrations of compounds. Error bars represent the standard errors of the mean (SEM) 
of two independent assays with two replicates. 
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Figure S2 Autophosphorylation inhibitory activity of the LBSS hits. (A) One-time point (30 
sec), one-concentration (2 mM) kinase assay with the LBVS hits and PhoRS and PhoRE HKs. 
The IC50 for PhoRS and PhoRE in presence of B7 (B), B13 (C) and B14 (D) were calculated 
from the autophosphorylation reaction assays at different concentrations of compounds. 
Error bars represent the standard errors of the mean (SEM) of two independent assays 
with two replicates. 
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Figure S3. Native PAGE-based aggregation analysis of five inhibitors. A5 and A6 (5 mM), 
and B7, B13 and B14 (2 mM) do not cause HK aggregation as demonstrated by native-
PAGE with PhoRS and PhoRE HKs. 
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Tabe S1. Selected compounds for experimental testing from SBVS (A1 to A10) and LBSS 
(B1 to B17) 
Name 
Provider´s 
Name Smile 
A1 PB-02322356 
O=C(CCN1C2=C(SC3=C1C=CC=C3)C=CC=C2)OCC1=CC(=O)N2C=C
SC2=N1 
A2 PB-04723907 
CC(OC(=O)C1=CC(=CC=C1)S(=O)(=O)N1CCC2=C(C1)C=CC=C2)C(
=O)NC(N)=O 
A3 PB404910184 
CC(NC(=O)C1CN(C(=O)C1)C1=CC=CC=C1)C1=CC(NC(=O)C2=CC=
CC=C2)=CC=C1 
A4 PB-06200251 
CNC(=O)NC(=O)CSC1=NC2=C(C3=C(CCCC3)S2)C(=O)N1C1=C(F)
C=CC=C1 
A5 BBV-129624 CCC(NC1=CC(NC(C)=O)=CC=C1)C1=CC=C(F)C=C1 
A6 BBV-174972 CC(NCC1=CC(Br)=CC=C1)C1=CC(NC(C)=O)=CC=C1 
A7 BBV-129155 C(NC1=CC2=C(OCCO2)C=C1)C1=CC2=C(C=CC=C2)C=C1 
A8 
BBV-
34226801 CC(NCC1=C2C=CC=CC2=CC=C1)C1=CC=C(F)C=C1 
A9 
BBV-
34226813 CC(NCC1=C2C=CC=CC2=CC=C1)C1=CC(F)=CC=C1 
A10 BBV-203039 CC(NCC1=CC(F)=CC=C1)C1=CC2=C(C=CC=C2)C=C1 
B1 310269 CCN(CC1=CC=C(C=C1)C(=O)OC)C2=CC(=CC=C2)NC(C)=O 
B2 73090 CC(=O)NC1=CC=C(C=C1)C2=CC=C(F)C=C2 
B3 214040 CC(=O)NC1=CC=C(NC(=O)C2=CC(=CC=C2)F)C=C1 
B4 86683 CC(=O)NC1=CC(=CC=C1)CC2=CC(=CC=C2)NC(C)=O 
B5 400630 CC(=O)NC1=C[N+](=CC=C1)CC(=O)C2=CC=C(F)C=C2 
B6 4288 CC(=O)NC1=CC=C(C=C1)C(O)C2=CC=C(NC(C)=O)C=C2 
B7 109741 CC(=O)NC1=CC(=CC=C1)C2=C(Cl)C=CC=C2 
B8 211557 CC(=O)NC1=CC(=CC=C1)OCC2=CC=C(C=C2)[N](=O)=O 
B9 85756 CC(=O)NC1=CC(=CC=C1)[S](=O)(=O)C2=CC(=CC=C2)NC(C)=O 
B10 12323 CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2=NC4=CC=C(F)C=C4 
B11 211552 CC(=O)NC1=CC(=CC=C1)C=CC2=CC=C(C=C2)[N](=O)=O 
B12 106213 CC(=O)NC1=CC=C(C=C1)C(O)C(=O)C2=CC=C(NC(C)=O)C=C2 
B13 32652 CCC(C(CC)C1=CC=C(F)C=C1)C2=CC=C(O)C=C2 
B14 48154 CC(C)(C)C1=CC(=C(O)C=C1)CNC2=CC=CC=C2 
B15 7436 CC(C)(C)C1=CC=C(N[S](=O)(=O)C2=CC=C(N)C=C2)C=C1 
B16 211556 CC(=O)NC1=CC(=CC=C1)OCOC2=CC=C(C=C2)[N](=O)=O 
B17 107560 CC(=O)NC1=CC(=CC=C1)OCC2=CC(=CC=C2)[N](=O)=O 
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Table S1 (continued). Selected compounds for experimental testing from LBSS (B18 to 
B25) 
Name 
Provider´s 
Name Smile 
B18 118968 COC1=C(NC(C)=O)C=CC(=C1)NCC2=CC=CC=C2 
B19 408367 CC(=O)NC(CC1=CC=CC=C1)C(=O)NC2=CC(=CC=C2)C 
B20 68235 CC(=O)NC1=CC2=C(C=C1)C3=CC=C(Br)C=C3C2 
B21 408365 CC(=O)NC(CC1=CC=CC=C1)C(=O)NC2=CC(=CC=C2)Cl 
B22 205456 ClC1=CC=CC(=C1)CNC(=O)NC2=CC=CC=C2 
B23 130858 CCC(C(C(C)=O)C1=CC=C(OC)C=C1)C2=CC(=CC=C2)Br 
B24 67710 CC[N]1C2=C(C=CC=C2)C3=C1C=CC(=C3)NC(C)=O 
B25 205718 CN(CC1=CC=CC=C1)C(=O)NC2=CC=CC(=C2)C(C)=O 
 
 
Table S2. Compounds selected from SBVS and their corresponding ChemPLP and ligand 
efficiency.  
Initial hits Docking score¥ 
Name ChemPLP Ligand efficiency 
      
ADP 85.4 3.16 
A1 95.12 3.171 
A2 96.14 3.214 
A3 93.48 2.918 
A4 97.21 3.24 
A5 82 3.905 
A6 80.38 3.828 
A7 84.21 3.828 
A8 80.11 3.815 
A9 81.97 3.903 
A10 82.15 3.912 
¥ The values for HK853 (PDB: 3DGE, chain A) are presented  
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Table S3 Bacterial strains 
Strain Source Resistance 
Staphylococcus aureus DSM 
20231 
DSMZ – German 
Collection of 
Microorganisms and 
Cell culture 
Control strain 
S. aureus 25293 ATCC  Control strain 
S. aureus 274/08 28 Tawam Hospital, Al 
Ain, UAE 
β-lactams, Ka, Ne, C, E 
S. aureus V4180 28 Tawam Hospital, Al 
Ain, UAE 
β-lactams, A, G, Ka, Ne, S, Sxt, 
Tet, C, Rif, E, Cl 
S. aureus T4/6 28 Tawam Hospital, Al 
Ain, UAE 
β-lactams, Ka, Ne, C, E, Cl 
S. aureus 145/08 28 Tawam Hospital, Al 
Ain, UAE 
β-lactams, Ka, Ne, S, Tet, Fu 
S. aureus 127/08 28 Tawam Hospital, Al 
Ain, UAE 
β-lactams 
S. aureus S908 28 Tawam Hospital, Al 
Ain, UAE 
β-lactams, C, E, Cl 
Staphylococcus epidermidis 
DSM 20044 
DSMZ – German 
Collection of 
Microorganisms and 
Cell culture 
Control strain 
S. epidermidis RP62A 
(biofilm producer) 29 
ATCC Control strain 
S. epidermidis 
RP62A/1(non-biofilm 
producer) 29 
ATCC Control strain 
S. epidermidis T7/3 Tawam Hospital, Al 
Ain, UAE 
 
S. epidermidis T37/8 Tawam Hospital, Al 
Ain, UAE 
 
S. epidermidis T61/9 Tawam Hospital, Al 
Ain, UAE 
 
Streptococcus pneumoniae 
DP1004 
 Control strain 
S. pneumoniae TIGR4 63  Control strain 
S. pneumoniae ATCC 49619 ATCC Control strain 
Streptococcus suis 
3881/ S10 64 
CVI, Lelystad  
Acinetobacter baumannii 
NM109 30 
Hospitals in Abu Dhabi 
Emirate, UAE 
All antibiotics commonly used 
to treat Acinetobacter infections 
A. baumannii NM8 30 Hospitals in Abu Dhabi 
Emirate, UAE 
All antibiotics commonly used 
to treat Acinetobacter infections 
A. baumannii NM35 30 Hospitals in Abu Dhabi 
Emirate, UAE 
All antibiotics commonly used 
to treat Acinetobacter infections 
A. baumannii NM75 30 Hospitals in Abu Dhabi 
Emirate, UAE 
All antibiotics commonly used 
to treat Acinetobacter infections 
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Talbe S3 (continued). Bacterial strains 
Strain Source Resistance 
Stenotrophomonas 
maltophilia B5/5 31 
Tawam Hospital, Al 
Ain, UAE 
meropenem 
S. maltophilia B6/2 31 Tawam Hospital, Al 
Ain, UAE 
meropenem 
S. maltophilia B32/1 31 Tawam Hospital, Al 
Ain, UAE 
meropenem 
Escherichia coli CFT 073 ATCC Control strain 
E. coli 25276 ATCC Control strain 
Klebsiealla pneumoniae 
700603 
ATCC Control strain 
Pseudomonas aeroginosa 
27853 
ATCC Control strain 
*A, amikacin; C, ciprofloxacin; Cl, clindamycin; E, erythromycin; Fu, fusidic acid; G, 
gentamycin; Ka, kanamycin; Ne, neomycin; Rif, rifampicin; S, streptomycin; Sxt, 
sulfamethoxazole+trimethoprim; Tet, tetracyline. 
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ABSTRACT 
 
Novel antibacterials are urgently needed to address the growing problem of 
bacterial resistance to conventional antibiotics. Two-component systems (TCS) have 
been previously proposed as promising antibacterial targets. TCS are widely used by 
bacteria to regulate gene expression in response to various environmental stimuli and 
physiological stress. They consist of a response regulator and a histidine kinase (HK) 
containing a highly conserved ATP-binding site that could be a good target for broad 
spectrum antibacterial drugs. Here we describe fragment-based screens using 
differential scanning fluorimetry and virtual ligand-based similarity searches that 
yielded HK autophosphorylation inhibitors with antibacterial effect against multi-drug 
resistant clinical isolates.  
 
Keywords: antibacterials, histidine kinase autophosphorylation inhibitors, 
fragment-based screening, two-component systems 
Abbreviations: TCS – two-component system/s; HK- histidine kinase; RR – 
response regulator; FBS – fragment-based screening; LBSS – ligand-based similarity 
search; DSF – differential scanning fluorimetry 
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INTRODUCTION  
 
Bacterial two-component systems (TCS) are signal transduction systems used by 
nearly all bacteria. TCS regulate a variety of processes including bacterial growth, 
cell-wall metabolism, virulence, biofilm formation and resistance to antibiotics 
1
. A 
prototypical TCS consist of a membrane bound histidine kinase (HK) and its cognate 
response regulator (RR) 
2
. Upon sensing an environmental stimulus the HK is 
autophosphorylated on conserved histidine residues in the dimerization and histidine 
phosphotransfer (DHp) domain. Subsequently, the phosphoryl group from the His is 
transferred to a conserved aspartic acid residue in the receiver (REC) domain of the 
RR. The phosphorylated state of the RR affects its binding affinity to a cognate DNA 
motif and/or other protein partners thereby modulating transcription of target genes 
2
. 
Inhibitors of HK autophosphorylation targeted at the nucleotide binding site of the 
catalytic and ATP-binding (CA) domains of HKs are expected to simultaneously 
inhibit multiple TCS due to the conservation between HKs CA domains (Figure S1). 
Here we describe the step-wise application of fragment-based screenings (FBS) by 
differential scanning fluorimetry (DSF)
3
 and ligand-based similarity searches (LBSS) 
4
 
to identify HKs autophosphorylation inhibitors with antibacterial activity against 
multi-drug resistant clinical isolates (Figure 1). 
 
Figure 1. 
Histidine kinase 
autophosphoryl
ation inhibitors 
with 
antibacterial 
effect for multi-
drug resistant 
Gram-positive 
and Gram-
negative 
bacteria were 
identified by the 
following 
workflow (A): 
First, a fragment 
library was 
screened for 
ligands of both 
the CA domain 
of Synechococcus sp. PCC 7942 NblS and CA and DHp domains of Streptococcus pneumoniae 
WalK. (B) The two hits in common (F1 and F2) were used as query molecules in a ligand-
based similarity search of the National Cancer Institute Developmental Theraupeutics 
Programme Database and 19 compounds (Figure S5) were selected for experimental 
testing. (C) 5 of the 19 tested fragments and F1 inhibited S. pneumoniae WalK and E. coli 
PhoR autophosphorylation and showed an antibacterial effect against Gram-positive or 
both Gram-positive and Gram-negative bacteria (Table 1)  
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Table 1. Antibacterial activities of selected fragments for a panel of clinical isolates and 
reference strains.  
Strain MIC (µg/mL) 
F1 F1.6 F1.8 F2.3 F2.4 F2.8 
Staphylococcus aureus 
20231 25 125 125 125 250 31 
25293 125 250 250 125 125 250 
274/08 125 500 250 >500 500 250 
V4180 125 >500 250 250 500 250 
T4/6 125 250 250 250 >500 250 
145/08 125 250 250 250 250 250 
127/08 n.d 250 250 250 500 250 
S908 n.d 500 250 250 500 n.d. 
Staphylococcus epidermidis 
20044 4 500 63 31 500 31 
RP62A >500 >500 500 125 > 500 250 
RP62A/1 250 >500 250 125 n. d.  250 
T7/3 63 125 31 31 n. d.  63 
T37/8 >500 >500 500 125 n. d.  250 
T6119 >500 >500 250 125 n. d.  250 
Streptococcus suis 
3881/ S10 >500º >500 250 >500 250 125 
Streptococcus pneumoniae  
 49619 n. d.  256 128 4 64 n. d. 
Acinetobacter baumanii 
NM109 n. d.  n. d.  125 n. d.  500 n. d.  
NM124 n. d.  n. d.  125 n. d.  500 n. d.  
NM8 >500 >500 125 >500 500 >500 
NM35 n. d.  n. d.  125 n. d.  >500 n. d.  
NM75 n. d.  n. d.  250 n. d.  >500 n. d.  
Stenotrophomonas maltophilia 
B5/5 n. d.  n. d.  n. d.  n. d.  >500 n. d.  
B6/2 n. d.  n. d.  n. d.  n. d.  500 n. d.  
B32/1 >500 >500 >500 >500 500 >500 
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Table 1 (continued).  
Strain  MIC (µg/mL) 
 F1 F1.6 F1.8 F2.3 F2.4 F2.8 
Escherichia coli 
CFT 073 >500 >500 250 >500 500 63 
ATCC 25276 >500 >500 250 >500 500 500 
Klebsiella pneumoniae 
ATCC700603 >500 >500 250 >500 >500 250 
Pseudomonas aeruginosa 
ATCC 27853 >500 >500 500 >500 >500 >500 
n.d. – not tested 
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MATERIALS AND METHODS 
 
REAGENTS 
A fragment library of 898 compounds (>95% purity) was purchased from Chem-
X-Infinity (Romanville, France) and the individual compounds were stored at -80°C at 
a concentration of 20 mM. For screening purposes cocktails of 10 compounds at final 
concentrations of 2 mM were prepared in a 96-well-plate. Re-supply of compounds F2 
and F2.5 to F2.9 (Table S2) were purchased from Sigma-Aldrich (Spain). Re-supply of 
F1 was purchased from Apolo Scientific (United Kingdom). Compounds F1.1 to F1.10 
and F2.1 to F2.3 (Table S2) were obtained from Developmental Therapeutics program 
of the National Cancer Institute and the National Institute of Health (DTP NCI/NIH). 
γ-32P-ATP was purchased from Perkin Elmer. 
 
CLONING, EXPRESSION AND PURIFICATION  
S. pneumoniae walK encoding the catalytic portion (DHp and CA domain) of 
WalK (amino acids from 208 to 449) was amplified by PCR from S. pneumoniae 
CDC3059-06 genomic DNA using the following primers: forward 5´-
aagttctgtttcagggcccgatggagcaggagaaggaagaacgc-3´ and reverse 5´-
atggtctagaaagctctagtcttctacttcatccac-3´. The PCR product was purified by PCR product 
purification kit (Macherey-Nagel) and cloned into a gel-purified pOpinF vector 
(kindly provided by Nick Berow, IRB, Spain) linearized with KpnI and HindIII 
(Fermentas). The insert was cloned into the pOpinF vector with InFusion HD cloning 
system (Clontech). Positive clones were confirmed by colony PCR and DNA 
sequencing. 
 S. pneumoniae WalK (WalK) was expressed in E. coli RIL. Luria Broth (LB) 
media supplemented with 100 µg/mL ampicillin and 33 µg/mL chloramphenicol was 
inoculated with an overnight pre-culture (1/50 of the culture volume). At exponential 
phase (OD600 0.2 – 0.4) protein expression was induced by addition of 1 mM IPTG for 
3 to 5 h at 37°C. The cells were harvested by centrifugation at 4000 g, 4°C for 25 min 
and the pellets were stored at -80°C until use. The cell pellets were resuspended in 
lysis buffer (100 mM Tris pH 8.0, 150 mM NaCl, 0.1 mM PMSF) and sonicated at 
4°C for 5 min at pulses of 15 sec every 1 minute The cell debris and the supernatant 
were separated by centrifugation at 11 000 g, 4°C for 60 min. The cell debris were 
resuspended in equilibration buffer (100 mM Tris pH 8.0, 150 mM NaCl) containing 
2M urea and incubated overnight at 4°C with rotation. After centrifugation at 11 000 
g, the supernatant was injected into a Ni-affinity chromatography column (GE 
Healthcare) equilibrated with equilibration buffer, washed with 5 volumes of 
equilibration buffer and eluted with equilibration buffer containing 0.5 M imidazole. 
WalK was concentrated with AmiconUltra (Millipore, USA) centrifugal filters, 
aliquoted and stored at –80°C until use. The yield was ≤ 0.5 mg/L culture.  
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The catalytic portion (DHp and CA domain) of E. coli PhoR (PhoR
E
), E. coli 
EnvZ, and S. aureus PhoR, and the CA domain of Synechococcus sp. PCC 7942 NblS 
were expressed and purified as previously described 
5, 6, 7, 8
. Shortly, proteins were 
expressed in E. coli RIL and purified by Ni-affinity and size-exclusion 
chromatography.   
Purified proteins were stored in 20 – 50 μl aliquots at -80°C.  
 
DIFFERENTIAL SCANNING FLUORIMETRY 
To monitor protein unfolding, the fluorescent dye Sypro orange was used 
9
. 
Differential scanning fluorimetry experiments (DSF) were conducted in the iCycleriQ 
Real Time Detection System (Bio-Rad, Hercules, CA). Solutions of 20 µl of 0.1 
mg/mL protein (final concentration), 200 µM fragment cocktails or individual 
fragments (final concentration), 10X sypro orange (final concentration) and buffer 
(100 mM TrisCl pH 8, 150 mM NaCl) were added to the wells of the 96-well iCycler 
iQ PCR plate. The plate was heated from 20 to 85 or 99 ºC at a heating rate of 1 
ºC/min. The fluorescent intensity was measured with Ex/Em: 490/530 nm. Prism 
GraphPad was used for curve fitting and statistical analysis 
10
. 
 
KINASE ASSAY 
To evaluate the inhibitory capacity of selected hits from DSF and LBSS in vitro 
autophosphorylation kinase assays with γ-32P-ATP was performed as previously 
described 
11
. Ligands were dissolved in 100% DMSO. When comparing the inhibitory 
capacity of ligands in one concentration-one time point experiments or when 
measuring IC50 (the concentration at which 50% residual HK autophosphorylation 
activity is observed), the final DMSO concentration in the assay was 10% (v/v). 
Controls lacking ligands contained an equal concentration of DMSO. Inhibition of 
autophosphorylation was determined by incubating 0,12 mg/mL ( ≈ 4 µM) HK and up 
to 20 mM fragment in kinase buffer (50 mM Tris HCl, pH 8.5, 50 mM KCl, 5 mM 
MgCl2, 0.5 mM EDTA and 0.1 mM DTT). Autophosporylation reactions were 
initiated by addition of 0.1 µCi/µl γ-32P-ATP containing from 0.03 to 0.06 µM ATP 
(final concentrations). Autophosphorylation was quenched with 2xSDS-PAGE sample 
buffer supplemented with 50 mM EDTA. Samples were applied without heating to 
15% (w/v) Tris-glycine SDS-polyacrylamide gels. After electrophoresis, the bottoms 
of the gels were removed to lower the background from the unincorporated 
radiolabeled ATP. Gels were dried without staining on a Bio-Rad Gel Air drying 
system and the phosphorylated protein was quantified by phosphor-imaging. Prism 
GraphPad was used for curve fitting and statistical analysis 
10
. 
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AGGREGATION ANALYSIS BY NATIVE POLYACRYLAMIDE GEL 
ELECTROPHORESIS 
E. coli PhoR and EnvZ, and S. aureus PhoR (0.12 µg/mL, final concentration) 
were prepared in kinase buffer. F1 and F2 were added to a final concentration of 2 
mM. DMSO in the assays was maintained to a final concentration 10% (v/v). After 30 
min of incubation at room temperature native polyacrylamide gel electrophoresis 
(native-PAGE) loading buffer was added and samples loaded. Coomassie blue staining 
was used for protein visualization.  
 
LIGAND-BASED SIMILARITY SEARCH 
The database from the National Cancer Institute (NCI) was searched for 
analogous structures of the F1 and F2 as query molecules; the similarity search was 
performed using the Morgan fingerprint as implemented in RDKit 
12
, which is a 
variation of the ECFP “extended connectivity fingerprints” 4, 13. The top 100 
compounds of each similarity search were visually inspected of which in total 14 
compounds were selected and experimentally tested.  
ANTIBACTERIAL SUSCEPTIBILITY TESTING  
Bacterial strains used in this study for antibacterial susceptibility testing (Table 
S3, Chapter 1) were propagated using standard microbiological procedures. Minimal 
inhibitory concentrations (MICs) were determined following a standard double-
dilution method 
14, 15
. MICs were recorded as the lowest concentration of the 
compound where no visible growth was observed. After plating the dilutions around 
the MIC or growing them in fresh MH media, minimal bactericidal concentration 
(MBC) was recorded as the lowest concentration of the compound at which no 
colonies were formed or no growth was observed, respectively. For S. pneumoniae 
MICs were determined by adapting  the standard double-dilution method to anaerobic 
conditions and of this microorganism (use of Todd Hewitt Yeast extract with 
200U/mL of catalase and continuous monitoring of growth) 
15
. MBCs for S. 
pneumoniae were determined by inoculation of 10 µl from each well that did not 
shown visible bacterial growth on THY 0,5% 3% blood agar plates. After 24 h of 
incubation at 37°C 5% CO2, the first dilution yielding three colonies or fewer was 
scored as the MBC, as described by the CLSI for starting inoculate of 1 x 105 
CFU/mL 
16
. 
 
HEMOLYSIS ASSAY 
Hemolytic activity against human erythrocytes taken from a healthy donor was 
measured as previously described 
17
. Erythrocytes were incubated with (up to) 500 
µg/mL compounds and the LC50 value was recorded as the mean concentration of 
compound producing 50% hemolysis in three independent incubations. 
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BINDING MODE PREDICTION  
Docking calculations to predict the binding modes of the reported fragments were 
performed using the ATP-binding domain of HK853CD (PDB: 3DGE, chain A, 
residues from 270 to 415) and the GOLD docking software 
18
. For each ligand 100 
solutions were generated of which the top 20 were visually inspected. In Figure 2 the 
dominant binding mode within the top 20 solutions is shown for the respective ligand.  
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RESULTS AND DISCUSSION 
 
To identify fragment-like ligands (MW < 300, ClogP < 3, number of hydrogen 
bond donors and hydrogen bond acceptors < 3, number of rotatable bonds < 3 
19
) of 
the CA domains of HKs we used the Chem-X-Infinity library (Chem-X-Infinity, 
Romanville, France) comprising 898 fragments and differential scanning fluorimetry 
(DSF) as screening method 
3
. As targets, we selected the HKs of two essential TCS, 
WalK-WalR of Streptococcus pneumoniae and NblS-RapB of Synechococcus sp. PCC 
7942 The presence of 4-(4-bromophenyl)-1,3-thiazol-2-amine (F1) and 2-hydroxy-
carbazole (F2) increased the temperature at which HK NblS (CA domain) unfolds 
(Tm) by 2.1 and 2.2 °C, respectively, suggesting both F1 and F2 are ligands for the 
CA domain of NblS. Encouragingly, the screening for ligands of HK WalK (DHp and 
CA domain) showed that F1 and F2 were also among the hits increasing WalK Tm. F1 
and F2 increased WalK Tm by 4.5 and 3.9 °C, respectively (Figure S2). Furthermore, 
in vitro kinase assays with γ-32P-ATP showed that F1 and F2 inhibited the 
autophosphorylation of the screened catalytic portion of WalK. In addition, these 
compounds also inhibited the autophosphorylation of PhoR from the Gram-negative 
Escherichia coli (PhoR
E
, Figure S3), suggesting a general HK inhibitory activity for 
F1 and F2. 
Compound library screens have previously identified non-drug like inhibitors of 
HK autophosphorylation with an unspecific mechanism of action due to protein 
aggregation
20
. However, even at high concentrations (up to 2 mM) F1 and F2 did not 
cause protein aggregation of the catalytic portions (DHp and CA domains) of E. coli 
PhoR, E. coli EnvZ or S. aureus PhoR as determined by native polyacrylamide gel 
electrophoresis (Figure S4).  
In an attempt to identify more potent HK autophosphorylation inhibitors than F1 
and F2, LBSS were performed using the Morgan fingerprint as implemented in 
RDKit
4,7
, the National Cancer Institute Developmental Therapeutics Programme 
database (NCI/DTP) and F1 and F2 as query molecules. From the LBSS 14 
compounds were selected plus 5 additional substituted carbazoles similar to F2, to a 
final pool of 19 compounds (Figure S5) that was evaluated for WalK and PhoR
E
 
autophosphorylation inhibitory activity and antibacterial effect in vitro.  
WalK and PhoR
E
 kinase assays with γ-32P-ATP and the 19 compounds at one 
concentration (2 mM) and one time point (30 sec) showed that the fragments inhibited 
WalK and PhoR
E
 autophosphorylation activity compared to the negative control from 
11 to 62% and 17 to 80%, respectively (Figure S3A). Only F1.6 inhibited WalK 
autophosphorylation by more than 50% at a concentration of 2 mM meaning that the 
remaining 18 of the tested compounds are weak (Ki >> 2 mM) WalK 
autophosporylation inhibitors. Inhibition of PhoR
E
 autophosphorylation was greater 
than 50% for F1, F1.8, F2, F2.1, F2.2, F2.8 and F2.9 meaning that the remaining 12 of 
the tested compounds are weak PhoR
E
 autophosphorylation inhibitors. The IC50 of the 
active compounds (F2.2. and F2.9 were excluded since they did not show antibacterial 
effect, see below) were measured in a multiple concentrations one time point (30 sec) 
PhoR
E
 kinase assays (Table 1, Figure S3B). F1 and F1.8 inhibited PhoR
E
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autophosphorylation with IC50 ≈ 2 mM and ≤ 1 mM, respectively, and the two 
compounds were not soluble in kinase buffer in the presence of 10% DMSO at 
concentrations higher than 1 mM (Table 1, Figure S3B). F2 and F2.1 inhibited PhoR
E
 
autophosphorylation with IC50 values of 0.3 and 0.24 mM, respectively, and F2.8 
inhibited PhoR
E
 autophosphorylation with an IC50 value of 0.72 mM (Table 1, Figure 
S2B). F2, F2.1 and F2.8 showed good solubility in kinase buffer in the presence of 
10% DMSO. 
The antibacterial effect of the 19 selected compounds was first studied by 
determining their minimal inhibitory concentrations (MICs) by standard micro-
dilution antibacterial susceptibility testing
21
 for two Gram-positive (Staphylococcus 
aureus DSM 20231 and Staphylococcus epidermidis DSM 20044) and one Gram-
negative (the uropathogenic E. coli CFT 073) strains (Table 1, Table S1, and Table S3, 
Chapter 1). The highest tested concentration was 500 µg/mL. F1, F1.6, F1.8, F2.3, 
F2.4 and F2.8 showed moderate antibacterial effects with MICs in the range of 31 to 
250 µg/mL for S. aureus DSM 20231 and 4 to 500 µg/mL for S. epidermidis DSM 
20044 (Table 1). Only F1.8 and F2.8 had antibacterial action on the Gram-negative E. 
coli CFT 073 with MICs < 250 µg/mL. With the exception of F2.2 and F2.9, those 
compounds showing HK autophosphorylation inhibitory activity also showed 
antibacterial activity, suggesting the possibility that the antibacterial activity might be 
mediated through the inhibition of HK autophosphorylation.  
Next, we studied the antibacterial effect of F1, F1.6, F1.8, F2.3, F2.4 and F2.8 on 
a panel of clinical isolates and reference strains of pathogenic bacteria (Table S3, 
Chapter 1). The methicillin-resistant S. aureus (MRSA) strains are well characterized 
and are resistant to all β-lactam antibiotics and a range of non-β-lactam antibiotics22. S. 
epidermidis clinical isolates were obtained from wounds of patients admitted to 
Tawam Hospital (Al Ain, United Arab Emirates). The clinical isolates of the Gram-
negative Acinetobacter baumannii 
23
 and Stenotrophomonas maltophilia 
24
 are well 
characterized and show multi-drug resistance. Additional reference strains included 
the Gram-positive S. aureus ATCC 25293, S. epidermidis RP62A and RP62A, S. 
pneumoniae 49619 and the emerging zoonotic pathogen Streptococcus suis 3881/S10, 
and the Gram-negative of E. coli ATCC 25276, Klebsiella pneumoniae ATCC 700603 
and Pseudomonas aeruoginosa ATCC 27853. 
F1 and F1.6 (halogen-substituted phenyl-thiazoleamines) showed similar 
antibacterial activities for the panel of clinical isolates and reference strains. Both F1 
and F1.6 showed antibacterial effect for the MRSA strains (with the exception of F1.6 
for V4180 MRSA strain; Table 2) and S. aureus 25293 with MICs in the range of 125 
– 500 µg/mL (Table 2). The V4180 MRSA strain is resistant to a wider range of 
antibiotics compared to the other MRSA strains tested (Table S3, Chapter 1) including 
the small molecule antibiotics chloramphenicol and sulfamethoxazole. Given the 
broad range of antibiotic resistance of V4180 MRSA it is reasonable to propose that 
the presence of putative efflux pumps for small molecules could be responsible for the 
lack of susceptibility to F1.6. F1 and F1.6 showed antibacterial effect on one of the 
three tested S. epidermidis clinical isolates with MICs of 63 and 125 µg/mL, 
respectively. F1.6 MIC for S. pneumoniae 49619 was 256 µg/mL. F1 and F1.6 did not 
show antibacterial effect on S. suis 3881/S10 or on any of the Gram-negative strains 
tested.  
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F1.8 (bromophenyl-pyrimidinediamine) showed antibacterial effect on all the 
Gram-positive strains tested. F1.8 MICs for the S. aureus reference strains and the 
MRSA strains were in the range of 125 to 250 µg/mL. F1.8 MICs for the S. 
epidermidis strains were in the range of 31 to 500 µg/mL. F1.8 MICs for S. suis 
3881/S10 and S. pneumoniae 49610 were 250 µg/mL and 128 µg/mL, respectively. 
F1.8 showed antibacterial effect for all the Gram-negative strains tested except for the 
S. maltophilia B32/1 strain. F1.8 MICs for A. baumannii strains, E. coli ATCC 25276 
and K. pneumoniae ATCC 700603 were in the range of 125 – 250 µg/mL and the MIC 
for P. aeruoginosa ATCC 27853 was 500 µg/mL. In a similar way to F1.6 with V4180 
MRSA, the lack of susceptibility of S. maltophilia B32/1 to F1.8 could be explained 
by the presence of efflux pumps. S. maltophilia B32/1 is also resistant to the small-
molecule β-lactam antibiotic, meropenem so that efflux pumps with broad substrate 
specificity may be involved
25
.  
The MICs of F2.3, F2.4 and F2.8 (substituted carbazoles) for the MRSA strains 
and S. aureus 25293 were in the range of 125 – 500 µg/mL. F2.3 and F2.8 MICs for 
the S. epidermidis strains were in the range of 31 – 250 µg/mL. F2.3 and F2.4 MICs 
for S. pneumoniae 49610 were 4 µg/mL and 64 µg/mL, respectively. F2.4 and F2.8 
MICs for S. suis 3881/S10 were 125 and 250 µg/mL, respectively. F2.3 and F2.8 did 
not show antibacterial effect for the A. baumannii and S. maltophilia strains. F2.4 
MICs for 3 of the 5 A. baumannii strains and 2 of the 3 S. maltophilia strains tested 
were 500 µg/mL. F2.4 and F2.8 MICs for E. coli ATCC 25276 were 500 µg/mL. F2.8 
MIC for K. pneumoniae ATCC 700603 was 250 µg/mL. None of F2.3, F2.4 and F2.8 
showed antibacterial effect for P. aeruginosa ATCC 27853.  
One of the side effects of previously described TCS inhibitors is membrane 
damage 
26
. To exclude this mechanism of action we performed hemolysis experiments 
with erythrocytes from a healthy donor. None of the selected inhibitors (F1, F1.6, 
F1.8, F2.3, F2.4 and F2.8) caused erythrocyte hemolysis at 500 µg/mL (LC50 > 500 
µg/mL) indicating that the inhibitors do not cause loss of integrity of the erythrocyte 
plasma membrane. 
To evaluate the cytotoxic effect of the selected fragments cell viability assays by 
neutral-red uptake by Caco-2 cells were performed. F1, F1.6, F1.8, F2.3, F2.4 or F2.8 
inhibited neutral-red uptake by Caco-2 cells with IC50 values of 294, 121, 134, 30, 51 
and 61 µg/ml, respectively, (Figure S6).  
Additionally, cytotoxicity was evaluated by 24 h incubation of 0.2, 1, 3, 13 and 50 
µg/ml of F1, F1.8, F2, F2.1, F2.3 and F2.8 with freshly isolated human peripheral 
blood mononuclear cells (PBMCs) and measurement of dead (propidium iodide (PI) 
positive) and apoptotic (annexin V (AV) positive) cells by flow cytometry. There was 
no significant difference in the number of dead cells in the control (DMSO treated) 
and inhibitors-treated samples. However, the number of cells binding annexin V, a 
marker of early apoptosis, was significantly higher in cells incubated with 50 µg/ml of 
F1.8, F2.3, and F2.8 (Figure S5) than the control cells (DMSO-treated). This is 
reflected in a reduction of viable (PI and annexin V negative) cells (Fig S5A). The 
results suggest that a concentration between 13 and 50 µg/ ml of F1.8, F2.3 and F2.8 
induces apoptosis in a proportion of the PBMCs after 24 h incubation. 
The IC50 values for neutral-red uptake by Caco-2 were mostly higher than the 
observed MICs and 24 h incubation with some of the hits (F1.8, F2.3 and F2.8) 
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induced apoptosis in human PBMCs suggesting off-target effects of the described HK 
autophosphorylation inhibitors. This requires that the further optimization of the hits 
should be multidirectional, including improving the affinity and specificity to the 
target bacterial HKs, enhancing the antibacterial effect and improving the toxicity 
profile of the hits. 
To get insights into the putative interaction mode of the described HK 
autophosphorylation inhibitors with the CA domains of HKs, molecular docking 
experiments were performed. F1, F1.6, F1.8, F2.3, F2.4, F2.8 and ADP as an internal 
control were docked to the CA domain of T. maritima HK853 (PDB: 3DGE) using the 
GOLD docking software 
18
. The root-mean square deviation (RMSD) between the 
docked ADP and the cognate ADP structure in the KH853 was 1.0 Å. This 
corresponds to a successful redocking calculation and, therefore, validates the used 
docking parameters. Due to low molecular weight of the fragments, it is possible that 
the fragments possess more than one binding mode. Encouragingly, within the top 20 
solutions for each fragment only one or two binding modes were predicted and the 
predicted binding modes of similar fragments were consistent with each other. This 
together with the low RMSD for the docked ADP gave us confidence about the 
predicted binding modes of the studied fragments.  
The predicted binding modes of the studied fragments resemble the binding mode 
of the cognate ligand, ADP (Figure 2), by forming also stabilizing hydrogen bonds 
with the conserved Asp411 (located at the bottom of the hydrophobic ATP-binding 
pocket in the so called G1 box) as well as with the ATP-lid (i.e. Ile424, Tyr429 and 
Arg430): All six fragments form hydrogen bonds with Asp411 either by classical 
hydrogen bond donor groups such as NH2 or OH (F1.6, F2.8) or by other polar groups 
such as Br and CH (F1, F1.8, F2.3, F2.4). The ATP-lid interacts by hydrogen bonds 
with four of the six compounds (F1, F1.8, F2.3, F2.4). The ATP-lid is a HK distinctive 
flexible and variable loop that covers the ATP-binding pocket and is crucially 
involved in nucleotide binding and in autophosphorylation reactions 
6, 27
. Overall, the 
predicted binding modes indicate that stabilizing interactions are formed by all six 
fragments with binding siteresidues that are conserved and crucial for 
autophosphorylation. This supports the in vitro results and suggests that the fragments 
might also inhibit further HKs not tested in this study.  
 
CONCLUSIONS 
 
In conclusion, by combining fragment-screenings by differential scanning 
fluorimetry and ligand-based similarity searches of a public repository database we 
identified multiple HK autophosphorylation inhibitors with antibacterial effect against 
Gram-positive and Gram-negative pathogens including multidrug resistant clinical 
isolates. The reported inhibitors present a promising starting point for the rational 
design of more potent HK general or specific inhibitors and the discovery of 
antibacterials with improved physicochemical and ADMET properties. 
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Figure 2. Predicted binding modes of selected fragments to the CA domain of T. maritima 
HK853 (PDB: 3DGE)15. The predicted binding modes indicate that these fragments form 
stabilizing hydrogen bonds with conserved elements of the CA domain of HKs represented 
by T. maritima HK853. The formed interactions include the D411 which also forms 
interactions with the adenine of the natural ligand ADP. Fragments interact as well with 
residues of the G1 box of the ATP-lid which are crucial for ligand binding and recognition. 
The binding modes are visualized with MOE 28. The sequence alignment in the upper right 
corner demonstrates that the binding sites residues Ile424, Tyr429, and Asp411, are 
conserved in HKs suggesting that the compounds might also bind to other HKs not tested 
in this study. 
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Figure S1. The ATP-binding site of 
HK CA domain is a well-defined and 
highly conserved pocket and allows 
the discovery and design of HK 
autophosphorylation inhibitors 
with broad-spectrum antibacterial 
activity following structure-based 
approaches A) Structure of B. 
subtilis WalK CA domain (PDB: 
3SL2). The conserved N-, G1- and 
G2-boxes are shown in red, blue 
and green, respectively. The 
variable ATP-lid is shown in pink. 
B) B. subtilis WalK CA domain 
(PDB:3SL2) coloured by 
conservation . The conservation 
scores were calculated using 
ConSurf 30. The ATP-binding pocket 
was calculated using PyMol 31 and is 
shown as a semi-transparent 
yellow surface. ATP is shown in 
ball-and-stick representation with 
carbon, nitrogen, oxygen and 
phosphate atoms in yellow, blue, 
red and orange, respectively. C) 
Alignment of WalK CA domains 
from different organisms D) 
Alignment of the CA domains of 
different E. coli HKs 
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Figure S2. Identification of F1 (D4.1) and 
F2 (G5.9) as putative CA ligands by DSF. 
The fragment-library was divided in 
cocktails of ten fragments, each at a final 
concentration of 2 mM in a 96-well plates. 
Each plate included negative controls 
(DMSO) and positive-control (ADP, ATP, 
AMP-PNP). A) The individual compounds 
from the cocktails which increased the Tm 
of NblS (A) and the Tm of WalK (D) were 
tested. F1 (D4.1) and F2 (G5.9) were 
identified as the compounds present in the 
D4 and G5 cocktails that most likely caused 
the observed increase of NblS and WalK 
Tm (B, C, E, F).  
 
 
 
 
 
 
 
Figure S3. Biochemical evaluation by in 
vitro kinase assay A) First, the 
autophosphorylation inhibitory activity 
was evaluated in a one concentration 
(2mM) one time-point (30 sec) in vitro 
kinase assays with WalK and PhoRE. The 
fragments inhibited WalK and PhoRE 
autophosphorylation with 10 to 62% and 
17 to 80%, respectively. B) IC50 of the 
more potent inhibitors (% inhibition at 2 
mM > 50 %) with antibacterial effect were 
measured in a multiple-concentrations one 
time-point (30 sec) experiments. 
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Figure S4. F1 and F2 (2 mM) do not cause HKs 
aggregation as demonstrated by native-PAGE with E. 
coli PhoR and EnvZ, and S. aureus PhoR.  
 
 
 
 
 
 
 
Figure S5. Selected fragments for 
experimental testing. F1 and F2 
were identified as hits in a 
screening for ligands of both the 
CA domain of NblS and the CA 
and DHp domain of WalK. F1.1 to 
F1.10 and F2.1 to F2.4 were 
identified by ligand-based 
similarity searches of the 
National Cancer Institute 
Developmental Therapeutics 
Programme database using F1 
and F2 as query molecules. 
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Figure S6. Cell viability assessed by neutral-red uptake assays with Caco-2 cell line. The 
error bars represent the SEM of at least two independent experiments in duplicate. IC50 is 
the concentration corresponding to 50% reduction of neutral-red uptake by Caco-2 cells.  
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Figure S7. Dose effect of identified inhibitors on PBMCs viability (A) and apoptosis 
evaluated by propidioum iodide and annexin V (AV) staining. 50 µg/ml of F1.8 (C) and F2.3 
(E), F2.8 (F) induce stronger expression of the early apoptotic marker AV compared to the 
control (0 µg/ml, DMSO-treated PBMCs) which is reflected in reduction of the live cells (A) 
with around or more than 50% compared to the control (DMSO-treated PBMCs). Error 
bars represent SEM for three independent donors. 
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Table S1. Autophosphorylation inhibitory activities and antibacterial activities of the 
tested compounds. 
 IC50 [mM] MIC [µg/ml] MBC [µg/ml] 
name PhoRE WalK 
S. 
aureus 
S. 
epidermidis E. coli 
S. 
aureus 
S. 
epidermidis E. coli 
   
DSM 
20231 
DSM 
20044 
CFT 
073 
DSM 
20231 
DSM 
20044 
CFT 
073 
F1  ≈ 2 > 2 25 4 >500 >500 250 n.d. 
F1.1 > 2 > 2 500 >500 500 >500 n.d >500 
F1.2 > 2 > 2 >500 >500 >500 n.d. n.d n.d. 
F1.3 > 2 > 2 >500 500 >500 n.d. 500 n.d. 
F1.4 > 2 > 2 >500 >500 >500 n.d. n.d n.d. 
F1.5 > 2 > 2 >500 >500 >500 n.d. n.d n.d. 
F1.6 > 2 < 2 125 500 >500 250 500 n.d. 
F1.7 > 2 > 2 >500 >500 >500 n.d. n.d n.d. 
F1.8 ≤ 1 > 2 125 63 250 250 125 500 
F1.9 > 2 > 2 >500 >500 >500 n.d. n.d n.d. 
F1.10 > 2 > 2 >500 >500 >500 n.d. n.d n.d. 
F2  0.3 > 2 31 >500 >500 >500 n.d. n.d. 
F2.4 > 2 > 2 250 500 500 250 500 500 
F2.1 0.24 > 2 8 >500 >500 >500 n.d. n.d. 
F2.2 < 2 > 2 >500 >500 >500 n.d. n.d. n.d. 
F2.3 > 2 > 2 125 31 >500 >500 63 n.d. 
F2.5 > 2 > 2 >500 >500 >500 n.d. n.d. n.d. 
F2.6 > 2 > 2 >500 >500 >500 n.d. n.d. 500 
F2.7 > 2 > 2 500 >500 500 >500 n.d. n.d. 
F2.8 0.72 > 2 31 31 63 63 250 500 
F2.9 < 2 > 2 >500 >500 >500 >500 n.d. n.d. 
n.d. – not tested 
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Table S2. Compounds purchased for experimental testing. 
Name Providers name Smile 
F1 (D4.1) OR5604 NC1=NC(=CS1)C2=CC=C(Br)C=C2 
F1.1 NSC 405294 NC1=NC(=CS1)C2=CC=C(O)C=C2 
F1.2 NSC 372682 NC1=NC(=CS1)C2=CC=C(Cl)C=C2 
F1.3 NSC 54436 CC1=CC=C(C=C1)C2=CSC(=N2)N 
F1.4 NSC 176404 NC1=NC=C(S1)C2=CC=C(Br)C=C2 
F1.5 NSC 614448 NC1=NN=C(O1)C2=CC=C(Br)C=C2 
F1.6 NSC 13534 NC1=NC(=CS1)C2=C(Cl)C=CC=C2 
F1.7 NSC 223276 BrC1=CC=C(C=C1)C2=CSC3=NCCN23 
F1.8 NSC 80819 NC1=NC(=CC=N1)NC2=CC=C(Br)C=C2 
F1.9 NSC 329206 COC1=C(OC)C=C(C=C1)C2=CSC(=N2)N 
F1.10 NSC 206952 CC(C)(C)C1=CC=C(OCC2=C[NH]C=N2)C=C1 
F2 (G5.9) 213497 ALDRICH OC1=CC2=C(C=C1)C3=CC=CC=C3[NH]2 
F2.4 NSC 305336 CC(C)NCC(O)COC1=C2C(=CC=C1)[NH]C3=CC=CC=C23 
F2.1 NSC 171107 NC1=CC2=C(C=C1)C3=CC=CC=C3[NH]2 
F2.2 NSC 402750 OC1=CC2=C([NH]C3=C(C=CC=C3)[C]2=O)C=C1 
F2.3 NSC 106510 NCCC1=CC2=C(C=C1)C3=CC=CC=C3[NH]2 
F2.5 C5132 SIGMA [NH]1C2=CC=CC=C2C3=CC=CC=C13 
F2.6 325325 ALDRICH C[N]1C2=CC=CC=C2C3=CC=CC=C13 
F2.7 I3408 ALDRICH [NH]1C=CC2=CC=CC=C12 
F2.8 543896 ALDRICH OC1=CC=CC2=C1C3=CC=CC=C3[NH]2 
F2.9 754781 ALDRICH CCC1=CC2=C([NH]C3=CC=CC=C23)C=C1 
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ABBREVIATIONS 
 
Gr- Gram negative 
Gr+ Gram positive 
TCS Two-component systems 
HK Histidine kinase 
RR Response regulator 
HKAI Histidine-kinase autophosphorylation inhibitor 
f n-[(3-trimethoxysilyl)propyl]ethylendiamine triacetic acid trisodium salt 
ePLL ε-poly-L-lysine  
N.X MCM-41 funcionalized with n-[(3-trimethoxysilyl)propyl]ethylendiamine 
triacetic acid trisodium salt and capped ε-poly-L-lysine (ePLL) cationic polymer and 
loaded with: 
N.Van – vancomycin 
N.HKAIs – histidine kinase autophosphorylation inhibitors 
N.Rho – rhodamine 
F.HKAIs – free histidine kinase autophosphorylation inhibitors  
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INTRODUCTION 
 
Infections caused by Gram negative (Gr-) multidrug-resistant (MDR) bacteria 
have become a growing challenge worldwide 
1
. The most important resistance 
problems are encountered in Enterobacteriaceae, Pseudomonas aeruginosa and 
Acinetobacter spp. which have developed resistance to last-line antibiotics such as 
expanded-spectrum cephalosporins and/ or carbapenems 
2
. Urinary tract infections 
(UTIs) caused by Gr- uropathogenic Escherichia coli (UPEC) are among the most 
common bacterial infections in humans. Recently multi-drug resistant E. coli have 
been reported 
3, 4, 5
. 
Most of the bacterial infections in fish are caused by Gr- bacteria, including 
Aeromonas hydrophilia, Aeromonas salmonicida, Flavobacterium columnare, Vibrio, 
and Pseudomonas spp. 
6
. Currently antimicrobials are routinely used to directly control 
bacterial infections in pet (ornamental) fish and are added to the water these fish are 
shipped in to suppress the growth of potential pathogens during transport 
7
. However, 
this activity has led to high prevalence of multi-drug tolerant or resistant bacteria and 
associated antimicrobial resistance genes both in ornamental fish and their carriage 
water 
7
. This might present a potential health risk as studies have suggested that there 
is bi-directional transfer of resistance genes between aquatic and other Animalia as 
evidenced by the fact that antimicrobial resistance (AMR) genes of bacteria recovered 
from the aquatic environment can share very high sequence homology to clinically 
important AMR genes on plasmids and integrons found in clinical isolates of human 
pathogens 
8 , 9, 10, 11 , 12 
. The transmission of zoonotic multidrug resistant Gr- bacteria 
between food-producing animals and humans and between companion animals and 
humans has also been reported 
13 , 14, 15
. 
Therefore, novel strategies to target infections caused by Gr- bacteria are urgently 
needed. Two-component systems (TCS) are signal transduction systems found in 
nearly all bacteria and have been proposed as promising antibacterial drugs targets for 
both Gram positive (Gr+) and Gr- infections 
16, 17, 18
. A prototypical TCS consist of 
membrane bound histidine kinase (HK) and its cognate response regulator (RR) 
19
. 
Upon environmental stimuli the catalytic and ATP-binding (CA) domain of the HK 
autophosphorylates a conserved histidine found within the dimerization and histidine 
phosphotransfer (DHp) domain, which subsequently serves as the phosphodonor for a 
cognate RR 
19
. Many HKs are bi-functional and also dephosphorylate their cognate 
response regulator 
20, 21
. The changes in the phosphorylation levels of the RR are 
usually related to changes of the expression of target genes involved in the regulation 
of variety of processes including growth, virulence, antibacterial resistance and 
adaptation to environmental changes 
22, 23, 16
. Following structure-based and fragment-
based drug discovery approaches (Chapter 2 and 3), bacterial histidine kinase 
autophosphorylation inhibitors (HKAIs) were identified (Figure 1). The HKAIs 
inhibited the autophosphorylation of HKs from both Gr+ and Gr- bacteria, including 
E. coli PhoR. PhoR belongs to the PhoR-PhoB TCS, which is involved in the 
regulation of the pho regulon. The pho regulon is not only a regulatory circuit of 
phosphate homeostasis but also plays an important adaptive role in stress response and 
bacterial virulence. 
24, 25, 26
. Despite the fact that the HKAIs inhibited 
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autophosphorylation of HKs from Gr- bacteria, they showed only moderate to strong 
antibacterial activity against Gr+ bacteria and not against Gr- bacteria. This was 
anticipated to be a consequence of the permeability barrier provided by the outer 
membrane (OM) of Gr- negative bacteria, which are inherently resistant to many 
hydrophobic antibiotics 
27, 28
. This resistance limits the arsenal of antibiotics that are 
effective in treating Gr-negative bacterial infections. To overcome this problem 
several compounds have been used to facilitate permeability of the OM and sensitize 
Gr- bacteria to hydrophobic antibiotics 
29, 30
. These compounds are typically cationic, 
amphiphilic molecules that can be prepared from peptides or steroids. Nanotechnology 
has also been proposed and exploited in addressing the problem related to Gr- 
membrane permeability 
31
.  
A nanodevice loaded with vancomycin was shown to possess antibacterial activity 
against a range of Gr- bacteria including E. coli (DH5α, 100, 405), Salmonella 
typhimurium and Erwinia carotovora 
32
. The device consisted of a nanometric 
mesoporous MCM-41 phase (ca. 100 nM; MCM-41) loaded with vancomycin, 
functionalized with n-[(3-trimethoxysilyl)propyl]ethylendiamine triacetic acid 
trisodium salt (f) and capped with a cationic polymer of ε-poly-L-lysine (ePLL), 
referred to here as N.Van. Vancomycin is glycopeptide antibiotic that selectively 
targets Gr+ bacteria 
33
. Most Gr- bacteria are intrinsically resistant to vancomycin due 
to its relatively high molecular weight and size and inability to pass through porins in 
the OM of Gr-.bacteria. Capping the NPs with polycationic ePLL is anticipated to 
promote ionic bonding with the negatively charged OM and facilitate permeability or 
antibacterial effects of the inhibitor through its disruptive effects on the bacterial 
membrane 
34
. Indeed, N.Van broadened the spectrum of vancomycin and enhanced the 
efficacy of ePLL 
32
.  
Here we employed a similar approach to N.Van 
32
 to investigate the potential to 
deliver novel HKAIs to Gr- bacteria. Silica-based nanoparticles were synthesized, 
loaded with HKAIs and capped with ePLL, referred here as N.HKAIs. The 
antibacterial effect of N.HKAIs against Gr- bacteria in vitro was studied against a 
range of Gr- bacteria. To facilitate the potential clinical translation of these 
nanomedicines we tested their potential cytotoxicity using epithelial and immune cells, 
as well as their possible immunotoxicity to macrophages, which are crucial for 
immune defence against pathogens. Furthermore, we evaluated the uptake of the 
nanoparticles in zebrafish models.  
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MATERIALS AND METHODS 
 
CHEMICALS 
The chemicals tetraethylorthosilicate (TEOS) (98 %), n-cetyltrimethylammonium 
bromide (CTAB) (≥99 %), sodium hydroxide (≥98 %), and rhodamide B were 
provided by Aldrich. ε-poly-L-lysine (ePLL) was purchased from Chengdu Jinkai 
Biology Engineering Co. Ltd. N-[(3-Trimethoxysilyl)propyl]ethylendiamine triacetic 
acid trisodium salt was purchased from FluoroChem. Na2HPO4·7H2O, KH2PO4, NaCl, 
NH4Cl, MgSO4, glucose and CaCl2 where purchased from Scharlab (used for the 
preparation of M9 minimal medium). All reagents were used as received.  
Histidine kinase autophosphorylation inhibitors (HKAIs; Table S1, Figure 1) were 
obtained from the National Cancer Institute Developmental Therapeutics Programme 
(NCI/DTP).  
 
GENERAL TECHNIQUES 
Powder XRD, TG analysis, elemental analysis, TEM and N2 adsorption-
desorption techniques were employed to characterize the prepared materials as 
previously described 
32
. Powder X-ray diffraction measurements were performed on a 
Philips D8 Advance diffractometer using Cu K radiation. Thermo-gravimetric analysis 
were carried out on a TGA/SDTA 851e Mettler Toledo balance, using an oxidant 
atmosphere (air, 80 mL/min) with a heating program consisting on a heating ramp of 
10⁰C per minute from 393 to 1273 K and an isothermal heating step at this 
temperature for 30 minutes. Elemental analysis was performed in a CE Instrument EA-
1110 CHN Elemental Analyzer. TEM images were obtained with a 100 kV Jeol JEM-
1010 microscope. N2 adsorption-desorption isotherms were recorded on a 
Micromeritics ASAP2010 automated sorption analyser. The samples were degassed at 
120⁰C in vacuum overnight. The specific surface areas were calculated from the 
adsorption data in the low pressures range using the BET model.  
 
SYNTHESIS OF THE MESOPOROUS SILICA SUPPORT 
The starting nanoparticulated MCM-41 mesoporous solid was prepared following 
well-known procedures using n-cetyltrimethylammonium bromide (CTAB) as 
template and tetraethylorthosilicate (TEOS) as hydrolytic inorganic precursor 
32
. N-
cetyltrimethylammonium bromide (CTAB, 1.00 g, 2.74 mmol) was first dissolved in 
480 mL of deionised water. Then 3.5 mL of NaOH 2.00 M in deionised water were 
added to the CTAB solution. The solution temperature was adjusted to 80°C. TEOS 
(5.00 mL, 2.57 x 10
-2 
mol) was then added dropwise to the surfactant solution. The 
mixture was stirred for 2 h to give a white precipitate. Finally, the solid product was 
centrifuged, washed with deionised water and ethanol, and was dried at 60°C (MCM-
41 as-synthesised). To prepare the final porous material (MCM-41), the as-synthesised 
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solid was calcined at 550°C using an oxidant atmosphere for 5 h in order to remove 
the template phase. 
 
SYNTHESIS OF MESOPOROUS SILICA-BASED NANOPARTICLES LOADED 
WITH RHODAMINE AND CAPPED WITH Ε-POLY-L-LYSINE (N.RHO) 
The material designed and synthesized in our previous work 
32
, (named in the 
current paper as N.Rho) was used as control solid in some of the experiments. It 
consisted on MCM-41 silica nanoparticles loaded with the Rhodamine B dye and 
externally functionalized with N-[(3-Trimethoxysilyl)propyl]ethylendiamine triacetic 
acid trisodium salt (f) and ε-poly-L-lysine (ePLL).  
 
SYNTHESIS OF Ε-POLY-L-LYSINE CAPPED MESOPOROUS 
NANOPARTICLES LOADED WITH HISTIDINE-KINASE 
AUTOPHOSPHORYLATION INHIBITORS (N.HKAIS) 
ε-poly-L-lysine capped mesoporous nanoparticles loaded with histidine-kinase 
autophosphorylation inhibitors (N.HKAIs; N.B2, N.B11, N.B13, N.B14, N.B15, 
N.F1.8, N.F2.3) were obtained essentially as previously reported
 32
. The solids 
N.HKAIs consist of mesoporous nanoparticles loaded with the free HKAIs (F.HKAIs; 
F.B2, F.B11, F.B13, F.B14, F.B15, F.F1.8 and F.F2.3; Table S1), externally 
functionalized with N-[(3-Trimethoxysilyl)propyl]ethylendiamine triacetic acid 
trisodium salt (f) and capped with ε-poly-L-lysine (ePLL). In a typical synthesis, 100 
mg (except for NB.11 where 30 mg was used) of the template-free MCM-41 was 
suspended in solution containing the corresponding antibacterial derivative. F.B13, 
F.B14 and F.F1.8 (corresponding to N.B13, N.B14, N.F1.8 final solids loading) were 
dis-solved in DMSO. The rest of the F.HKAIs (F.B2, F.B7, F.B11, F.B15, F.F2.3) 
were dis-solved in H2O:2DMSO. After stirring at room temperature for 24 h, an excess 
(15 mmol/g MCM-41) of N-[(3-Trimethoxysilyl)propyl]ethylendiamine triacetic acid 
trisodium salt (f) was added and the mixture stirred for 12 h at room temperature. 
After that, the solid was centrifuged and washed with 1mL of water. Then, the solids 
were dried under vacuum. In a second step, the pre-functionalized solid was suspended 
in a solution containing ε-poly-L-lysine in M9 minimal medium (1.8 mL/100mg of 
prefunctionalized solid of a 0.033M ε-poly-L-lysine solution). This suspension was 
stirred for 1 h at room temperature. Finally, each solid was filtered and washed once 
by centrifugation with 1 mL of M9 medium. The final solids were labelled as N.B2, 
N.B11, N.B13, N.B14, N.B15, N.F1.8 and N.F2.3 and were dried under vacuum for 12 
h.  
 
BACTERIAL STRAINS 
Escherichia coli CFT 073, E. coli DH5α and S. marcescens 21639 were obtained 
from Leibniz Institute DSMZ – German Collections of Microorganisms and Cell 
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Cultures (Braunschweig, Germany) and were propagated using standard 
microbiological procedures.  
 
ANTIMICROBIAL SUSCEPTIBILITY TESTING 
Minimal inhibitory concentrations (MICs) of MCM-41, N.Rho, ε-poly-L-lysine 
(ePLL), N.HKAIs (N.B2, N.B7, N.B11, N.B13, N.B14, N.B15, N.F1.8 and N.F2.3), 
and F.HKAIs (F.B2, F.B7, F.B11, F.B13, F.B14, F.B15, F.F1.8 and F.F2.3) were 
determined using a standard double dilution method 
35, 36, 37
. Antimicrobial 
susceptibility testing was performed with inoculum of 1.10
5 – 1.106 CFU/ml. N.HKAIs 
were suspended in water and Mueller Hinton (MH) broth (1:1) to concentration 
corresponding to 1.10
5
 µg/ml (N.B2, N.B7, N.B11, N.B13, N.B14, N.B15) or 2.5x10
4
 
µg/ml (N.F1.8 and N.F2.3) F.HKAIs and sonicated until obtaining homogenous 
suspension. The suspensions were serially diluted in MH broth in 96-well plates. The 
MIC was recorded as the lowest concentration where no visible growth was observed. 
Minimal bactericidal concentrations (MBCs) were determined by plating 10 µl of the 
wells where no growth was observed on MH agar plates and incubating overnight at 
37 °C or by inoculating 90 µl MH broth with 10 µl of the wells where no growth was 
observed. MBC was recorded as the lowest concentration where no colonies were 
formed or no visible growth was observed after overnight incubation at 37°C. 
 
SYNERGY ASSESSMENT 
Synergy between ε-poly-L-lysine (ePLL) and F.HKAIs (F.B2, F.B7, F.B11, 
F.B13, F.B14, F.B15, F.F1.8 and F.F2.3) was assessed by the check-board method 
38
 
in 96-well-plates. Fractional inhibitory concentrations (FICs) were calculated based on 
the content in the wells in the growth-no growth area. FIC > 0.5 indicates no synergy 
38
.  
 
CELL LINES AND MEDIUM 
Cells were grown in medium supplemented with 10% fetal bovine serum (FBS; 
PAA Laboratories, Colbe, Germany),100 U/ml penicillin and 100 μg/ml streptomycin 
(Sigma, St. Louis, MO) in an atmosphere of 5% CO2-95% O2 at 37°C and were 
passaged weekly. 
Caco-2 BBE cells (CRL 2102), and Raw 264.7 (Mouse leukemic monocyte 
macrophage cell line) were purchased from the American Type Culture Center 
(Manassas, VA) and grown in DMEM (Invitrogen, Paisley, UK) containing Glutamax, 
in RPMI 1640 (Invitrogen, Paisley, UK) supplemented with 2mM Glutamine, in 
DMEM, respectively. 
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NEUTRAL RED UPTAKE ASSAY OF CELL VIABILITY 
Neutral red uptake assay of cell viability with Caco-2 cells was performed as 
previously described 
39
. Briefly, after overnight incubation with the NPs (MCM-41, 
N.Rho and N.HKAIs), the F.HKAIs or ePLL, 10 µl of neutral red solution (33 µg/ml) 
was added to the wells. After 3 h of incubation at 37°C, the medium was removed and 
cells were washed rapidly with PBS. Neutral red was extracted from the cells with 150 
μl 1% acetic acid-50% ethanol, shaken for 10 min at RT. The neutral red content was 
measured on a SpectraMax M5 microplate reader (Molecular Devices) at 540 nm. The 
readings were expressed as neutral-red uptake relative to the uptake of the cells 
exposed to the negative control (medium or DMSO). 
 
ACTIVATION OF MACROPHAGES AND TREATMENT WITH NPS AND 
FREE HISTIDINE KINASE AUTOPHOSPHORYLATION INHIBITORS  
Raw cells were seeded in 96-well-plates (1.10
5
cells/well) and allowed to attach to 
the bottom of the wells at 37°C and 5% CO2 for 1 h. Cells were treated with NPs 
(MCM-41, N.Rho, N.HKAIs) or F.HKAIs, in the presence or absence of 1 μg/ml LPS. 
Controls containing solvent (water or DMSO) were run in parallel. A NO assay and a 
viability assay (XTT) were run consecutively for every treatment group. The 
macrophages cultures were incubated at 37°C and 5% CO2 for 24 h before performing 
the appropriate assays. 
 
NITRIC OXIDE ASSAY 
The NO production of the macrophages was indirectly determined using the 
Griess reaction, a colorimetric assay to measure the accumulation of the stable end 
product of NO degradation, nitrite, within the culture supernatant 
40
. Briefly, after 
overnight incubation with NPs or F.HKAIs, plates were centrifuged at 2000 rpm, at 
RT for 7 min. 75-μl volumes of the supernatants were transferred to a new 96-well 
plate. 100 μl of 1% sulfanilamide (Sigma) in 2.5% phosphoric acid was added to each 
well. This was followed by addition of 100 μl of 0.1% N-naphthyl-ethylenediamine 
(Sigma) in 2.5% phosphoric acid. The plate was gently tapped to mix the contents, 
incubated at RT for 5 min, and the optical density (OD) at 540 nm with 690 nm as a 
reference was determined using an automated spectrophotometer SpectraMax M5 
microplate reader (Molecular Devices).  
 
CELL RESPIRATION (XTT VIABILITY ASSAY) 
Changes in macrophage viability were assessed using the XTT viability assay. 
This assay measures the respiratory activity of mitochondria by determining the 
accumulation of a coloured formazan by-product within the supernatants of treated 
wells 
41
. Briefly, a 20% volume of 1 mg/ml sodium 3,3′-[1[(phenylamino)carbonyl]-
Chapter 4 
2014 
 
100 
3,4-tetrazolium]-bis (4-methoxy-6-nitro)benzene sulphonic acid hydrate (XTT) in 1× 
RPMI was added to each well of the treatment plate. The plates were gently tapped to 
mix the contents, incubated for up to 2 h at 37°C and 5% CO2, and the OD at 450 
using 690 nm as a reference was determined using an automated spectrophotometer 
SpectraMax M5 microplate reader (Molecular Devices). 
 
TUMOR NECROSIS FACTOR ALPHA ELISA 
Tumor-necrosis factor alpha (TNFα) protein levels were measured by quantitative 
enzyme linked immunosorbet assays (ELISA) using the Mouse TNF alpha ELISA 
Ready-SET-Go!® reagent set (Affymetrix, eBioscience, Netherlands). Briefly, after 
overnight incubation of Raw cells with NPs or F.HKAIs before or after stimulation 
with 1 µg/ml LPS, plates were centrifuged at 2000 rpm, at RT for 7 min. 75-μl 
volumes of the supernatants were transferred to a new 96-well plate and ELISA was 
performed according to the manufactures protocol.  
 
ZEBRAFISH MAINTENANCE 
Zebrafish (Danio rerio) were bred at the animal facility of Wageningen University 
and Research Centrum as previously described 
42
, 
43
. Experiments with zebrafish 
embryos were conducted in accordance with the guidelines of the Wageningen 
University Animal Experiments Committee. The breeding tank was cleaned twice a 
day until hatching by removing debris and unfertilized eggs. Embryos were collected 
as eggs on different days and maintained in oxygenated water at 28˚C. For 
experiments zebrafish embryos between 1 and 4 days post-hatching were used. After 4 
days post-hatching, embryos were killed by incubation on ice for at least 30 minutes. 
  
INCUBATION OF ZEBRAFISH WITH N.RHO 
Zebrafish were cultured to 96-well plates (1 embryo/ well) in a total volume of 
100 µl oxygenated water at 28˚ C. Then 1, 2, 5, 10 µl of the nanoparticle stock 
solution (1 mg/ml) were added to the wells. Each treatment group contained 5 
embryos 3 days post-hatching and 5 replicates were tested per group. To visualize the 
NPs two embryos per group were anesthetized using tricaine (MS-222) at standard 
concentration. Images were taken after 1.5, 6 and 24 hours post incubation using Leica 
M205 FA Fluorescence Stereo Microscope (Leica Microsystems). 
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RESULTS AND DISCUSSION 
 
The growing number of reports about the spread of multi-drug resistant (MDR) 
Gr- pathogens demands urgent development of novel approaches to combat the health 
risks associated with infections caused by Gr- bacteria 
1
. Due to low number of new 
classes of antibacterials entering the market over the past decade and growing 
incidence of infections due to MDR bacteria, effort is also being directed towards the 
improving pharmacological properties, potency and delivery of known antibiotics 
30, 44, 
32, 45, 31
. Here we describe a new approach using polycationic ε-poly-L-lysine capped 
nanoparticles loaded with bacterial histidine kinase autophosphorylation inhibitors 
(HKAIs) as a mean to enhance permeability of the outer membrane (OM) of Gr-
negative bacteria. Newly identified two-component systems (TCSs) inhibitors 
(Chapter 2 and 3, Figure 1, Table S1) were used to evaluate the nanodelivery approach 
as they were demonstrated to inhibit HKs from Gr- in vitro but lacked antibacterial 
activity against Gr- bacteria.  
 
Figure 6. 
Histidine-kinase 
autophosphoryla-
tion inhibitors 
(HKAIs) Selected 
HKAIs inhibited 
the 
autophosphorylati
on of E. coli PhoR 
with IC50 ranging 
from 0.2 to > 2 
mM. The HKAIs 
showed 
antibacterial effect 
for a panel of 
Gram-positive 
bacteria (Chapter 
2 and 3) with 
MICs in the range 
of 8 to > 500 
µg/ml. Only B14 
and F1.8 showed antibacterial effect for Gram-negative bacteria with MICs ≥ 250 or ≥ 125, 
respectively. The IC50 (the concentration causing 50% reduction in autophosphorylation 
activity; mM) of each HKAIs for E. coli PhoR (PhoR IC50) is presented together with a 
consensus MIC (minimal inhibitory concentrations) in antimicrobial susceptibility testing 
assays with a panel of Gram-positive (Gr+) and Gram-negative (Gr-) bacteria. 
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SYNTHESIS AND CHARACTERIZATION OF MESOPOROUS SILICA-BASED 
NANOPARTICLES CAPPED WITH Ε-POLY-L-LYSINE AND LOADED WITH 
HK AUTOPHOSPHORYLATION-INHIBITORS  
To evaluate the antibacterial effect of the newly identified HKAIs to Gr- bacteria, 
mesoporous silica-based nanoparticles (MCM-41) were loaded with HKAIs or 
rhodamine dye as a control (N.HKAIs or N.Rho) and capped with ε-poly-L-lysine 
(ePLL, Figure 2 and 3) as previously described 
32
. The organic content of N.HKAIs 
and N.Rho was verified and is shown in Table 1 and details are provided in the 
Supporting Information. The content of the N.HKAIs was between 5 and 138 mg 
HKAIr/g solid (0.02 to 0.45 mM HKAI/ g solid). The ePLL and silica content for the 
N.HKAIs or N.Rho was in the same range, between 91 and 220 mg ePLL/ g solid 
(0.022 – 0.054 mmol ePLL/g solid) and between 51 and 59% silica, respectively.  
 
Figure 2. 
Schematic 
representatio
n and putative 
mechanism of 
action of the 
nanoparticles 
Nanometric 
mesoporous 
MCM-41 
phase (ca. 100 
nM; MCM-41) 
functionalized 
with n-[(3-
trimethoxysily
l)propyl]ethyl
endiamine 
triacetic acid 
trisodium salt 
(blue 
cylinder) was 
capped with ε-poly-L-lysine cationic polymer (ePLL) and loaded with histidine kinase 
autophosphorylation inhibitors (HKAIs, yellow balls). Putative mechanism of action of the 
nanoparticles (NPs) is attributed to interaction of the positively charged capped NPs with 
the negatively charged Gr- bacterial cell wall (blue lines) and displacement of the capping 
ePLL which results in release of the loaded HKAIs and subsequently to inhibition of two-
component systems (TCS) signalling.  
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Figure 3. TEM image of the inorganic MCM-41 calcined matrix (A) and some of the final 
solids (B, C, D and E, correspond to N.Rho, NB.2, NB.14 and NF1.8 final solids, 
respectively). The images clearly show the mesoporous structure of the matrix which was 
maintained after capping with ePLL and loading with HKAIs. 
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Table 1. Content (α, mmol/g of solid) of the different HKAIs (αHKAIs), n-[(3-
trimethoxysilyl)propyl]ethylendiamine triacetic acid trisodium salt (f, αf), ε-poly-L-lysine 
(ePLL, αePLL) and silica content (silica, %) in the prepared nanoparticles. 
 α HKAIs αf αePLL silica  
N.Rho 0.021 0.388 0.025  
NB.2 0.44 0.269 0.036 55 
NB.7 0.18 0.325 0.052 55 
NB.11 0.05 0.541 0.042 53 
NB.13 0.12 0.325 0.054 51 
NB.14 0.23 0.465 0.030 54 
NB15 0.34 0.034 0.033 57 
NF1.8 0.024 0.88 0.022 57 
NF2.3 0.026 0.403 0.042 59 
 
Table 2. Antibacterial activities of free HK 
autophosphorylation inhibitors (Free) 
and HK autophosphorylation inhibitors 
loaded to silica-based mesoporous 
nanoparticles capped with ε-poly-L-lysine 
(Nano). HKs inhibitors part of the nano-
formulations showed > 10 fold lower 
MICs for Gram negative strains compared 
to the free HKs autophosphorylation 
inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Antibacterial 
activity of MCM-41, the 
control N.Rho and ePLL 
 
 
 
 
 
 
ePLLnano ePLL part of the nanoformulation N.Rho 
 
MIC µg/ml 
 
E. coli CFT 073 E. coli DH5α S. marcescens  
  Nano Free Nano Nano Free 
B2 100 >500 >100 > 100 n.t. 
B7 50 >500 50 100 >100 
B11 13 >500 >100 100 >500 
B13 25 >500 50 100 >500 
B14 50 500 >100 >100 500 
B15 50 >500 >100 >100 >500 
F1.8 6 250 >25 25 250 
F2.3 6 >500 >25 25 >500 
  E. coli CFT 073 S. marcescens 
  MIC [mg/ml] MBC [mg/ml] MIC [mg/ml] 
ePLL 0.13 1.6 0.25 
N.Rho > 10 > 10 > 1 
ePLLnano > 1 > 1 > 0.1 
MCM-41 > 11 > 11 > 11 
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ANTIBACTERIAL ACTIVITIES 
The antibacterial activities of N.HKAIs, F.HKAIs, ePLL, MCM-41 and N.Rho 
were evaluated by determining the optical density at 600 nm (OD600) of bacterial 
suspensions incubated overnight (16 to 24 h) in 96-well plates. The F.HKAIs did not 
inhibit bacterial growth at concentrations even as high as 500 µg/ml (MIC > 500 
µg/ml) except for F.B14 and F.F1.8. F.B14 and F.F1.8 showed antibacterial effect for 
E. coli CFT 073 and S. marcescens 21639 with MICs of 500 and 250 µg/ml, 
respectively (Table 2). The N.HKAIs showed antibacterial effect for E. coli CFT 073 
with MICs corresponding to 3 to 100 µg/ml HK inhibitors (Table 2) which in all cases 
is more than 10 times lower than the MICs of the F.HKAIs. To exclude the possibility 
that the observed antibacterial effect is due to the antibacterial action of the MCM-41 
or of the ePLL in the nanoformulations, the MICs of MCM-41 and N.Rho were 
determined. MCM-41 and N.Rho did not inhibit bacterial growth, even at 
concentrations as high as 11 mg/ml (MIC > 11 mg/ml) and 10 mg/ml (MIC > 10 
mg/ml), respectively. 10 mg/ml N.Rho corresponds to 1020 µg/ml ePLL (MICePLL 
nanoformulation > 1020 µg/ml, Table 3). The highest tested concentrations of MCM-41 and 
ePLL as part of N.Rho were higher than the MCM and ePLL content of the highest 
tested concentrations of the N.HKAIs. To exclude the possibility that the observed 
antibacterial effect of the N.HKAIs is due to a synergy effect of the HKAIs and ePLL 
within the nanoformulations, synergy effects against E. coli CFT 073 were tested by 
the checkboard method and no synergy between ePLL and the free HK inhibitors was 
observed (FICs > 0.5). Therefore, the antibacterial effect of the N.HKAIs is solely 
dependent on the release of the NPs cargo (the HKAIs) and not on the synergistic 
effect between the HKAIs and ePLL, or due to the presence of MCM-41 and/ or ePLL 
in the nanoformulations. 
 
ADVERSE EFFECTS ON HOST CELLS IN VITRO 
To be used as effective drugs, antibacterials should not cause adverse effects such 
as cytotoxicity and immunotoxicity to host cells. Although silica is generally 
considered to be non-cytotoxic, the formulations of the silica-based NPs described 
here may affect their biocompatibility because of altered physicochemical properties. 
Therefore, to assess this we investigated the cytotoxicity and immunotoxicity of the 
NP formulations described in this chapter with and without incorporation of the HKAI 
to determine how it affected host toxicity of the HKAI. 
 
Cytotoxicity  
Viability of human colon carcinoma cells (Caco-2) incubated with MCM-41, 
N.Rho, N.HKAIs or F.HKAIs or ePLL was measured using the neutral-red uptake 
assay 
39
. The N.HKAIs showed lower cytotoxicity compared to the F.HKAIs (Table 4, 
Figure S3). The IC50 (the concentration of test material that causes a 50% decrease in 
neutral-red uptake, relative to the solvent control) of the N.HKAIs corresponded to ≥ 
100 µg/ml HKAIs, whereas, the IC50 of the F.HKAIs varied between 3 and 134 µg/ml. 
The selectivity index, i.e. mammalian cell cytotoxicity (IC50)/antibacterial effect 
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(MIC), was improved for the N.HKAIs compared to the F.HKAIs. This is an expected 
result because mesoporous NPs capped with cationic ePLL are designed to interact 
with the negatively charged OM of Gr- bacteria 
32
. Their proposed mechanism of 
action is attributed to ionic interaction of the positively charged ePLL capped NPs 
with the bacterial OM, followed by displacement and binding of ePLL to the Gr- cell 
membrane, thereby allowing the NKAIs to be released 
32
. Furthermore, MCM-41 and 
ePLL were not cytotoxic at concentrations as high as 2742 µg/ml and 673 µg/ml, 
respectively, corresponding to the highest content of MCM-41 and ePLL present in the 
N.HKAIs. N.Rho was also not cytotoxic at 1000 µg/ml, corresponding to 102 µg/ml 
ePLL as part of the nanoformulation. This indicates that there is no synergistic effect 
between MCM-41 and the capping ePLL on cytotoxicity and suggests that ePLL 
capped mesoporous NPs are save to be used for antibacterial drug delivery.  
 
Table 4. Effect on cell viability of Caco-2 cells of free 
HKs autophosphorylation inhibitors (Free) and HKs 
autophosphorylation inhibitors loaded to silica-based 
mesoporous nanoparticles capped with ε-poly-L-lysine 
(Nano) evaluated by neutral-red uptake assay. IC50 is 
the concentration at which 50% reduction in neutral-
red uptake relative to the solvent control is observed. 
Detailed dose-effect curves are presented in Figure S3 
  IC50 [µg/ml] Selectivity index  
 
Caco-2 IC50/MICE.coli* 
  Nano Free Nano Free 
B2 ≥ 100 n.t. > 1 n.t. 
B7 > 100 105 > 2 < 0.21 
B11 ≥ 100 ≥ 500 ≥ 7.7 < 1 
B13 ≥ 100 29 ≥ 4 < 0.06 
B14 ≥ 50 3 ≥ 1 0.006 
B15 > 100 ≈ 500 > 2 < 1 
F1.8 > 25 134 > 4.2 0.54 
F2.3 > 25 30 > 4.2 < 0.06 
*E. coli CFT 073 
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Activation of NO production by macrophages and macrophage viability  
The high-output isoform of nitric oxide synthase (NOS2 or iNOS) lies at the 
interface between the innate and adaptive immune systems 
46
. Human NOS2 is most 
readily observed in monocytes or macrophages from patients with infectious or 
inflammatory diseases. Sustained production of NO endows macrophages with 
cytostatic or cytotoxic activity against viruses, bacteria, fungi, protozoa, helminths, 
and tumor cells. Other macrophage products such as acid, glutathione, cysteine, 
hydrogen peroxide, or superoxide enhance the antibacterial and cytotoxic actions of 
NO. To investigate whether the NPs and the HKAI B13 interfered with NO production 
by immune cells we incubated cultured macrophages with MCM-41, N.Rho, N.B13 
and F.B13 with and without LPS (1µg/ml) stimulation for 16 to 24 h and then 
measured NO production (Figure 4 and S4). Simultaneously, the effect of MCM-41, 
N.Rho, N.B13 and F.B13 on macrophage viability and TNFα protein levels were 
evaluated using the XTT assay and TNFα ELISA respectively (Figure 5, 6, and S4).  
 
Figure 4. Dose offects of MCM-41 (A), N.Rho (B), N.B13 (C) and F.B13 (D) on NO 
production by cultured macrophages (Raw cells). NO production is not affected by MCM-
41 (A), N.Rho (B), N.B13 (C), F.B13 (D) or the solvents (H2O and DMSO, E) with or without 
stimulation with 1 µg/ml LPS. The results are presented relative to the NO production 
induced by stimulation with 1 µg/ml LPS. The error bars present the SEM of at least three 
independent experiments in duplicate.  
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Figure 5. Dose effects of MCM-41 (A), N.Rho (B), N.B13 (C) and F.B13 (D) on cell viability 
of cultured macrophages (Raw cells). Cell viability is not affected by MCM-41 (A), N.Rho 
(B) or the solvents (H2O and DMSO, E) with or without stimulation with 1 µg/ml LPS. 
Reduction in cell viability by N.B13 (C) is observed only at the highest tested concentration 
(100 µg/ml B13) with stimulation with 1 µg/ml LPS. Reduction of cell viability by F.B13 
(D) is observed at the highest tested concentration (100 µg/ml B13) with or without 
stimulation with 1 µg/ml LPS and at 20 µg/ml B13 with stimulation with 1 µg/ml LPS. The 
results are presented relative to the viability of the solvent controls (H2O or DMSO). The 
error bars present the SEM of at least two independent experiments in duplicate. 
 
1 mg/ml MCM-41 or N.Rho did not cause significant changes in NO production 
by macrophages or in macrophage viability compared to the solvent control before or 
after stimulation with 1 µg/ml LPS. These results indicate that MCM-41 and N.Rho do 
not stimulate NO production by themselves and do not inhibit NO production induced 
by LPS. The production of NO before and after stimulation with 1 µg/ml LPS after 
incubation with N.B13 and F.B13 at concentrations corresponding to 100 µg/ml B13 
was comparable to the solvent control However, free HKAI F.B13 reduced viability of 
macrophages stimulated with LPS by more than 50% at a concentration of 100 µg/ml 
and LPS stimulated macrophage viability by more than 50% at a concentration of 20 
µg/ml F.B13.This finding suggests that F.B13 might induce an increase in NO 
production by macrophages which is masked by its cytotoxic effect. . The macrophage 
viability was decreased by N.B13 at concentrations corresponding to 100 µg/ml B13, 
implying that N.B13 also stimulates some NO production by macrophages. 
Nevertheless, these effects are observed at concentrations higher than the MIC of 
F.B13 for Gr+ bacteria and of N.B13 for Gr- bacteria (Chapter 2 and Table 2, 
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respectively). As the nanomaterials, MCM-41 and the control N.Rho did not cause 
significant changes in NO production or in macrophages viability, the N.B13 effect on 
NO production and macrophage viability can be attributed to release of the cargo, i.e. 
HKAI B13. This is in agreement with the cell viability study of free HKAI B13 and 
Caco-2 cells (Table 4 and Figure S3).  
 
Production of tumor necrosis factor alpha by macrophages activated 
with NPs and F.HKAIs  
Tumor-necrosis factor alpha (TNFα) is involved in the process of inflammation 
and in cellular processes mediating protection to bacterial infections 
47
. Antibacterials 
ideally should not alter the level of TNFα production by activated and resting 
macrophages. Indeed, neither the NPs (MCM-41, N.Rho or N.B13) nor the HKAI 
F.B13 caused changes in TNFα secretion by Raw cells before or after stimulation with 
1 µg/ml LPS (Figure 6).  
 
ZEBRAFISH EMBRYOS CAN BE USED IN INFECTION STUDIES WITH 
MESOPOROUS SILICA-BASED NPS CAPPED WITH EPLL 
To evaluate the toxicity of the NPs capped with ePLL and the suitability of 
zebrafish embyos for future infection studies, the toxicity of N.Rho to zebrafish 
embryos was evaluated. Given the low toxicity of the HKAIs loaded NPs (N.HKAIs) 
and their antibacterial activity we evaluated the potential to deliver antibacterials via 
nanoparticles to zebrafish embryos via dispersion in the water.  
Zebrafish infection models are becoming a valuable tool in pre-clinical 
antibacterial drug discovery 
48, 49, 50
. Experimental candidate drugs can be injected via 
the yolk sack or the blood vessels using a microinjection device. However, 
microinjection is time-consuming, laborious and not always accurate. Ideally, 
antibacterials delivered via nanoparticles are dispersed in the water to test their uptake, 
distribution and adverse effects.  
N.Rho was dispersed in the water where the zebrafish embryos were incubated. 
The dispersion of the N.Rho in the water did not result in signs of toxicity and lethality 
of the zebrafish embryos for up to 24h hours post incubation (Figure 7) at 
concentrations of 10, 20 and 50 µg/ml. Incubation with N.Rho led to concentration 
dependent increase of rhodamine fluorescence and increased over time in the intestine 
and in the yolk sac (Figure 7). These can be attributed to uptake of N.Rho via the gills 
or the skin 
51
, distribution in the blood and accumulation in the yolk sac and intestine. 
The gills have been suggested as the main site for antigen uptake in fish, however, the 
skin was shown to play a significant role in the uptake of antigens as well 
51
. If N.Rho 
is taken up via the gills, N.Rho might circulate through the vasculature to the yolk sac 
and the intestine. A similar distribution in the body was observed with liposomes 
delivered by immersion 
52
. Possible release of the rhodamine cargo due the encounter 
of the N.Rho with the yolk content or with Gr- negative bacteria normally present in 
the intestine may also be a factor influencing the results.  
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Figure 6. Dose effects of MCM-41 (A), N.Rho (B), N.B13 (C) and F.B13 (D) on TNFα levels 
of cultured macrophages (Raw cells). TNFα levels in Raw cells are not after incubation 
with MCM-41 (A), N.Rho (B), N.B13 (C), F.B13 (D) or by the solvents (H2O and DMSO, E) 
with or without stimulation with 1 µg/ml LPS. The results are presented relative to the 
TNFα levels after stimulation with 1 µg/ml LPS. The error bars present the SEM of at two 
independent experiments in duplicate.  
 
The observations made after incubation of N.Rho with zebrafish embryos open up 
new targeted strategies for treating bacterial infections in aquaculture industry using 
mesoporous silica-based NPs capped with ePLL thanks to the simplicity, absence of 
toxicity and accuracy of the cargo delivery. 
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Figure 7. Incubation of zebrafish embryos with N.Rho. Rhodamine fluorescence in the yolk 
sack and the intestine is increased in concentration-dependent and time-dependent 
manner.  
 
SUMMARY 
 
By combining two novel strategies, loading of nanoparticles with antibacterials on 
the one hand, and targeting TCS signalling on the other hand, it was possible to 
achieve antibacterial effect against Gr- bacteria in vitro. The antibacterials-loaded NPs 
did not show adverse effects to mammalian cell viability, or immunotoxicity in vitro. 
The NPs did not cause adverse effects on zebrafish embryos. All together, these open 
promising possibilities for the treatment of Gr- infections and development of novel 
antibacterials and/ or delivery of antibacterials using nanoparticles.  
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SUPPLEMENTARY MATERIAL CHAPTER 4 
 
MATERIALS CHARACTERIZATION 
MCM-41 as-synthesized, MCM-41 and the final N.Rho and N.HKAIs (N.B2, 
N.B7, N.B11, N.B13, N.B14, N.B15, N.F1.8 and N.F2.3) synthesized materials were 
characterized through standard techniques. Figure S1 shows the X-ray diffraction 
(XRD) patterns of the nanoparticulated MCM-41 matrix as-synthesised, the MCM-41 
calcined and the final N.Rho solid. (The rest of X-ray diffraction patterns of the 
antibacterial loaded solids are not shown due to the low amount of final solids 
obtained). The MCM-41 as-synthesised (curve a) displayed the four typical low-angle 
reflections of a hexagonal-ordered matrix indexed at (100), (110), (200) and (210) 
Bragg peaks. In curve b (MCM-41 calcined), a significant shift of the (100) peak in the 
XRD and a broadening of the (100) and (200) peaks are observed. These changes are 
due to the condensation of silanols in the calcination step, which caused an 
approximate cell contraction of 4 Å. Finally, curve c shows the N.Rho solid XRD 
pattern.  
For this material, reflections (110) and (200) were mostly lost due to a reduction 
in contrast related to the functionalisation process and to the filling of mesopores with 
rhodamine B. Although these reductions, the intensity of the (100) peak in this pattern 
strongly indicates that the loading process with the dye and the additional 
functionalisation with N-[(3-Trimethoxysilyl)propyl]ethylendiamine triacetic acid 
trisodium salt and the covering with ε-poly-L-lysine did not modify the mesoporous 
MCM-41 scaffold nature. 
Likewise, TEM analysis of the different prepared solids was performed. TEM 
images showed the typical channels of the MCM-41 scaffolding and can be visualised 
as alternate black and white stripes in which the typical hexagonal porosity of the 
MCM-41 calcined material can also be observed (see Figure 2). In the same way, 
TEM images of some of the final solids loaded with the antibacterial products are also 
shown in Figure 2. The remaining final solids also showed the same morphology 
under the TEM analysis. TEM images also show that the materials were obtained as 
spherical nanoparticles of ca 80 - 100 nm. Then, it can be concluded that the spherical 
shape and mesoporous nature of the inorganic matrix remains after the loading and 
functionalization processes. 
Figure S2 (curve a) displays the N2 adsorption-desorption isotherms of the MCM-
41 calcined nanoparticles. This curve shows an adsorption step with a P/P0 value 
between 0.2 and 0.35, due to a type IV isotherm, which is typical of mesoporous 
materials. This first step corresponds to nitrogen condensation in the mesopore inlets. 
With the BJH
[3]
 model on the adsorption curve of the isotherm, a narrow pore size 
distribution with an average pore diameter of 2.56 nm (see Figure S2 inlet) and a pore 
volume of 0.64 cm
3
g
-1
 were calculated. The absence of a hysteresis loop in this 
pressure range and the low BJH pore distribution is due to the cylindrical uniformity 
of mesopores. The total specific area was 916 m
2
g
-1
, calculated with the BET model.
[4]
 
The a0 cell parameter 42.9 Å (d100= 37.17 Å), the pore diameter (2.56 nm) and the wall 
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thickness value (17.31 Å) were calculatedfrom the XRD, porosimetry and TEM 
measurements. Other important feature of the curve is the characteristic H1 hysteresis 
loop that appears in the isotherm at a high relative pressure (P/P0> 0.8) which can be 
closely associated with a wide pore size distribution. This hysteresis loop is due to the 
filling of the large pores among the nanoparticles (0.22 cm
3
g
-1
 calculated by the BJH 
model) because of textural porosity. In relation to the control syntehsized N.Rho 
material, the N2 adsorption-desorption isotherm of this solid was associated to the 
typical mesoporous systems with filled mesopores (see Figure S2, curve b). Thus, as it 
was expected, a lower N2 adsorbed volume (BJH mesopore volume = 0.15 cm
3
g
-1
) and 
surface area (204.9 m
2
g
-1
) were found, compared with the initial MCM-41 material. As 
it can be observed, this solid presents a curve with no gaps at low relative pressure 
values if compared to the mother MCM-41 matrix (curve a). Another important feature 
of N.Rho is that no maximum was found in the pore size distribution curve, which can 
be associated with the closed pores due to the functionalization process. Table S2 
shows a summary of the BET-specific surface values, pore volumes and pore sizes 
calculated from the N2 adsorption-desorption isotherms for MCM-41 calcined and 
N.Rho. 
Thermogravimetric studies and elemental analyses of all final prepared solids 
were carried out, in order to quantify the organic contents of  each material. In 
particular, the amount of the different loading products and functionalization with 
product f and ePLL were calculated. All the resuts are summarized in Table 1 in the 
body text. 
2014 
 
118 
 
Figure S1. Powder X-Ray diffractograms showing X-Ray patterns of MCM-41 scaffolding as 
synthesized (a), MCM-41 after the calcination process(b) and the final control solid 
N.Rho(c). 
 
 
Figure S2. Nitrogen adsorption-desorption isotherms for (a) MCM-41 mesoporous 
material (b) N.Rho. Inlet:Pore size distributions of the MCM-41 mesoporous material. 
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Figure S3. Cell viabillity of Caco-2 cells assessed by neutral-red uptake after 24 h exposure 
to NPs or to free HKAIs. Error bars represent the SEM of at least two independent 
experiments in duplicate.  
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Figure S4. Dose effect of the NPs MCM-41 (A, B), N.Rho (A, B) or N.B13 (C, D) and F.B13 (C, 
D) on NO production and cell viability of macrophages before (A, C) or after stimulation 
with 1 µg/ml LPS (B, D). Results are expressed as the effect of the NPs or F.B13 relative to 
the effect of the solvent controls (water or DMSO, respectively). The error bars represent 
the SEM of at least two independent experiments in duplicate. 
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Table S1. Selected histidine kinase autophosphorylation inhibitors (HKAIs) and their 
physychochemica properties 
  NCI number logS logP logD MW HBD HBA TPSA Flexibility RB* 
F.B2 73090 2.9 3 3 229 1 2 29.1 0.2 3 
F.B7 109741 2.3 3.6 3.6 246 1 2 29.1 0.2 3 
F.B11 211552 2.2 3.2 3.2 282 1 5 74.9 0.2 5 
F.B13 32652 0.9 5.3 5.3 272 1 1 20.2 0.2 5 
F.B14 48154 1.7 4.3 2.3 255 2 2 32.3 0.2 4 
F.B15 7436 2.3 3.3 1.7 304 2 4 72.2 0.2 4 
F.F1.8 80819 2.4 2.2 1.3 265 2 4 63.8 0.1 2 
F.F2.3 106510 3.1 2.5 1.1 210 2 2 41.8 0.1 2 
*RB-rotatable bonds 
 
 
Table S2. BET specific surface values, pore volumes and pore sizes calculated from the N2 
adsorption-desorption isotherms for selected materials. 
 SBET (m2g-1) Pore Volume (cm3g-1) Pore Size (nm) 
MCM-41 916 0.64 2.56 
N.Rho 204.9 0.15 - 
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ABBREVIATIONS 
 
QSAR – quantitative structure-activity relationship 
LEI – ligand-efficiency index 
SEI – surface-efficiency index 
BEI – binding-efficiency index 
TCS – two-component systems 
HK – histidine kinase 
RR – response regulator 
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INTRODUCTION 
 
Computational chemistry has been applied widely in the pharmaceutical industry 
for drug discovery, lead optimization, risk assessment, toxicity prediction and 
regulatory decisions 
1
. Over the past four decades, quantitative structure–activity 
relationship (QSAR) modelling has completely changed the way the interaction of 
organic compounds with the various forms of life is studied 
2
. It attempts to formulate 
the relationship between structure and activity as a mathematical model. Therefore, the 
binding affinity of a new molecule can be predicted using a QSAR model derived 
from the known inhibitors and their experimental bioassay values 
3
. Using such an 
approach, a large library of possible drug candidates can be tested for their predicted 
selectivity and potency 
4
, saving time and money in drug discovery research. 
Successful drug discovery requires not only identifying hits with desired biochemical 
properties (e.g. target affinity) but also hits with optimal physicochemical and 
ADMET (adsorption, distribution, metabolism, excretion and toxicity) properties 
5
. 
Once a hit is identified its optimisation should be bidirectional. Ligand-efficiency 
indices (LEIs) connect the physicochemical properties of hits (e.g. MW and polar 
surface area [PSA]) with the biological target via the affinity parameter (IC50, enzyme 
activity or other related measures of affinity) 
6, 7
. 
Herein we describe the application of computer-aided drug discovery approaches 
(including QSAR modelling, ligand-based similarity search and LEIs-based 
evaluation) for the identification of putative HK autophosphorylation inhibitors with 
antibacterial activity and low toxicity. 
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MATERIALS AND METHODS 
 
QSAR PREDICTIVE MODEL BUILDING 
The experimental E. coli PhoR autophosphorylation inhibition data (% inhibition 
at 2 mM) of 39 compounds (Chapter 3 and 4) were used as a dataset for building a 
quantitative structure–activity relationship (QSAR) model for inhibition of E. coli 
PhoR autophosphorylation (Table S1). The percentage inhibition range was from 6 to 
85%. Predictive QSAR model was built automatically using the Auto-Modeller 
module of StarDrop (Optibrium, Cambridge) 
8
.  
 
LIGAND-BASED SIMILARITY SEARCHES 
The National Cancer Institute Developmental Theraupeutics Programme database 
(DTP NCI/NIH) was searched for analogue structures of the query molecules B7, B11, 
B13, B15, F1.8, F2.4, F2 (Figure 1) using the Enhanced NCI database browser v 2.2 
9
. 
Molecules with more than 80% similarity to the query molecules (Tanimoto 
coefficient > 80%) and with predicted drug-like properties were saved for further 
scoring. 
 
SCORING AND SELECTION OF COMPOUNDS FOR EXPERIMENTAL 
TESTING 
Ligand-based similarity searches (LBSS) hits were evaluated using the StarDrop 
Oral non central nervous system (CNS) scoring profile ( logS>1, importance 90%; 
positive HIA category, importance 85%; 0<logP<0.35, importance 60%; -0.2<BBB 
log<1, importance 55%; positive BBB category, importance 55%; P-gp category 
´´no´´, importance 50%; hERG IC50≤5, importance 50%; 2C9 pKi≤6, importance 
30%; 2D6 affinity category ´´low to medium´´, importance 30%; PPB90 category 
´´low´´, importance 20%). 
Predicted E. coli PhoR autophosphorylation inhibition score was calculated using 
the QSAR Random Forest Regression model built with StarDrop.  
After visual inspection, 18 compounds with oral non-CNS score > 0.4 and 
predicted E. coli PhoR autophosphorylation inhibition higher than 0.45, were 
purchased for experimental testing.  
The predicted E. coli PhoR autophosphorylation activity was used as input to 
calculate binding efficiency indices (nBEIs) and surface efficiency indices (NSEIs) 
using AtlasCBS 
6
 and the following equations: 
NSEI = -log10 pREA/ NPOL, where pREA stands for predicted residual enzyme 
activity in one concentration (2 mM) one time-point (30 sec) kinase assay experiments 
with PhoR
E
, and NPOL is number of polar N and O atoms in the compound. 
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nBEI = - log10[pREA/NHEA], where NHEA is the number of non-hydrogen 
atoms in the compound.  
Out of the 1012 LBSS hits, 36 were purchased for experimental testing following 
visual inspection.  
 
CHEMICALS 
All chemicals (Figure S1 and Table S2) were obtained from DTP NCI/NIH.  
 
ANTIMICROBIAL SUSCEPTIBILITY TESTING 
Strains used for antimicrobial susceptibility testing (Table 1) were propagated 
using standard microbiological procedures and Müller-Hinton (MH) agar or broth. For 
all microorganisms minimal inhibitory concentrations (MICs) were determined as 
previously described following a standard double-dilution method 
10
, 
11
. 
 
PROTEIN EXPRESSION AND PURIFICATION 
The catalytic portions (DHp and CA domain) of E. coli PhoR (PhoR
E
) were 
expressed and purified as previously described 
12
. In brief the protein was expressed in 
E. coli RIL and purified by Ni-affinity and size-exclusion chromatography. 
 
KINASE ASSAY  
Kinase assay was performed as previously described 
13
. When comparing the 
inhibitory capacity of ligands and measuring IC50, the final DMSO concentration in 
the assay was 10% (v/v). Controls lacking ligands and containing an equal 
concentration of DMSO were carried out in parallel. Inhibition of HKs 
autophosphorylation was determined by incubating 0.12 mg/ml (≈ 4 µM HK) and up 
to 20 mM of test compound in kinase buffer (50 mM Tris HCl, pH 8.5, 50 mM KCl, 5 
mM MgCl2, 0.5 mM EDTA and 0.1 mM DTT). Autophosporylation reactions were 
initiated by addition of 0.1 µCi/µl [γ-32P] ATP containing from 0.03 to 0.06 µM ATP 
(final concentrations). Autophosphorylation was stopped by addition of 2x SDS-
PAGE sample buffer supplemented with 50 mM EDTA. Samples were applied 
without heating to 15% (w/v) Tris-glycine SDS-polyacrylamide gels. After 
electrophoresis, the bottom part of the gels were removed to lower the background 
signal from the unincorporated radiolabeled ATP. Gels were dried without staining on 
a Bio-Rad Gel Air drying system and the phosphorylated protein was quantified by 
phosphor-imaging using a Fluoro Image Analyzer FLA-5000 (Fujifilm, Japan) and 
evaluated with the MultiGauge software (Fujifilm, Japan). IC50 is the concentration at 
which 50% residual enzyme activity was observed compared to the negative control, 
DMSO. Prism GraphPad v.4 was used for curve fitting and statistical analysis 
14
.  
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BINDING MODE PREDICTION 
The binding mode of selected ligands to the structure of the CA domain of B. 
subtilis WalK (PDB: 3SL2) was predicted by molecular docking using SwissDock 
15
. 
In Figure 2 the lowest energy binding pose is shown.  
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RESULTS AND DISCUSSION 
 
SELECTION OF COMPOUNDS FOR EXPERIMENTAL TESTING 
To facilitate the selection of putative histidine kinase inhibitors for experimental 
testing in the process of hit-to-lead optimization quantitative structure–activity 
relationship (QSAR) models were built using a trial version of StarDrop
8
. The best 
among the generated models was the random forest regression QSAR model however, 
it was not of high merit with r2 of 0.71 (Figure 1, Figure S2). In many QSAR studies 
the criterion r2 greater than 0.9 is employed to decide whether a model is internally 
self-consistent. However, r2 makes no assessment of the intrinsic precision or 
accuracy of the data itself. Nevertheless, we used this model to predict the E. coli 
PhoR autophosphorylation inhibitory capacity of 1012 hits from ligand-based 
similarity searches (LBSS) with previously identified histidine kinase 
autophosphorylation inhibitors as query molecules. The predicted autophosphorylation 
activities were used to evaluate the physicochemical properties of the selected LBSS 
hits using AtlasCBS 
6
. The hits fell into one of seven groups based on NSEI (surface 
efficiency index) with the group around B13 showing highest predicted surface 
efficiency (Figure S3). The following group in terms of NSEI grouped around the F1.8 
but with nearly two-fold lower predicted NSEIs. In total 54 compounds were ordered 
for experimental testing based on the StarDrop and AtlasCBS evaluation and visual 
inspection of the hits for promising functional groups. 
 
H30 AND H31 SHOW ANTIBACTERIAL EFFECT FOR BOTH GRAM-
POSITIVE AND GRAM-NEGATIVE BACTERIA 
To evaluate the antibacterial effect of the selected hits, the MICs (minimal 
inhibitory concentrations) and MBCs (minimal bactericidal concentrations) for S. 
aureus DSM 20231, S. aureus CH3657, S. epidermidis DSM 20044 and E. coli CFT 
073 were determined. H30 and H31 showed the strongest antibacterial effect. H30 
inhibited S. aureus CH3657, S. epidermidis DSM 20044 and uropathogenic E. coli 
CFT 073 with MICs of 62.5, 500 µg/ml and 500 µg/ml, respectively (Table S4). H31 
inhibits S. aureus CH3657, S. epidermidis DSM 20044 and E. coli CFT 073 with 
MICs of 62.5, 125 and 250 µg/ml, respectively. H12 and H27 also showed some 
antibacterial effect with MICs higher than 250 µg/ml. Therefore, only H30 and H31 
were tested against a panel of Gram-positive and Gram-negative bacteria and the 
results are summarized in Table 1. H30 did not show antibacterial effect for any of the 
additional bacterial strains tested. H31 inhibited the growth of all tested bacterial 
strains, including the vancomycin resistant E. faecium strains with MICs of 125 µg/ml 
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. 
 
Figure 1. A) Computer-aided drug discovery approach B) Histidine kinase 
autophosphorylation inhibitors used as query molecules for ligand-based similarity search 
 
H30 INHIBITS E. COLI PHOR AUTOPHOSPHORYLATION AND IS 
PREDICTED TO BIND TO THE ATP-BINDING SITE OF THE CA DOMAIN 
OF B. SUBTILIS WALK 
To confirm the autophosphorylation inhibitory capacity of H30 and H31 in vitro 
kinase assay with E. coli PhoR was performed. E. coli PhoR autophosphorylation 
activity was inhibited by H30 and H31 in a concentration dependent manner with IC50 
≥ 1 and IC50 > 2 mM, respectively. Both compounds showed good solubility in kinase 
buffer. As H30 showed antibacterial effect against S. aureus CH3657 and S. 
epidermidis DSM 20044 (Table 1) and not to the other tested Gram-positive strains, 
we hypothesized that it might interact with WalK. WalK belongs to the WalKR two-
component system which is ubiquitous among Gram positive bacteria and in some 
species it is reported as essential for bacterial growth 
16,
 
17
. 
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Table 1. Antibacterial activities of H30 and H31. E. faecium Van and VanB strains are 
vancomycin resistant strains.  
MIC [µg/ml] 
Strain H30 H31 
Staphylococcus aureus 
  CH3657 63 63 
Enterococcus faecalis 
  DMS 20478 500 < 4 
Streptococcus epidermidis 
  DMS 20444 500 125 
Enterococcus faecium  
  S1 > 500 125 
VanA > 500 125 
VanB >500 125 
Escherichia coli 
  CFT 073 500 250 
Serratia marcescens 
    >500 500 
 
H30 was docked to the structure of the catalytic and ATP-binding domain (CA) of 
B. subtilis WalK (PDB: 3SL2) 
18
. The predicted binding mode (Figure 2) suggested 
that H30 interacts with the ATP-binding site of B. subtilis WalK and forms contacts 
with key residues involved in ATP-binding (Figure 2). In the same experimental 
settings H31 was not docked to B. subtilis WalK and this together with the E. coli 
PhoR IC50 > 2 mM suggests that the antibacterial effect of H31 against the bacterial 
strains tested might be mediated via targets different than HKs.  
NCI antitumor screen results suggest that H30 scaffold possess good safety 
profile. 400 mg/kg/injection did not cause death of mice on the toxicity evaluation day. 
Therefore, H30 might be a good starting point for the development of inhibitors of HK 
autophosphorylation using a structure-based approach. 
100 mg/kg/injection of H31 caused 50% death of mice on the toxicity evaluation 
day in a NCI antitumor screen. This supports the hypothesis that H31 has (a) target(s) 
different than HKs.  
In summary, we identified H30 as putative HK autophosphorylation inhibitors 
with weak antibacterial effect using a combined computer-aided drug discovery 
approach. H30 might serve as a good starting scaffold for the design of more potent 
HK autophosphorylation inhibitors.  
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Figure 2. A) predicted binding mode of H30 to the ATP-binding site of B. subtilis WalK 
(PDB:3SL2) B) Concentration-dependent effect of H30 on E. coli PhoR 
autophosphorylation C) Concentration-dependent effect of H31 PhoR 
autophosphorylation. 
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Figure S1. Compounds selected for experimental testing 
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Figure S2. QSAR model for inhibition of E. coli PhoR autophosphorylation 
 
 
Figure S3. Ligand-efficiency indices facilitate the selection of hits for hit-to-lead 
optimisation 
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Table S1. Dataset  
Name 
% 
Inhibition 
PhoRE 
st.error; 
n=4 
B1 42% 9% 
B2 73% 7% 
B3 29% 3% 
B4 36% 6% 
B5 17% 3% 
B6 46% 4% 
B7 62% 3% 
B8 35% 2% 
B9 28% 5% 
B10 28% 4% 
B11 71% 5% 
B12 25% 7% 
B13 85% 2% 
B14 40% 10% 
B15 43% 1% 
B16 28% 5% 
B17 59% 2% 
B18 28% 13% 
B19 43% 8% 
B20 47% 9% 
B21 32% 9% 
B22 30% 6% 
B23 24% 6% 
B24 39% 7% 
B25 6% 13% 
F1 (D4.1) 54% 4% 
F1.1 45% 3% 
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Table S1 (continued). Dataset 
Name 
% 
Inhibition 
PhoRE 
st.error; 
n=4 
F1.2 44% 4% 
F1.3 26% 3% 
F1.4 49% 10% 
F1.5 17% 5% 
F1.6 28% 4% 
F1.7 24% 6% 
F1.8 61% 2% 
F1.9 18% 2% 
F1.10 25% 6% 
F2 (G5.9) 74% 2% 
F2.4 18% 6% 
F2.1 51% 13% 
F2.2 60% 6% 
F2.3 19% 9% 
F2.5 44% 10% 
F2.6 25% 13% 
F2.7 30% 5% 
F2.8 64% 4% 
F2.9 80% 10% 
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BACKGROUND 
 
LactoferricinB (LfcinB) is an antimicrobial peptide with broad-spectrum of 
antibacterial activity. It has been shown by in vitro and in vivo experiments that 
LfcinB inhibits the phosphorylation of the response regulators (RRs), BasR and CreB, 
and their cognate histidine kinases (HKs), BasS and CreC. Co-crystal structures of 
(peptide) inhibitors bound to their two-component system (TCS) targets would open 
up possibilities for the structure based drug design of more potent inhibitors. Here we 
investigated interaction of LfcinB-derived peptides with the T. maritima TCS HK853-
RR468, for which X-ray structures of both components have been solved in different 
conformations.  
 
FINDINGS 
 
We show that LfcinB-derived peptides inhibit the phosphatase activity of T. 
maritima HK853-RR468 and seem to interact with T. maritima HK853 and E. coli 
PhoB. However, a possible mechanism of interaction is non-specific protein 
aggregation.  
 
CONCLUSIONS 
 
LfcinB has been proposed as a promising broad-spectrum inhibitor of bacterial 
TCS. LfcinB-derived peptides seem to be non-specific TCS inhibitors acting via 
protein aggregation. The latter would be in agreement with the broad-spectrum of 
antibacterial activity of LfcinB as protein aggregation would affect multiple targets.  
 
List of abbreviations: TCS – two component systems; HK – histidine kinase; RR – 
response regulator; LfcinB – lactoferricin B 
 
Key words: Lactoferricin B, antimicrobial peptides, two-component system inhibitors, 
antibacterials 
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INTRODUCTION 
 
Antimicrobial peptides have been proposed as a promising alternative to fight 
resistant bacterial infections and to address the growing problem of multi-drug 
resistance 
1, 2, 3.
 Eukaryotic cationic antimicrobial peptides (AMPs) are produced at 
sites of infection or inflammation in many different organisms 
4, 5
. Typically they are 
peptides of 12 to 45 amino acids with a net positive charge and a high proportion of 
hydrophobic amino acids 
6
. There are four structural classes of AMPs, the most 
common being the β-sheet peptides stabilized by 2–4 disulphide bridges, and the 
unstructured peptides that fold into amphipathic α-helices upon contact with 
membranes. Interaction with the membrane may form pores, or act by thinning the 
membrane or by destabilizing the membrane bilayer. As net result interaction of AMPs 
and membranes increases permeability of the membrane, leads to loss of pH gradient 
and cell death. Some cationic peptides have been shown to interact with intracellular 
targets 
7
, 
8
 but in most cases the exact mechanism of intracellular AMPs action 
remains unclear.  
One of the AMPs proposed to possess intracellular targets is bovine lactoferricin 
(LfcinB). LfcinB is a typical cationic antibacterial peptide produced by gastric pepsin 
digestion of the N-terminal region of bovine lactoferrin and has be identified in vivo 
9, 
10
. The antibacterial core LfcinB includes six residues (positions 20 – 25 in the 
parental sequence) with the C-terminus amidated (peptide RRWQWR-NH2) 
11, 12
. A 
physiologically diverse range of Gram-positive and Gram-negative bacteria have been 
found to be susceptible to inhibition and inactivation by LfcinB-derived peptides 
including LfcinB20-25 and LfcinB17-31 
13, 14, 9
. Concentrations of LfcinB required to cause 
complete inhibition of bacterial growth vary within the range of 0.3 to 150 µg/ml, 
depending on the strain and the culture medium used 
9
. The broad spectrum of 
antibacterial action of LfcinB suggests a common mechanism of action and/ or a wide-
spread intracellular target present in all susceptible strains.  
It has been shown that LfcinB-derived peptides (Lfcin17-41, LfcinB17-31 and D-
Lfcin17-31) enter the cytoplasm of E. coli and S. aureus 
15
. In a recent study the 
intracellular LfcinB protein targets were identified by hybridisation of biotin-labelled 
LfcinB to an Escherichia coli K12 proteome chip 
16
. In total 16 proteins were shown to 
interact with LfcinB, including two response regulators (RRs), BasR and CreB, 
belonging to the two-component systems (TCS) BasSR and CreCB. TCS are the 
predominant signalling systems in bacteria. TCS connect input stimuli and output 
responses with a core phosphotransfer between a membrane bound histidine kinase 
(HK) and a cognate response regulator (RR) 
17, 18
. Simply described, the signalling 
pathway is a series of steps including autophosphorylation of the HK, phosphotransfer 
to the cognate RR, and output modulation, usually via transcription regulation, 
mediated by the phosphorylated RR 
19, 18
. TCS are highly conserved between bacterial 
species and TCS signalling inhibition by LfcinB seemed a logical common mechanism 
explaining the broad-spectrum antibacterial effect of LfcinB. It has been shown by in 
vitro and in vivo experiments that LfcinB inhibits the phosphorylation of the RRs 
(BasR and CreB) by their cognate histidine kinases (HKs), BasS and CreC 
16
 but does 
not inhibit the DNA binding capacity of both RRs suggesting that LfcinB-derived 
Discovery of Inhibitors of Bacterial Histidine Kinases 
 
145 
peptides most likely do not interact with the effector domain of RRs, but with the REC 
domain of RRs. Additionally, antibacterial assays have shown that LfcinB reduced the 
tolerance of E. coli to environmental challenges, such as excessive ferric ions and 
minimal medium conditions. TCS are known to be involved in the regulation of 
adaptive response to stress and logically TCS signalling inhibition could be correlated 
with reduced stress tolerance. Taken together, these results were the first indication 
that an AMP inhibits the growth of bacteria by influencing the catalytic activities of a 
TCS directly 
16
 and seemed to provide a promising starting point for the development 
of broad-spectrum antimicrobial-peptide drugs targeted at TCS signalling. TCS have 
been proposed as attractive targets for novel antibacterial as they are well-conserved 
among bacteria and not present in higher eukaryotes 
20, 21
.  
The aim of this study was to investigate the interaction between LfcinB with TCS 
at atomic level by using X-ray crystallography. The structure of a LfcinB-RR complex 
would i) elucidate the molecular mechanism of RRs inhibition by LfcinB, ii) identify 
putative target sites in the RR which can further be exploited in structure-based drug 
design approaches, and iii) point to RR-peptide interactions and possible peptide 
modifications which would lead to stronger inhibitory effect. Altogether, these would 
facilitate the rational design of modified peptides with higher affinity of binding to 
TCS and may lead to the development of more potent peptide TCS inhibitors. For this 
purpose we have used the T. maritima HK853-RR468 which is a well-studied TCS 
22, 
18
 and the X-ray structures of both components, HK853 and RR468, alone and in 
complex are known 
23, 24, 25
. E. coli PhoR-PhoB is a prototypical two-component 
system involved in the regulation of the pho regulon and structures of the RR PhoB are 
known 
26, 27, 26
. As a first step towards a structure of a RR in complex with LfcinB, we 
verified whether LfcinB-derived peptides inhibit the catalytic activities of T. maritima 
HK853-RR468 and E. coli PhoR-PhoB TCS.  
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RESULTS AND DISCUSSION 
 
INHIBITION OF PHOSPHOTRANSFER AND PHOSPHATASE ACTIVITIES OF 
PURIFIED BACTERIAL TWO- COMPONENT SYSTEMS. 
To check whether LfcinB-derived peptides inhibit the phosphorylation of RR468 
and/or PhoB by their cognate HKs, HK853 and PhoR, respectively, phosphotransfer 
assays were performed in the presence of two LfcinB-derived peptides (LfcinB17–25 
and LfcinB17–32). The two peptides were chosen as both contain the antibacterial core 
sequence (positions 20 – 25 in the parental sequence) 11, 12. In the phosphotransfer 
assays the HKs were first auto-phosphorylated using [γ-32P]ATP 24. This leads to 
accumulation of [γ-32P]ATP-autophosphorylated HK which in a SDS-PAGE gel 
appears as a well-defined band (Figure 1). The autophosphorylated HK was then 
diluted in ATP-free phosphorylation solution containing an equimolar amount (in 
terms of subunits) of RR and 0.5 mM of analysed peptide. Upon mixture of the HK 
and the RR phosphotransfer occurs, and in a SDS-PAGE gel the intensity of the band 
corresponding to the HK becomes lower and a band corresponding to the 
phosphorylated RR appears. As several HKs have phosphatase activity (i.e. HK853) 
28, 
19, 29, 18
, the band corresponding to the phosphorylated RR in the SDS-PAGE gel lower 
its intensity over time. The time course of the reaction (10 min) showed that in the 
absence of LfcinB-derived peptides the radioactive band corresponding to 
autophosphorylated HK853 almost completely disappeared by 1 min and coincided 
with appearance of a labelled band corresponding to phosphorylated RR468 indicating 
phosphotransfer from HK853 to RR468 (Figure 1A). However, the intensity of the 
bands corresponding to the phosphorylated RR468 at 1 min was lower than the 
intensity of the band corresponding to HK853, confirming dephosphorylation of the 
RR468 due to HK853 phosphatase activity. In the presence of LfcinB-derived peptides 
phosphotransfer from HK853 to RR468 did occur but to a lesser extend compared to 
the negative control evidenced by the slightly higher intensity of the bands 
corresponding to the autophosphorylated HK853. In the presence of Lfcin B17–25 or 
LfcinB17–32 a proportion of the autophosphorylated HK853 remained visible, indicating 
either inhibition of phosphotransfer to RR468, or inhibition of the phosphatase activity 
leading to putative shift in the phosphotransfer/ phosphatase reaction balance. 
Furthermore, in the presence of LfcinB17–25 and LfcinB17–32 the bands corresponding to 
the phosphorylated RR468 were with higher intensity compared to the negative control 
or Peptide 3 (a pentapeptide of different sequence) and with similar intensity over 
time, indicating that the phosphatase activity of HK853 was inhibited. In the case of 
PhoR-PhoB, the band corresponding to the autophosphorylated PhoR almost 
completely disappeared by 1 min and a band corresponding to the phosphorylated 
PhoB appeared. In the presence of LfcinB-derived peptides, the intensity of the bands 
corresponding to the autophosphorylated PhoR was similar to the assay in the absence 
of peptide indicating that phosphotransfer was not affected. In the absence of peptide, 
the intensity of the bands corresponding to the phosphorylated PhoB remained similar 
over time indicating no or very slow phosphatase activity. Intriguingly, in the presence 
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of both LfcinB17–25 and LfcinB17–32 the amount of phosphorylated PhoB was 
considerably lower. In the presence of control Peptide3 the intensity of the bands 
corresponding to autophosphorylated PhoR and phosphorylated PhoB was similar to 
the assay in the absence of peptides. As it appears that phosphotransfer activity of the 
PhoR-PhoB TCS is not affected by the LfcinB-derived peptides and the phosphatase 
activity in the absence of LfcinB-derived peptides is missing or very slow, the lower 
intensity of the bands corresponding to the phosphorylated PhoB could be explained 
by activating the PhoB dephosphorylation. Further experiments with in vitro 
phosphorylated PhoB are required to proof or discard this hypothesis.  
 
INHIBITION OF THE PHOSPHOTRANSFER AND PHOSPHATASE ACTIVITY 
OF HK853-RR468 IS LIKELY MEDIATED VIA INTERACTION WITH 
HK853 
Native polyacrylamide gel electrophoresis (native PAGE) was employed to check 
whether the observed inhibition of phosphotransfer and phosphatase activity of the 
HK853-RR468 TCS by LfcinB17–25 and LfcinB17–32 is due to interaction with the HK 
and/ or with the RR. The RR was first phosphorylated in vitro by incubation with 
acetyl phosphate 
30
. The in vitro phosphorylated RR468 was combined with LfcinB17–
25 or LfcinB17–32, or LfcinB17–25 or LfcinB17–32 together with the HK853. HK853 alone 
incubated with or without LfcinB17–25 or LfcinB17–32, or with Peptide 3 were run in 
parallel. In the absence of LfcinB-derived peptides in the native PAGE gel three well 
defined bands corresponding to RR468 (lowest band), HK853 (intermediate band) and 
the complex HK853-RR468 (highest band; Figure 2) were evident. Addition of 
LfcinB17–25 and LfcinB17–32 resulted in loss of the band corresponding to HK853. 
Whereas, in the presence of LfcinB17–25 and LfcinB17–32 RR468 was only slightly 
influenced as a smear was observed. This suggests that the LfcinB-derived peptides 
interact with HK853 much stronger than RR468 (Figure 2) evidenced by the 
significant change in the mobility of HK853 in the native gel after incubation with 
LfcinB-derived peptides. The putative interaction of LfcinB-derived peptides with 
HK853 does not affect the formation of the complex with RR468 as evidenced by the 
band corresponding to the HK853-RR468 complex in the presence of the LfcinB-
derived peptides. Furthermore, in the presence of LfcinB-derived peptides the complex 
HK853-RR468 is formed and phosphotransfer and dephosphorylation of the RR can 
still occur to some extend (Figure 1A). Nevertheless, the amount of complex formed in 
the presence of the LfcinB peptides was much less than that observed with peptide 3 
and control samples (Figure 2).The events observed with HK853 and RR468 were 
specific to the LfcinB-derived peptides as no change in the mobility of HK853 or 
smear were evident after incubation with Peptide 3. 
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Figure 1. Phosphotransfer assays A) LfcinB17-25 and LfcinB17-32 inhibit the phosphorylation 
of RR468 by HK853 and the phosphatase activity of HK853 as evidenced by the higher 
intensity of the bands corresponding to autophosphorylated HK853 and the bands 
corresponding to the phosphorylated RR468, respectively, in the presence of the LfcinB-
derived peptides compared to the negative control. B) LfcinB17-25 and LfcinB17-32 seem not 
to inhibit the phosphorylation of PhoB by PhoR as evidenced by the similar intensities of 
the bands corresponding to the autophosphorylated PhoR. The lower intensities of the 
bands corresponding to the phosphorylated PhoR in the presence of LfcinB-derived 
peptides point to the possibility that LfcinB-derived peptides stimulate dephosphorylation 
of PhoB.  
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Figure 2. LfcinB17-25 and LfcinB17-32 seem to interact with HK853 as evidenced by the 
disappearance of the band corresponding to HK853 in the presence of the LfcinB-derived 
peptides. LfcinB17-25 and LfcinB17-32 interact with RR468 to a lesser extend compared to 
HK853 as evidenced by smear of in the presence of the LfcinB-derived peptides. The 
strong interaction with HK853 and the weaker interaction with RR468 do not prevent the 
formation of the HK853-RR468 complex and the band corresponding to the complex 
appears even in the presence of the LfcinB-derived peptides. Nevertheless, the amount of 
the formed HK853-RR468 complex in the presence of LfcinB-derived peptides less than in 
the controls. 
 
LFCINB-DERIVED PEPTIDES INTERACT WITH PHOB IN A 
CONCENTRATION-DEPENDENT MANNER 
Native PAGE indicates that LfcinB-derived peptides interact with PhoB as a 
smear appeared after incubation of LfcinB-derived peptides with PhoB which had 
been or had not been in vitro phosphorylated (Figure S1 and S2). The interaction with 
the in vitro phosphorylated PhoB seemed to be concentration dependent as the smear 
was observed only at concentrations higher than 0.125 mM (Figure S2). The putative 
interaction was specific to the LfcinB-derived peptides as the mobility of in vitro 
phosphorylated PhoB in the native gel was not affected after incubation with Peptide3 
(Figure S1). 
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SUMMARY  
 
In summary, it seems the inhibition of phosphotransfer and phosphatase activities 
of the T. maritima TCS HK853-RR468 caused by LfcinB17–25 and LfcinB17–32 can be 
attributed to interaction with HK853 although some interaction with RR468 might also 
have contributed to this effect. The LfcinB-derived peptides seem to interact in a 
concentration dependent manner with in vitro phosphorylated E. coli response 
regulator PhoB. Changes in the mobility in native gels of PhoB after incubation with 
LfcinB-derived peptides indicate possible interaction with this protein. Further 
experiments are needed to check the hypothesis that incubation with LfcinB-derived 
peptides might activate the dephosphorylation of E. coli PhoB. The observed changes 
in the mobility of T. maritima HK853 and PhoB in native gels could be due to protein 
aggregation. However, further experiments such as size-exclusion chromatography 
and/ or protein-aggregation evaluation by cross-linking and SDS-PAGE are required 
to confirm this hypothesis. Taken together, the results point to the possibility that the 
antibacterial effect caused by LfcinB-derived peptides might be attributed to 
interaction with multiple cellular targets after entering into the cell. This is in 
agreement with the fact that multiple E. coli proteins were shown to interact with 
LfcinB using proteomics 
16
. Furthermore, non-specific mechanism of action such as 
protein aggregation could not be excluded at this point. Attempts to solve the structure 
of T. maritima RR468 co-crystallized with LfcinB-derived peptides resulted in high-
resolution twinned crystals of RR468 and the LfcinB-derived peptides were not 
encountered in the asymmetric unit (data not shown). It was not possible to obtain 
diffracting crystals of PhoB co-crystallized with LfcinB-derived peptides. No attempts 
have been made to co-crystallize LfcinB-derived peptides with any HK. However, 
before any future crystallization trials additional biochemical experiments are required 
to confirm that the mechanism of interaction of LfcinB-derived peptides with TCS is 
not mediated via non-specific protein aggregation. 
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MATERIALS AND METHODS 
 
PEPTIDES 
Lactoferricin B17-25 and Lactoferricin B 17-32 were kindly provided by Paloma 
Manzanares, IATA, CSIC (Valencia, Spain).  
 
PROTEIN EXPRESSION AND PURIFICATION 
T. maritima HK853 and RR468, E. coli PhoR and PhoB were expressed and 
purified as previously described 
23, 22, 24, 25, 31, 31
. Shortly proteins were expressed in E. 
coli and purified by anion-exchange (HK853 and RR468) or Ni-affinity 
chromatography (PhoR and PhoB), and size-exclusion chromatography.  
 
PHOSPHOTRANSFER ASSAY 
Phosphotransfer assays were performed as previously described 
22
. HK853 and 
PhoR were autophosphorylated in kinase buffer (50 mM Tris pH 8.0, 100 mM KCl, 10 
mM MgCl2) with 0.1 μCi μl
−1[γ-32P] ATP (3000 Ci/mmol Perkin Elmer) for 30min 
(exceeding equilibrium time) at room temperature. Then, each sample was aliquoted 
into three tubes and phosphotransfer reactions were initiated by the addition of 
equimolecular amounts of each RR (the final concentration of RRs and HKs in 
reaction was 2 μM) pre-incubated with 0.5 mM Lactoferricin B17-25,  Lactoferricin B 17-
32, Peptide 3 or buffer. Aliquots were removed from each tube at different times (1, 2.5 
and 10 min) and the reactions were stopped by adding 1/4 SDS-PAGE loading buffer 
(62.5 mM Tris pH 6.8, 30% glycerol, 0.01% bromophenol blue) supplemented with 50 
mM EDTA. Afterwards, the samples were subjected to SDS-PAGE on a 15% gel to 
separate the protein from free nucleotide. After drying, the phosphorylated proteins 
were visualized by phosphorimaging using a Fluoro Image Analyzer FLA-5000 (Fuji). 
 
NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS (NATIVE PAGE) 
Purified PhoB and RR468 were autophosphorylated in kinase buffer (50 mM Tris 
pH 8.0, 100 mM KCl, 10 mM MgCl2) containing 12.5 mM acetyl phosphate for 1 h at 
room temperature. Phosphorylated PhoB and RR468 were mixed with 0.5 mM 
Lactoferricin B17-25,  Lactoferricin B 17-32, Peptide 3 or buffer. RR468 mixed with 0.5 
mM Lactoferricin B17-25,  Lactoferricin B 17-32, Peptide 3 or buffer was incubated with 
or without equimolar amounts of HK853. After 30 min of incubation at room 
temperature Native polyacrylamide gel electrophoresis (Native-PAGE) loading buffer 
was added and samples loaded. Coomassie blue staining was used for protein 
visualization. 
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SUPPLEMENTARY MATERIAL CHAPTER 6 
 
Figure S1. LfcinB17-25 and LfcinB17-32 interact with E. coli PhoB as evidenced by the smear 
observed after incubation of PhoB with the LfcinB-derived peptides and not in the negative 
control or after incubation with Peptide 3. 
 
 
Figure S2. Interaction of LfcinB-derived peptides with E. coli PhoB. LfcinB-derived 
peptides seem to interact with in vitro phosphorylated PhoB in a concentration dependent 
manner as only incubation with LfcinB-derived peptides at concentrations higher than 
0.025mM cause change in the mobility of PhoR evidenced by a smear and/ or reduction of 
the band corresponding to PhoB. 
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7.1. CO-CRYSTALLIZATION OF HISTIDINE-KINASE 
AUTOPHOSPHORYLATION INHIBITORS WITH THERMOTOGA MARITIMA 
CHEA 
 
INTRODUCTION 
 
Obtaining the structure of a putative target histidine kinase (HK) and a histidine-
kinase autophosphorylation inhibitor (HKAI) would allow the rational structure-based 
design of more potent and specific inhibitors. The structure of Thermotoga maritima 
CheA CA domain has been previously crystallized in complex with the native ligand 
ATP/ADP (PDB:1I58, 1I59) to atomic resolution (1.6 Å). and the conditions to obtain 
high-resolution well-diffracting crystals are well-known
1,2
.  Thus the aim of this study 
was to obtain X-ray structures of T. maritima CheA in complex with the HKAIs 
discovered in this thesis (Chapter 2, 3, and 5).  
The structure of the CA domain of T. maritima CheA contains the characteristic 
ATP-binding Bergerat fold including the ATP-lid (Figure 1). The ATP-lid is a loop 
variable in sequence and in length crucial for nucleotide binding and catalytic activity 
3 , 4
. The ATP-lid is proposed as promising feature for the design of specific HK 
autophosphorylation inhibitors with reduced adverse effects to host cells 5, 6.  
 
 
Figure 1. Catalytic and 
ATP-binding (CA) 
domain of T. maritima 
CheA (PDB: 1I58, chain 
A). Residues are 
coloured based on their 
conservation score 
calculated with ConSurf. 
ATP is shown in sticks. 
The ATP-lid is a variable 
loop that can be used to 
design more specific HK 
inhibitors.  
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MATERIALS AND METHODS 
 
PROTEIN EXPRESSION AND PURIFICATION 
T. maritima CheA (CA) was expressed and purified as previously described 
1, 2
. In 
brief, protein was expressed in E. coli RIL and purified by Ni-affinity and size-
exclusion chromatography.  
 
CO-CRYSTALLIZATION AND SOAKING WITH HISTIDINE-KINASE 
AUTOPHOSPHORYLATION INHIBITORS  
Crystals of CheA (25-50 mg/ml) were obtained by the hanging-drop method in 
solution containing 28-33 % PEG 8000, 0.6M Ammonium acetate, and 0.065 M 
sodium acetate pH 4.5. Co-crystals with histidine kinase autophosphorylation 
inhibitors (HKAIs) were obtained by incubating CheA with 100 mg/ml of the HKAI 
for at least 16h at 4°C. In some cases (B13) co-crystals were additionally soaked in 
crystallization solution containing 100 mg/ml HKAI for at least 3 h.  
 
DATA COLLECTION AND PROCESSING  
Single crystals were harvested with a loop and vitrified in liquid nitrogen. 
Diffraction data of CheA-HKAI crystals (Table 1) were collected at the synchrotrons 
Diamond Light Source (Didcot, United Kingdom), European Synchrotron Radiation 
Facility (Grenoble, France), and ALBA (Barcelona, Spain), or at IBV-CSIC (Valencia, 
Spain) using SuperNova (Agilent). Diffraction images were indexed and integrated 
using Mosflm 
7
, XDS 
8
, or CrysAlisPro (Agilent) and the data were scaled using Scala 
9
. Data collection and processing statistics of representative crystals are summarized in 
Table 2. Structures were solved by molecular replacement using as template the 
previous solved structure of the CheA CA domain (PDB: 1I58, Chain A)) and the 
software MolRep 
10
. All models were improved by alternating manual building using 
Coot 
11,
 
12
 with automatic refinement using Refmac 
12
 or Phenix Refine 
13,
 
14,
 
15
.  
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RESULTS AND DISCUSSION 
 
Crystals of the CA domain of T. maritima CheA co-crystallized with the histidine-
kinase autophosphorylation inhibitors (HKAIs, Table 1) diffracted at very high 
resolution between 1.5 to 2.5 Å (Table 2). In the case of inhibitors A5, B13, B14, F1, 
F1.5, F2, F2.2, F2.4, and H30 (Table 1) the CheA-inhibitor structures, solved by X-ray 
crystallography, revealed electron density in the ATP-binding site (Figure 2). 
However, the structures of the HK inhibitors could not be fully resolved, probably due 
to partial occupancy and/or multiple conformations. In all cases the ATP-lid was not 
visible.  
 
Table 1. Co-crystals of CheA with inhibitors 
Inhibitor Data set(s) collected at: Electron density in the ATP-
binding site 
A1 DLS No 
A5 DLS, Agilent Yes/No 
A6 DLS No 
A11 DLS No 
B7 ALBA No 
B11 ALBA No 
B13 ALBA Yes 
B14 ALBA Yes 
F1 DLS, Agilent, ALBA Yes/No 
F1.5 DLS Yes 
F1.6 DLS No 
F1.7 DLS No 
F1.8 DLS No 
F2 DLS, Agilent, ALBA Yes 
F2.1 DLS No 
F2.2 DLS Yes 
F2.4 DLS Yes 
F2.5 DLS No 
F2.6 DLS No 
F2.7 DLS No 
H30 ALBA Yes 
H31 ALBA No 
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Table 2. Data collection and processing statistics for representative CheA-HKAI crystals 
 CheA-F2 CheA-B13 
Synchrotron  DLS ALBA 
Wavelength (Å) 0.97890 1.07217 
Space group P 21  P 21 
Cell (Å, °) a=40.7730  
b=60.2130  
c=65.6980 
α=90.0 
β=98.2850 
γ=90.0 
a=41.01 
b=59.24 
c=66.79 
α=90.0 
β=97.68 
γ=90.0 
Resolution (Å) 28.60 – 2.16  
(2.28-2.16) 
66.20 – 1.85 
(1.95 – 1.85) 
R merge  0.029 0.06 
I/δ(I) 27.0 11.4 
No. of reflections (observed/unique) 62363/16957 
(9120/2454) 
86960/27188 
(12139/3946) 
Completeness 99.6 (99.6) 99.3 (99.2) 
Multiplicity 3.7 (3.7) 3.2 (3.1) 
The data for the outer shell is shown in parenthesis. 
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Figure 2. T. maritima CheA-HKAI structures solved by X-ray crystallography. A) Co-
crystals of T. maritima CheA (CA domain) and the initial hits from the structure-based 
virtual screening (A5, Chapter 2) and the fragment-based screening by differential 
scanning fluorimetry (F1 and F2) were obtained by co-crystallization with 100 mM HKAI. 
B) Co-crystal of T. maritima CheA and the most promising HKAI described in the thesis 
B13 (Chapter 2) was obtained by co-crystallization followed by soaking with 100 mM B13. 
The 2Fo-Fc (blue) and Fo-Fc (green) electron density maps contoured to 1 and 2.5 σ, 
respectively, showed extra density in the active site that was not possible to explain by the 
protein model and were ascribed to the HKAI. However, the HKAIs could not be fully 
resolved, probably due to partial occupancy and/or multiple conformations. 
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 7.2. PURIFICATION, CRYSTALLIZATION AND PRELIMINARY X-RAY 
DIFFRACTION ANALYSIS OF SYNECCOCYSTIS SPP. COPM 
 
INTRODUCTION 
 
Copper is an essential trace element for organisms living under aerobic condition 
16
. It is required in fundamental cellular processes such as oxidative phosphorylation, 
photosynthesis, and free radical control. However copper is highly toxic when it is 
present in excess, thus, many organisms have developed homeostatic mechanism to 
tightly regulate its cellular concentration 
17
. Cyanobacteria are an attractive model to 
investigate the systems involved in copper homeostasis since they are unique bacteria 
with internal copper requirement for two proteins: the blue-copper protein 
plastocyanin, and the caa3-type cytochrome oxidase 
18
. These two proteins are 
localized in the thylakoids, a special internal structure where photosynthesis and 
respiration take place in cyanobacteria. Cyanobacteria are model microorganisms for 
the study of photosynthesis, carbon and nitrogen assimilation, evolution of plant 
plastids, and adaptability to environmental stresses. Synechocystis sp. PCC 6803 is one 
of the most highly studied types of cyanobacteria as it can grow both autotrophically 
or heterotrophically in the absence of light. Copper resistance in cyanobacteria has 
been mainly investigated in Synechocystis sp. PCC 6803 (hereafter Synechocystis), 
which involves a two-component system, CopRS, a protein of unknown function, 
CopM, and an HME-RND exports system, CopBAC 
19,
 
17
 . These proteins are encoded 
by two operons: copMRS, and copBAC. Both copM and copBAC are regulated by the 
CopRS two-component system, and are specifically induced by the presence of Cu
2+
 
19
. CopM is an unknown protein that contains a predicted periplasmic signal domain 
and a high number of histidine (8) and methionine (23) residues, which are usually 
implicated in direct metal binding in proteins. Furthermore, CopM has two domain of 
unknown function DUF305, which is present in other secretion proteins in bacteria and 
belongs to the ferritin superfamily 
20
. Herein, we report the purification, crystallization 
and preliminary X-ray diffraction analysis of Synechocystis CopM.  
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MATERIALS AND METHODS 
 
CLONING, EXPRESSION AND PURIFICATION 
A 519-bp band (from ORF sll0788) coding for the CopM25-196 periplasmic domain 
was PCR amplified from genomic DNA with oligonucleotides ACOPMSTF-
COPMSTR (Table 1), digested with KpnI and SacI, and cloned into pET51 digested 
with the same enzymes. CopM25-196 was expressed in E. coli BL21. An overnight pre-
culture was used to inoculate Luria broth medium and was grown to an optical density 
at 600 nm of 0.6. The culture was cooled down on ice for 20 min, protein expression 
induced by addition of 0.2 mM isopropyl-b-D-thiogalactopyranoside, and incubation 
continued for 4 h at 25°C. Cells were harvested by centrifugation and frozen at -80°C. 
Frozen pellets were re-suspended in buffer S (100 mM Tris HCl pH 8, 150 mM NaCl, 
1 mM BCSA, 1 mM EDTA, and 2 mM Tris (2-carboxyethyl)-phosphine) and broken 
by sonication. The suspension was centrifuged 30 min at 30, 000 g at 4°C and the 
supernatant was loaded into a 5-ml streptavidin beads (IBA GmbH) column 
equilibrated in buffer S. Beads were washed with 50 mL of buffer S and CopM25-196 
was eluted with 1x Strep-Tag elution buffer (IBA GmbH). CopM25-196 was further 
purified by gel filtration in a Hi-Load 75 (GE-Healthcare) column equilibrated with 20 
mM Tris HCl pH 8, 150 mM NaCl. The purified protein was concentrated using a 3K 
Vivaspin concentrator and store at -20 °C until use.  
 
CRYSTALLIZATION 
Initial sitting-drop vapour-diffusion crystallization trials to identify promising 
crystallization conditions for CopM were performed using the commercial 
crystallization screens JCSG+ (Qiagen, Germany), JBC I and JBC II (Jena Bioscience, 
Germany). In an attempt to obtain crystals of both the apo and Cu
2+
-bound CopM 
initial crystallization conditions screenings were performed in the presence of 1 mM 
EDTA and 1 mM CuSO4, respectively. Crystallization drops of 0.6 µl 
(protein:precipitant ratio of 1:1) were set up in 96-well plates containing 75 µl 
reservoir solution. Initial hits were obtained after 4-6 days in multiple conditions 
(Table S1). Optimization of the crystallization conditions was attempted by varying 
the concentration of PEGs and salts under the conditions that initially generated 
diffracting crystals.  
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DATA COLLECTION AND PROCESSING 
For data collection, the crystals were soaked in cryoprotectant (reservoir solution 
supplemented with 40% PEG 3350) for 5-10 sec. A single crystal was harvested with a 
loop and vitrified in liquid nitrogen. Diffraction data were collected the synchrotronsat 
Diamond Light Source (Didcot, United Kingdom) or European Synchrotron Radiation 
Facility (Grenoble, France). Diffraction images were indexed and integrated using 
Mosflm 
7
 or XDS 
8
 and the data were scaled using Scala 
9
. Data collection and 
processing statistics are summarized in Table 2.  
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RESULTS AND DISCUSSION 
 
Recombinant CopM was cloned from genomic DNA, overexpressed in E. coli and 
purified to homogeneity using streptavidin-affinity chromatography and size-exclusion 
chromatography (SEC). The SEC elution profile showed a large peak (data not shown) 
eluting at apparent molecular mas between 17 and 44 kDa. This suggested that 
recombinant CopM with a theoretical molecular mass of 22.65 kDa is a monomer or a 
dimer in solution. Analysis of the purified CopM by SDS-PAGE and Coomassie 
staining showed a purity of at least 95 % (Figure 1). From a 2 L culture, 4.5 mg pure 
CopM was obtained. CopM was concentrated to 6.5 mg/ml and used in initial 
crystallization conditions screenings. Crystals with different shapes grew in various 
conditions (Table S1). In JBS I C7 (25% PEG 4000, 0.1 M Na MES pH 6.5, 0.2 M 
MgCl2) rectangular crystals of CopM diffracting at 4 Å were obtained. In JCSG H9 
(25% PEG 3350, 0.1 M Bis-Tris pH 5.5, different salts) in the presence of EDTA 
CopM crystals diffracting at 2.9Å and C2 space group were obtained (Figure 2). Based 
on these initial results optimization of the crystals was attempted by varying PEG, salt 
and/ or buffer concentrations in the presence or absence of EDTA or Cu2+. 
Crystallization in the presence of EDTA was performed in order to eliminate any 
possible interacting ions and to obtain unbound CopM crystals (CopM apo). As CopM 
is related to copper resistance and it is hypothesized that it might interact with CopM 
we tried to obtain CopM bound to Cu
2+ 
(CopM Cu
2+
). CopM was overexpressed in E. 
coli and during the expression and purification it might have bound to ions present in 
the medium and crystallization of the overexpressed CopM might have resulted in 
CopM bound to unknown ligands (CopM medium). The optimization of the 
crystallization conditions resulted in crystals with different shapes diffracting between 
2.5 – 2.75 Å with P21 (CopM Cu
2+
) and P212121 space group (CopM apo). Complete 
datasets from 2.5 to 3 Å resolution were collected from single crystals (Table 2). Data-
collection and processing statistics are summarized in Table 2. Preliminary diffraction 
data analysis using POINTLESS 
21
 suggested the presence of 5 (CopM EDTA, space 
group C2), 1 (CopM medium, space group P21) or 2 (CopM Cu2+, space group 
P212121) molecules per asymmetric unit. Attempts of structure solution of CopM by 
molecular replacement using the coordinates of a fragment from Deinococcus 
radiodurans DUF305 (PDB: 3BT5) and Streptomyces coelicolor DUF305 (PDB: 
2QF9) as search models and/ or with MRBUMP 
22
 automatic mode were not 
successful. D. radiodurans DUF305 and S. coelicolor DUF 305 share 26.5 and 21.9 % 
sequence identity with CopM, respectively.  
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Figure 1. CopM purity assesed by SDS-PAGE 
 
 
Figure 2. CopM crystals 
 
Table 1. Oligonucleotides used in this work. 
Name Sequence 
ACOPMSTF caggtaccgtatcgcaatcaatctcc 
COPMSTR atgagctctcactgaccataccagt 
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Table 2. Data collection and processing statistics for CopM crystals 
 CopM apo CopM Cu2+ CopM medium 
Synchrotron  DLS ESRF ESRF 
Wavelength (Å) 0.97889 0.87260 0.87260 
Space group C 2  P 21 21 21  P  21  
Cell (Å) a=199.29 b= 54.09 
c=139.38  
β=125.970  
a=64.43 b=85.35 
c=99.12  
a=29.84 b=86.49 
c=52.18  
β=96.21  
Resolution (Å) 52.6 - 2.92  
(3 - 2.92) 
49.56 - 2.90  
(3.08 - 2.9) 
51.87 - 2.70  
(2.83 - 2.70) 
R merge  0.062 0.062 0.124 
I/δ(I) 11.3 11.1 8.4 
No. of reflections 
(observed/unique
) 
86654/26359  
(5915/1945) 
51235/12654 
(8263/2002) 
53148/7219 
(5678/880) 
Completeness 99.5 (99.5) 99.9 (100) 99.0 (93.3) 
Multiplicity 3.3 (3.0) 4.0 (4.1) 7.4 (6.5) 
The data for the outer shell is shown in parentheses 
DLS – Diamond Light Source 
ESRF – European Synchrotron Radiation Facility 
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Table S1. Crystallization screenings results  
Sample Screening, 
position, 
morphology 
Condition 
CopM 
glycerol 
JBS I, A11 25% PEG 1000, 0.1 M Na Hepes pH 7.5 
CopM JBS I, C7 cubes 25% PEG 4000, 0.1 M Na MES pH 6.5, 0.2 M MgCl2 
CopM JBS I, C11 very 
small 
30% PEG 4000, 0.1 M Na Hepes pH 7.5, 0.2 M CaCl2 
CopM MIDAS, H3 20% glycerol ethoxylate, 3% polyethylene imine 
CopM MIDAS, G7, needles 30% glycerol ethoxylate, 0.2 M Amm Acetate pH 6.5, 0.1 
M MES-NaOH 
CopM 
EDTA 
JBS I, G2 10% PEG 8000, 0.1 M Na Hepes pH 7.5, 0.2 mM Na 
Acetate 
CopM, 
EDTA 
JBS I, C8 25% PEG 4000, 0.1 M Tris HCl 8.5, 0.2 M CaCl2 
CopM 
EDTA 
JCSG+, from H6 to 
H11 
25% PEG 3350, 0.1 M Bis-Tris pH 5.5, different salts 
CopM 
EDTA 
JCSG+, G1, needles, 
thin plates 
30% Jeaffamine ED 2001, 0.1 M Hepes pH 7 
CopM 
EDTA 
JCSG+, E1 1M Tri-Na citrate, 0.1 M Na cacodylate pH 6.5 
CopM 
EDTA 
JCSG+, E2 0.2 N NaCl, 0.1 M Na cacocylate pH 6.5, 2M AmSO4 
CopM 
EDTA 
JCSG+, G10 0.15 M KBr, 30% PEG MME 2000 
CopM 
EDTA 
JCSG+, G11 2M AmSO4, 0.1 M Bis-Tris pH 5.5 
CopM  JBS I, F4 15% PEG 6000, 50 mM KCl, 10 mM MgCl 
CopM  JBS I, B12 12% PEG 4000, 0.1 M Na Hepes pH 7.5, 0.1 M Na 
Acetate 
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ABSTRACT 
 
Resistance to antibiotics used in the treatment of bacterial infectious diseases is a 
global health problem. More than a decade ago, two-component systems such as 
WalKR were proposed as ideal targets for the development of new antibiotics. 
Biochemical screens for WalKR inhibitors using compound libraries have identified 
many hits, some of which were shown to have non-specific effects. The recently 
published structures of the S. mutans and B. subtilis WalK provide the opportunity to 
study inhibitors of WalK autophosphorylation at the atomic level and means to design 
compounds with improved specificity and affinity using a structure-based approach. 
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Recently scientists have been watching in awe as bacteria develop resistance to 
the latest antibiotics. Multidrug resistant tuberculosis (MDR-TB), penicillin-resistant 
Streptococcus pneumoniae, and hospital-acquired infections with vancomycin-
resistant enterococci (VRE) or methicillin-resistant Staphylococcus aureus (MRSA) 
are regularly making headline news. The problem is not only one of resistance to front 
line drugs and the fear that one day, infections will be incurable, but also the increased 
cost of patient care and the prospect of future inability to perform trivial medical 
procedures without significant risk. 
The scarcity of new antibiotics has been put down to dwindling returns on 
screening natural sources but also poor incentives for companies to invest in this sector 
as opposed to treatment for cancer and chronic diseases. However, the challenge of 
developing anti-infective drugs has been taken up by small enterprises and academia 
with the support of governments and other funding organizations. 
The genomics revolution has accelerated finding new targets for anti-infective 
drugs, but designing drug-like inhibitors against specific targets remains highly 
challenging, costly, and not without significant risk of failure. 
Against this somewhat gloomy perspective, there are some promising 
developments unfolding, one of which concerns bacterial two-component systems 
(TCSs) as drug targets. Bacteria respond and adapt to a large variety of environmental 
and intracellular signals via TCS signal transduction. The minimum components of a 
TCS are a sensor histidine kinase (HK) and an effector response regulator 
(RR)(8)(Figure 1). Typically, the sensor histidine kinase (HK) is membrane-bound, 
and signal recognition alters the phosphorylation state of a cognate response regulator 
(RR). HK sensing of specific signals occurs via a variable domain that is commonly 
exposed to the extracellular milieu, whereas the remaining protein domains are 
generally conserved, cytoplasmic, and required for signal transduction (8) (Figure1). 
RRs are usually transcription factors of which the DNA-binding capacity and 
consequently, gene transcription is determined by their phosphorylation state. TCSs 
may directly or indirectly control numerous genes, including those involved in the 
regulation of metabolism, cell physiology, virulence, persistence, and resistance to 
antibiotics or antimicrobial peptides. Targeting virulence is a promising antibacterial-
drug discovery strategy as it exerts less selective pressure on the pathogen and 
resistance development will be slower. 
TCSs were proposed as attractive targets more than 20 years ago because they are 
absent in mammals and essential or conditionally essential for viability in several 
important bacterial pathogens. WalKR system (a.k.a., YycGF, VicKR, MicAB) is an 
obligate essential regulatory system in Firmicutes including MRSA, VRE, and some 
other notorious pathogens. Other TCSs might not be essential for growth in vitro, but 
in vivo they can be necessary for survival or persistence (e.g., the DosRS system in 
Mycobacterium). Besides, some bacteria possess as many as 200 TCSs depending on  
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Figure 1. TCS signaling. TCS signaling is triggered by the recognition of the signal 
(1) by the HK sensor variable domain, which regulates the autophosphorylation of a 
histidine residue in the conserved portion of HK (2).(8) Signal is then transduced to 
the cognate RR by the transfer of the phosphoryl group from the histidine to a 
conserved aspartic residue in the RR (3). Typically, RRs are transcription factors, and 
their phosphorylation state regulates their DNA-binding capacity (4) and, 
consequently, gene transcription (5)(1-4) 
 
their lifestyle and requirements for adaptation and metabolism in different 
environments. Presumably the combined effect of inhibiting all or multiple TCSs and 
thus the ability of a bacterium to adapt to changing physiological conditions would 
also greatly weaken their ability to cause infections. Given that the first TCS inhibitors 
were described more than a decade ago, one might think that finding TCS inhibitors is 
an intractable problem, and it might be better to focus on other essential pathways in 
bacteria. Nevertheless, there is no doubt that TCSs are good antibacterial drug targets 
because they have a high degree of conservation in the active sites of their catalytic 
domains. This fact implies that inhibitors of one TCS may in fact block multiple TCS 
regulatory networks, effectively incapacitating the ability of bacteria to adapt to 
environmental and physiological changes. 
Perhaps the lack of drug candidates against WalKR or other TCSs is due to the 
limitations of the previously adopted approach. 
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The pioneering work by the Utsumís group identified imidazole and zerumbone 
derivatives as the first inhibitors of WalK. Afterward, the same group developed 
biochemical and genetic high-throughput (HTP) screening methods resulting in the 
discovery of a number of WalKR inhibitors.(5) However, some of these inhibitors 
were not exclusively selective to WalKR suggesting that HTP screening approach may 
favor the identification of compounds that inhibit through mechanisms that are not 
specific for TCSs and may be toxic. A more promising avenue of research seems to be 
structure-based virtual screenings (SBVS) with tailored libraries or rational structure-
based drug design. Targeting WalKR following structure-based approach is expected 
to help identify specific inhibitors of WalKR and general inhibitors of TCSs. Both 
these will expedite the urgently needed development of novel antibacterial drugs. 
The more druggable component of TCS is the HK due to the presence of the 
catalytic ATP-binding domain (CA domain). The CA domain contains a well-defined 
and partially conserved pocket, which accommodates the ATP required for autokinase 
activation, i.e., initiation of signal transduction (Figure 2A,B). This pocket is 
hydrophobic in nature but presents two conserved polar residues, aspartic acid (Asp) 
and asparagine (Asn), which are responsible for ATP selectivity and Mg
2+
 chelation, 
respectively. In addition, three conserved structural water molecules increase the 
pocket polarity and are involved in hydrogen bonds between the ATP and the 
conserved Asp and Asn. 
The major bottleneck for structure-based discovery of WalK inhibitors has been 
the lack of high-resolution structures of WalK. Instead, structural homology models of 
the CA domain of S. pneumoniaeand and S. epidermidis WalK based on the structures 
of Thermotoga maritima HK853 (PDB:2C2A) and E. coli EnvZ (PDB:1BXD) were 
used for SBVS. These screenings yielded WalK autophosphorylation inhibitors 
belonging to different classes of chemical structures, such as imidazole analogues and 
derivatives of furan, thiophene, thiazolidinone, benzamide, and pyrimidinone.(6),(7) 
This suggests that the ATP-binding pocket can accommodate a variety of ligands, a 
feature that can be exploited to design potent and selective HK inhibitors with a 
desired ADMET (absorption, distribution, metabolism, elimination, and toxicology) 
profile. Notably, unfavorable ADMET properties are one of the major reasons for high 
attrition rates of candidate molecules in drug discovery. 
WalK autophosphorylation inhibitors identified by SBVS inhibited the growth of 
S. pneumoniae and S. epidermidis and showed bactericidal effects toward both 
planktonic and biofilm cells. Furthermore, some of them decreased the mortality of 
mice infected with S. pneumoniae in an in vivo sepsis model, supporting the idea that 
SBVS is a viable tool for the identification of WalK inhibitors with therapeutic effect. 
Nevertheless, the design of potent ATP-competitive inhibitors specific for WalK is 
challenging, even more so when structural homology models are used. This issue is 
crucial when attempting to generate a WalK inhibitor with higher specificity and 
affinity in the hit-to-lead optimization phase. Although the overall fold of the CA 
domain as well as the catalytic residues is generally conserved, there are large  
Discovery of Inhibitors of Bacterial Histidine Kinases 
 
179 
 
Figure 2. Structure of WalK. (A) S. mutans WalK (PDB:4I5S) is a long-rod dimer anchoring 
a HAMP signal-transducer domain (green) and a PAS sensor domain (blue) directly 
connected to the catalytic DHp (yellow) and CA (pink) domains. (B) B. subtilis WalK CA 
domain (PDB:3SL2). The ATP-binding site (semitransparent surface, ATP shown as sticks) 
is generally conserved except for the variable ATP-lid (magenta). More potent and specific 
WalK inhibitors can be redesigned by optimizing the interactions of previously identified 
hits with the ATP-binding site, particularly with the conserved structural water molecules 
(blue spheres) and the ATP-lid. (C) Close up view of S. mutans WalK PAS domain shows the 
putative ligand-binding pockets with a large cavity and a unique tunnel; these structural 
characteristics can be exploited to identify WalK PAS domain ligands. 
 
variations in size and sequence in the ATP-lid, a HK distinctive flexible loop that 
covers the ATP-binding pocket and is crucially involved in the autophosphorylation 
reactions (8)(Figure 2A,B). 
Recent elucidation of WalK structures of the entire intracellular portion from 
Streptococcus mutans (PDB:4I5S) (Figure 2A,C) and the CA domain from Bacillus 
subtilis (PDB:3SL2) (Figure 2B) might provide the key to design improved WalK 
inhibitors. These structures have not only revealed specific characteristics of the WalK 
CA domain but also insights into the molecular mechanism of WalK autokinase 
activation. These WalK structures might be used to generate potent and selective 
WalK inhibitors by the rational redesign of the previously identified hits by optimizing 
interactions with the ATP-binding site and particularly with the ATP-lid. Moreover, 
the structure of S. mutans WalK has also revealed specific folds of the HAMP 
transducer, the PAS sensor, and the DHp catalytic domains of WalK (Figure 2), 
opening up new possibilities to explore these domains for structure-based drug design. 
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PAS (Per-Arnt-Sim) domains are small sensor modules that bind a chemically 
diverse range of small molecules and present a conserved three-dimensional 
architecture but a divergent primary sequence. The B. subtilis PAS domain is required 
for WalK activity and localization to the divisome during cell division. The structure 
of S. mutans WalK shows that the putative ligand binding site forms unique pockets 
for a variety of ligands to bind (Figure 2C) suggesting that WalK PAS domain might 
bind ligands differently from other HK PAS domains. Therefore, the WalK PAS 
domain appears to be a promising target for novel antimicrobials, and its structure 
might also facilitate the rational design of specific and potent WalK inhibitors. 
Furthermore, WalK PAS ligands remain unknown, and their identification might 
generate chemical reagents to facilitate mechanistic studies. 
In summary, we argue that discovery of new WalKR, and in general TCS, 
inhibitors, which will be further developed into antibacterial drugs, is still a realistic 
scenario. However, the focus should be on structure-based approaches. Certainly, 
ongoing efforts to solve the structures of HK from other important pathogens will help 
to design inhibitors with optimized activity. The high homology between TCSs and 
their wide distribution among bacteria imply that such inhibitors can be developed into 
broad-spectrum antibiotics. The road ahead is still challenging and arduous, but given 
the importance of the problem of drug resistance, we are convinced it is a road we 
should take. 
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THE NEED OF NEW ANTIBACTERIALS AND THE IDEAL ANTIBACTERIAL 
TARGETS  
 
The growing problem of bacterial multi-drug resistance (MDR) requires the 
urgent development of novel antibacterials with different mechanisms of action from 
known antibiotics 
1, 2
. At the outset of this thesis bacterial two-component systems 
(TCS) were selected as targets for the discovery of novel lead candidates for the 
development of antibacterial drugs. At this point it seems prudent to revaluate TCS 
suitability as drug targets based on the results presented in the thesis and developments 
published in the literature. Recent reviews 
3, 4, 5, 6, 7, 8
 from opinion leaders in the field 
suggest that from pharmaceutical point of view novel antibacterial targets should fulfil 
the following criteria:  
1. Have no human homologues or structurally similar proteins. 
2. Be highly conserved among various bacterial species to assure broad-
spectrum of antibacterial action.  
3. Be strictly essential for bacterial viability such that their inhibition would lead 
to bacterial death but as targeting essentiality might increase the rise of resistance, 
targeting virulence targets has been proposed as an alternative.  
4. Be ´´assayable´´, i.e. should have easy measurable activity, assays amenable 
to high-throughput screening (HTS), target structural data should be available or easy 
to disclose and genetic tools should be available to validate the target in a key species. 
5. Be patentable. 
The suitability of TCS as targets for novel antibacterials is discussed below in 
relation to the first four criteria listed above.  
 
1. HOMOLOGUES OF TWO-COMPONENT SIGNALLING SYSTEMS ARE 
ABSENT IN HIGHER EUKARYOTES  
In all living organisms cellular processes are regulated via signal transduction. 
Both prokaryotes and eukaryotes depend on the ability to rapidly sense and respond to 
changes in intracellular and extracellular signals to adapt and survive. Two-component 
systems (TCS) are the major mode of signal transduction in bacteria 
9
. They are 
attractive antibacterial (drug) targets because multiple TCS are found in nearly all 
bacteria and homologues have not been identified in mammals, including humans 
10
 
11
, 
12
. TCS signalling involves autophosphorylation of a membrane-bound histidine kinase 
(HK), phosphotransfer of the phosphoryl group to a cognate response regulator (RR), 
and ultimately modulation of the expression of target genes (Figure 1) 
13
. The  
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Figure 1. Two-component system domain organization and signalling. A) A two-
component system consist of a membrane-bound HK composed of a sensor domain 
(periplasmic sensor domain, Sp, and/or cytosolic sensor domain, Sc), transmembrane 
helices (TM1 and TM2) and the DHp and CA domains, and of an RR composed of a REC and 
an effector domain. ATP is used to first phosphorylate a His in the DHp domain and the 
phosphoryl group is then transferred to an Asp residue in the RR REC domain. The 
composition of the Sc can vary and is not always present in all HK, whereas the DHp and 
the CA domain are present in all HKs (modified from 13). B) HK domain organisation 
exemplified by S. mutans WalK (PDB: 4I5S). 
 
phosphorylation levels of the RR are tightly regulated by the phosphatase activity 
of the HK, the RR or a partner protein 
13
, 
14
. HK autophosphorylation is mediated via 
the catalytic and ATP-binding (CA) domain, which binds ATP and phosphorylates the 
HK at conserved histidine (His) residues in the dimerization and histidine 
phosphotransfer (DHp) domain. The CA and DHp domains are conserved and present 
in all HKs, whereas the remaining sensor domains (periplasmic, PAS; GAF, HAMP) 
are variable and not present in all HKs (Figure 1) Furthermore, the ATP-binding site 
of the CA domain is a well-defined and highly conserved binding pocket (Figure 2). 
The conserved features of the CA domain and its essential role in signal transduction 
highlight it as an attractive target for structure-based virtual screening and phenotypic 
screening of biochemical inhibitors
13
. Moreover, the high degree of sequence 
conservation in the CA catalytic site implies that inhibitors targeted against this site 
will possess broad-spectrum of antibacterial activity. Altogether, this makes the CA 
domain the most attractive HK target site for the discovery and development of broad-
spectrum antibacterials. 
Discovery of Inhibitors of Bacterial Histidine Kinases 
 
187 
The only caveat with targeting the CA domain is the presence of the ATP-binding 
Bergerat fold which is shared with GHKL family of proteins, including mammalian 
proteins as Hsp90 or MutL[4] (Figure 3). The Bergerat fold includes four conserved 
motifs common to the GHKL family of proteins. Three of the four motifs correspond 
to the conserved N, G1 and G2 boxes in the HK CA domain 
13
. These similarities 
might lead to off target inhibitory effects of putative HK autophosphorylation 
inhibitors (HKAIs) and therefore toxicity to mammalian cells. Indeed, the novel 
HKAIs described in this thesis (Chapter 2 and 3) were cytotoxic to Caco-2 cells. The 
observed IC50 values for cell viability were mostly lower than the observed minimal 
inhibitory concentrations (MICs) against the bacterial strains tested suggesting off-
target activities. Nevertheless, these were small molecule hits and there is considerable 
potential to improve their specificity and target selectivity through structure-based 
drug design and medicinal chemistry approach. 
The similarity between the CA domain of bacterial TCS and eukaryotic proteins 
containing the Bergerat fold is exemplified by the demonstration that the eukaryotic 
Hsp90 inhibitor radicicol is an inhibitor of PhoQ autophosphorylation and was co-
crystallized with the CA domain of PhoQ 
15
. However, other GHKL family member 
protein inhibitors, such as novobiocin and geldanamycin, could not be co-crystallized 
successfully with PhoQ and had no inhibitory effect on PhoQ autophosphorylation 
15
. 
The differences between radicicol and the other Hsp90 inhibitors with respect to PhoQ 
inhibition were attributed to differences in the putative interaction with the ATP-lid 
and the ATP-lid conformation in the CA domain. The ATP-lid (Figure 1) is a variable 
loop that connects the G1 and G2 boxes or the corresponding motifs in other GHKL 
family members. The ATP-lid is crucially involved in autophosphorylation 
13
, 
16
. 
Although HKs are structurally similar to eukaryotic proteins belonging to the GHKL 
family, the differences in the ATP-lid can be a valuable feature for designing 
inhibitors that are specific to HKs with limited effect on eukaryotic GHKL proteins 
and therefore with low toxicity to host cells 
15
.  
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Figure 2. The ATP-binding site of HK CA domain is a well-defined and highly conserved 
pocket and allows the discovery and design of HK autophosphorylation inhibitors with 
broad-spectrum antibacterial activity following structure-based approaches A) Structure 
of B. subtilis WalK CA domain (PDB: 3SL2). The conserved N-, G1- and G2-boxes are shown 
in red, blue and green, respectively. The variable ATP-lid is shown in pink. B) B. subtilis 
WalK CA domain (PDB:3SL2) coloured by conservation. The conservation scores were 
calculated using ConSurf 106. The ATP-binding pocket was calculated using PyMol 107 and is 
shown as a semi-transparent yellow surface. ATP is shown as ball-and-stick in A and B. C) 
Alignment of WalK CA domains from different organisms D) Alignment of the CA domains 
of different E. coli HKs 
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Figure 3. The ATP-lid is a flexible loop variable in length and in sequence playing a critical 
role in ligand-binding and catalytic activity of members of the GHKL-superfamily of 
proteins. Features of the ATP-lid can be exploited to design histidine-kinase 
autophosphorylation inhibitors with higher specificity to bacterial histidine kinases and 
reduced off-target effects to mammalian members of the GHKL-superfamily, i.e. with lower 
toxicity. Conservation scores were calculated using ConSurf 1. Ligands are shown in sticks.  
 
2. TCS ARE HIGHLY CONSERVED IN THE BACTERIAL KINGDOM AND 
TCS INHIBITORS ARE EXPECTED TO SHOW BROAD-SPECTRUM OF 
ANTIBACTERIAL ACTIVITY AND LOWER POTENTIAL FOR RESISTANCE 
DEVELOPMENT 
TCS and especially the HK CA domains are highly conserved among various 
bacterial species (Figure 1). The high conservation on the one hand assures broad-
spectrum of antibacterial activity and on the other hand simultaneous inhibition of 
multiple targets. Simultaneous inhibition of multiple targets (drug polypharmacology) 
has been proposed as a strategy to slow down resistance development to drugs 
including to novel antibacterials 
17, 18, 19, 19, 20
. As bacteria possess multiple sometimes 
as many as 160 TCSs, inhibitors of the highly conserved CA domain are likely to shut 
down multiple signaling pathways compromising the ability of the bacteria to rapidly 
adapt to environmental changes including those encountered in the host during 
infection.  For some bacteria TCS inhibition may not be bactericidal but it is likely to 
compromise efficient growth, especially under the physiological stresses encountered 
by pathogens in the host.  
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The notion that inhibitors of TCS could inhibit multiple TCS targets is supported 
by the activity studies performed on the novel histidine kinase autophosphorylation 
inhibitors (HKAIs) described in this thesis (Chapter 2 and 3). Promising HKAIs were 
discovered by structure-based virtual screening (SBVS) and fragment-based screening 
(FBS) for putative ligands of three or two different HKs, respectively. Inhibition of 
autophosphorylation was then shown in biochemical assays with HKs not used for 
screening, indicating the potential to identify inhibitors with a broad-spectrum of HK 
autophosporylation inhibitory activity using such approaches. The broad spectrum of 
activity against HKs was also reflected in the capacity of these inhibitors to prevent 
growth of several species of Gram-positive bacteria (Chapter 2 and 3). Furthermore, 
the most promising inhibitors were effective against multi-drug resistant (MDR) 
clinical isolates, including MRSA strains resistant to a wide range of β-lactam and 
non-β-lactam antibiotics 21. These results suggest that the HKAIs possess different 
mechanism of action than the known antibiotics and/or the mechanisms of resistance 
present in the MDR strains are not active against the HKAIs. The activity of the novel 
HKAIs against Gram-negative bacteria was initially found to be low (minimal 
inhibitory concentrations (MICs) ≥ 63 µg/ml for the active compounds, and > 500 
µg/ml for the majority of the tested inhibitors) but when combined with ε-poly-L-
lysine capped nanoparticles (Chapter 4) the activity increased more than 10-fold. The 
antibacterial activity of the nanoparticles was only observed when combined with the 
HKAIs, suggesting that the cell envelope of Gram-negative bacteria is most likely 
limiting intracellular uptake of the HKAIs. Despite the evidence stated above, it 
remains possible that the antibacterial activity is due to inhibition of targets other than 
TCS HKs. Until this is proven we cannot unequivocally conclude that inhibition of 
multiple HKs is the reason for their antibacterial activity of the identified HKAIs.  
 
3. SOME TCS ARE ESSENTIAL FOR BACTERIAL GROWTH AND/OR 
INVOLVED IN THE REGULATION OF VIRULENCE 
Ideally novel antibacterials should target essential proteins or processes to assure 
bactericidal effect but most TCS are not essential for viability of bacteria in their 
normal habitat. This has been demonstrated by the systematic knock out of TCS in 
different bacteria 
22, 23, 24
. However, this approach does not rule out the possibility that 
simultaneous inhibition of multiple TCS would cause bacterial death. In only a few 
organisms, more than one TCS has been genetically deleted or inactivated and this is 
restricted to typically just two or three TCS 
24
. One TCS that is known to be essential 
for bacterial viability is WalKR, which is highly conserved among Gram-positives 
with a low G+C content in their genomic DNA (Figure 1) 
25
. 
In this thesis (Chapter 3) inhibitors of S. pneumoniae WalK autophosphorylation 
with moderate antibacterial effect for Gram-positive strains, including S. pneumoniae 
and MRSA 
21
, and Gram-negative strains, including multidrug resistant Acinetobacter 
baumanii 
26
 were discovered by FBS for putative ligands of S. pneumoniae WalK and 
then ligand-based similarity searches (LBS) with the two best hits. The SBVS hits, A5 
and A6 (Chapter 2), also inhibited S. pneumoniae WalK autophosphorylation in vitro 
and showed antibacterial effect for Gram-positive bacteria. Nevertheless it is difficult 
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to demonstrate that the antibacterial effect is due to inhibition of WalKR even more so 
when multiple-target inhibition is expected. Possible approaches to demonstrate target 
specificity and to elucidate the mechanism of action of the novel antibacterial HKAIs 
include overexpression of the putative target and checking of inhibitor-induced 
changes in the growth rate or the morphology of the mutant strain 
27
; transcriptomics 
signatures 
28
, transcriptional profiling of conditional mutants 
29
. Furthermore, some of 
the identified fragment-like HKAIs (Chapter 3) showed antibacterial effect against the 
Gram-negative A. baumannii, S. maltophilia and/ or E. coli. WalKR is not present in 
Gram-negative bacteria. The high IC50 values of the fragment-like HKAIs for WalK 
autophosphorylation inhibitors (≥ 2mM) and their antibacterial effect for Gram-
negative strains where WalKR is not present indicate that the identified HKAIs inhibit 
more HK targets and/ or possess mechanism of action different than HK 
autophosphorylation inhibition.  
It has been suggested that inhibiting essential targets would lead to fast(er) 
development of resistance than inhibition of virulence mechanisms because there 
would only be selection for resistance in pathogens causing an infection in the host 
25
, 
30
. High throughput screening for ligands of E. coli QseC periplasmic domain 
identified Led209 as a promising hit for the development of antibacterials that act via 
inhibiting virulence. QseCB is a TCS involved in the response to host adrenergic 
signals and in quorum sensing mediated via AI-2 
31, 32, 33, 34
. Led209 was shown to 
inhibit the binding of signals to QseC, preventing its autophosphorylation and 
consequently inhibiting QseC-mediated activation of virulence gene expression 
30
. 
Altogether, this led to inhibition of virulence in vitro and in vivo of several susceptible 
pathogens such as UPEC and Salmonella spp. 
30
. The results obtained with Led209 
highlight the potential of targeting virulence for the development of novel 
antibacterials. Other TCS such as PhoQP and PhoRB involved in responses to 
environmental stimuli have also been linked to regulation of virulence 
35
, 
36
 and 
therefore might also be promising targets for the discovery of antibacterials reducing 
virulence. Interestingly the HKAIs identified in this thesis (Chapter 2 and 3) inhibited 
autophosphorylation activity of E. coli PhoR and S. aureus PhoR. In the future it 
would be interesting to study their specific effects on the regulation of genes 
controlled by the PhoRB TCS under phosphate limiting conditions in order to 
demonstrate that these inhibitors act on the targets that are inhibited in vitro. 
Furthermore, evaluation of the effect of these HKAIs in phor knockout strains will 
give crucial information about the specificity of the compounds. 
An example of a promising antimicrobial target that is crucial for virulence and 
persistent infections is the Mycobacterium DosRST composed of the RR DosR and the 
HKs DosS and DosT. DosRST plays an essential role in triggering and maintaining 
dormancy and in enabling resuscitation in tuberculosis 
37, 38, 39, 40.
 The metabolic 
adaptations occurring in non-duplicating, drug resistant dormant M. tuberculosis are 
triggered by hypoxia and respiratory poisons (i.e. NO, CO), and are regulated by the 
DosR RR. DosR is activated by phosphorylation catalyzed by two HKs, DosS and 
DosT. Due the conservation of the CA domains of HKs a future possibility is to test 
the activity of the discovered HKAIs (Chapter 2 and 3) against DosS and DosT and 
their antimicrobial effect against M. tuberculosis. In a genomics-based in silico target 
identification pipeline for M. tuberculosis incorporating a network analysis of the 
protein-protein interactome, a flux balance analysis of the reactome, a structural 
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assessment of targetability as well as experimentally derived phenotype essentiality 
data, DosS was selected as a high-confidence target  for dormant mycobacteria 
41
.  
 
4. A VARIETY OF DRUG-DISCOVERY APPROACHES CAN BE APPLIED TO 
TCS INHIBITORS DISCOVERY 
The first published TCS inhibitors were discovered by high-throughput screenings 
of natural products or chemical libraries for biochemical inhibition of the target 
42
. 
With the elucidation of TCS structures, structure-based virtual screenings were 
employed to identify TCS inhibitors hits 
43, 43, 43, 44, 45
 and some of the hits have been 
further improved by rational design 
46, 47, 45
. Drug design strategies for identifying TCS 
inhibitors with broad spectrum of inhibition as well as specific TCS inhibitors is 
facilitated by the available structural and genomic information for TCS as well as the 
large body of research on their role in bacterial physiology and virulence. Virtual 
structure-based or in vitro fragment-based screenings with multiple targets (Chapter 2 
and 3, respectively) and selecting for common hits facilitates the discovery of broad-
spectrum inhibitors, whereas selecting hits specific to particular target will facilitate 
the discovery of narrow-spectrum inhibitors. In this case high-resolution structures of 
TCS targets in complex with their inhibitors are still needed to facilitate the rational 
design of improved inhibitors against specific TCS targets that are either essential or 
controlling key virulence factors. With the advance of high-throughput crystallography 
48
, 
49
, 
50
 it seems feasible to crystallize the kinome of a bacterial pathogen or promising 
HK targets from different pathogens and use the structural information to design more 
potent and/or specific inhibitors following structure-based design approach. 
Complementary approaches should include the structural determination of co-crystals 
of putative target HK CA domains that has been previously crystallized (e.g. WalK 
from B. subtilis, PDB:3SL2) with fragment libraries or known kinase inhibitors and 
co-crystals with mammalian members of the GHKL protein family (e.g. Hsp90) to 
facilitate structure-based design of inhibitors with improved affinity and specificity. 
 
APPROACHES FOR TCS INHIBITORS DISCOVERY  
 
STRUCTURE-BASED VIRTUAL SCREENINGS USING MULTIPLE HK 
STRUCTURES INCREASES THE CHANCES OF IDENTIFYING HK 
INHIBITORS WITH BROAD SPECTRUM OF INHIBITION 
Molecular docking and receptor-based virtual screening have been an 
indispensable component within structure-based drug discovery, including TCS 
inhibitors discovery, for hits identification and hit-to-lead optimization 
43, 51, 44, 35, 45, 52, 
53, 54, 55
. Although, ligand flexibility can be handled by variety of algorithms in current 
docking implementations 
56, 57
, receptor flexibility remains a major outstanding 
challenge in the practice of molecular docking-based virtual screening 
58, 59
. The 
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challenge is mainly because of the high dimensionality of the conformational space 
and the complexity of scoring energy function. It is generally accepted protein 
flexibility to be often coupled to ligand binding in numerous experimental and 
theoretical studies 
60, 61
. Two kinds of ligand-binding mechanisms have been well 
discussed 
62
. The first is conformational selection, which assumes that the ligand binds 
to a pre-existing receptor conformation in an equilibrated ensemble; and the second is 
induced fit, which presumes that the binding of the ligand induces conformational 
changes in the receptor. In both cases, structural conformations of the receptors need 
to be taken into account in molecular docking studies and, ideally, (multiple) ligand-
bound structures should be used instead of apo-structures.  
Various modeling methods have been developed to account for receptor flexibility 
in molecular docking and structure-based virtual screening. 
58, 63
. Soft docking, which 
docks ligands to a rigid receptor with a soft scoring function tolerating some steric 
clashes, has been reported to be worse for identifying known ligands than the hard 
scoring function when multiple receptor conformations were used. 
64
. Several docking 
programs limit protein flexibility to side chains by exploration of rotamer libraries and 
make the problem of protein flexibility less computationally demanding 
65
. However, 
this approach cannot deal with backbone movement or other major structural re-
arrangements. Another implementation is docking of ligands to multiple receptor 
conformations 
66
, which may either be obtained experimentally by X-ray 
crystallography and NMR spectroscopy or computationally by molecular dynamics, 
normal-mode analysis, and other techniques.  
In Chapter 2 we applied an approach combining structure-based virtual screenings 
for putative ligands of three different HK X-ray structures followed by ligand-based 
similarity searches with the most promising hits as query molecules. The problem of 
receptor flexibility in the docking approach was addressed by using three different 
receptor structures. The use of multiple structures in the docking experiments 
increases the chance of finding broad-spectrum ligands because it implicitly considers 
the receptors plasticity, sequence and conformation variability in the docking 
approach. This approach mimics an ensemble based docking which has been shown to 
improve the overall performance of virtual screening experiments 
67
. 
Screening by molecular docking for putative ligands of three different HKs 
successfully identified two hits, A5 and A6, which inhibited the autophosphorylation 
activity of multiple HKs and showed weak antibacterial effects. A5 and A6 inhibited 
the autophosphorylation of three HKs not employed in the virtual screenings (i.e. E. 
coli and S. aureus PhoR, and S. pneumoniae WalK). Therefore, A5 and A6 were used 
as query molecules in ligand-based similarity searches (LBSS). The LBSS 
successfully identified B13 as a promising lead candidate. B13 (R,S)-4-[1-Ethyl-2-(4-
fluorophenyl)butyl]phenol) inhibited the autophosphorylation of E. coli PhoR and S. 
aureus PhoR with IC50 values of 16 and 212 µM, respectively (Chapter 2). The fact 
that B13 inhibited the autophosphorylation of multiple HKs including targets not used 
in the structure-based virtual screening supports the concept that use of multiple 
structures in the virtual screening by molecular docking, facilitates the identification of 
broad-spectrum inhibitors. Furthermore, even the next generation hits identified by 
other methods, in this case ligand-based similarity search (LBSS), possessed broad-
spectrum inhibitory capacity. The putative broad spectrum HK autophosphorylation 
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inhibitory capacity of B13 was reflected in its broad-spectrum antibacterial effect 
(Chapter 2). B13 showed antibacterial effect for a range of Gram-positive bacteria, 
including MRSA clinical isolates. The MICs for the different Gram-positive strains 
ranged between 1 and 16 µg/ml.  
Antibacterials should not cause adverse effects to host cells. Furthermore, one of 
the main causes of high attrition rates in drug discovery is so called adverse "off-
target" effects. Therefore, as early as possible in the developmental program the 
toxicity of the hits has to be evaluated. B13 inhibited cell viability of Caco-2 cells and 
macrophages with IC50 values of 29 µg/ml and > 20 µg/ml, respectively (Chapter 2 
and 4). The selectivity index (IC50/MICs) > 1 indicates that B13 is a promising 
candidate for hit-to-lead optimisation in the preclinical development of antibacterials 
for Gram-positive bacteria. B13 showed no antibacterial effect for Gram-negative 
bacteria. We hypothesized that this was most probably due to inability of B13 to cross 
the outer membrane of Gram-negative bacteria and explored the possibility to use 
nanoparticles for enhanced delivery to Gram-negative bacteria (Chapter 4). Indeed, as 
part of a nano-formulation for delivery of antibacterials to Gram-negative bacteria 
68
 
B13 showed antibacterial effect for the uropathogenic E. coli CFT 073 with MIC of 25 
µg/ml (Chapter 4). The latter is in agreement with B13 autophosphorylation inhibitory 
capacity for HKs from Gram-negative bacteria (Chapter 2). This is encouraging 
because it might be possible to enhance the permeability of next generation hits based 
on B13 using medicinal chemistry approaches 
69
.  
The other two promising hits coming from the LBSS following SBVS (Chapter 
2), B7 and B14, showed lower HK autophosphorylation inhibitory capacity, weaker 
antibacterial effect and stronger cytotoxicity to Caco-2 cells than B13. Nevertheless, 
B7 and B14 are worth considering as starting points for the design of improved HK 
inhibitors because they are predicted to interact with the ATP-lid. The ATP-lid is a 
highly flexible and variable in sequence component of the ATP-binding site of HKs 
and is critically involved in autophosphorylation 
13
, 
16
. The variability of the ATP-lid 
has been proposed as a valuable feature for the design of inhibitors that are specific to 
bacterial HKs with limited off-target effects on eukaryotic proteins sharing the ATP-
binding Bergerat fold (the so called GHKL proteins, including Hsp90 and MutL) 
15
 or 
for the design of strain-specific HK inhibitors 
20
.  
 
FRAGMENT-BASED SCREENING BY DIFFERENTIAL SCANNING 
FLUORIMETRY IS A POTENT TOOL FOR THE DISCOVERY OF HK 
AUTOPHOSPHORYLATION INHIBITORS WITH DESIRED SPECTRUM OF 
INHIBITION  
So far, TCS inhibitors have been discovered mainly by high-throughput 
screenings (HTS) 
70, 30, 71
 or by structure-based virtual screenings 
43, 51, 44, 35, 45
. 
Fragment-based screening (FBS) is a more recent approach and the methodology 
behind it is complementary to HTS 
72
, 
73
. Fragments are small molecules with low 
affinity (usually Kd > 0.1 mM) following the rule of three (MW < 300, ClogP < 3, 
number of hydrogen bond donors and hydrogen bond acceptors < 3, number of 
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rotatable bonds < 3) 
74, 75
. Fragments serve as starting point for the elaboration of more 
potent inhibitors by rational design 
76
. The main advantage of FBS over HTS is that 
fragment libraries are much smaller than conventional compound libraries 
77, 78, 79
. It 
has been estimated that there are only ~ 10
7
 molecules of up to 11 heavy atoms which 
are also fragment-like (MW ≤ 300 Da), compared to ~ 1063 molecules of molecular 
weight less than 500 Da, i.e. drug-like. This means that a library of 10
3
 fragments 
covers 0.01 % of the fragment-like chemical space compared to 10
-58
 % of the 
chemical drug-like space.  
The low molecular weight of fragments (typically ≤300Da) and their 
corresponding reduced functionality implies that they will generally bind a target 
protein with weak affinity (Kd > 0.1 mM), if at all. Despite their weak affinities, 
fragments possess high intrinsic binding energy to overcome a large entropic barrier 
upon binding 
80
 and often exhibit high ligand efficiency (∆G of binding per non-
hydrogen atoms) 
81
. Therefore, fragments are suitable starting points for elaboration 
into larger, more potent inhibitors.  
Considering the advantages of FBS over HTS mentioned above, we performed 
fragment-based screenings (FBS) by differential scanning fluorimetry (DSF) for 
ligands of multiple HKs (Chapter 3). By choosing the hits identified with different 
targets we were able to identify HKAIs that inhibited the autophosphorylation of HKs 
that were not used in the screens, showing that the use of multiple targets selects for 
inhibitors with broad-spectrum inhibitory capacity. The hits identified by FBS by DSF 
were used as query molecules in ligand-based similarity searches (LBSS) and the 
LBSS hits showed broad-spectrum antibacterial effect against multi-drug resistant 
Gram-positive and Gram-negative strains (Chapter 3). Probably due to their small size, 
the fragment-like HKAIs showed lower affinity to HKs (indicated by their IC50s for E. 
coli PhoR autophosphorylation) and higher cytotoxicity to Caco-2 cells compared to 
the hits identified by SBVS and LBSS in Chapter 2. The antibacterial activity of the 
FBS hits was comparable to the less potent hits identified by SBVS and LBSS, B7 and 
B14 (Chapter 2). The comparable antibacterial effect despite of the lower affinity to 
HKs and the higher cytotoxicity might be related to off-target effects as these hits are 
fragment-like and most likely bind also to multiple prokaryotic and eukaryotic targets. 
The structural similarity with previously published TCS inhibitors (F1 and F1.6, 
43, 46, 
47
) and the limited options for further improvement of the carbazoles from drug 
discovery perspective (F2.1, F2.3 and F2.8) makes these hits unattractive for further 
investigation. Nevertheless, F1.8 (4-N-(4-bromophenyl)pyrimidine-2,4-diamine) 
seems to present a promising starting point for structure-based drug design of HK 
inhibitors with broad-spectrum antibacterial effect. F1.8 possess weak HK 
autophosphorylation inhibitory capacity, however, it shows broad-spectrum 
antibacterial activity including against multi-drug Gram-negative strains. The latter 
suggests that F1.8 scaffold is attractive for the development of antibacterials with 
improved permeability for Gram-negative bacteria.  
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COMPUTER-AIDED APPROACHES CAN FACILITATE HIT IDENTIFICATION 
AND OPTIMISATION PROVIDED SCREENINGS ARE PERFORMED BY 
STANDARDISED METHODS 
Nowadays early-stage antibacterial drug discovery is largely done by academic 
organisations or SMEs. It is unlikely that such organisations would have the resources 
for extensive screening 
82
. However, if screening and in vitro evaluation of screening 
hits are performed under standardized conditions in different laboratories and the 
information is made (publicly) available different computational methods can be 
exploited to speed up the discovery and optimisation of hits. These include predictive 
quantitative structure-activity relationship (QSAR) 
83, 84
 models and ligand-efficiency 
indices (LEIs) approaches 
85, 86 
(Chapter 5).  
 
MOLECULAR MODELING CAN GUIDE RATIONAL OPTIMISATION OF HITS 
IN THE ABSENCE OF EXPERIMENTAL TARGET-INHIBITOR STRUCTURES  
The hits identified by SBVS, FBS, LBSS, QSAR and LEIs approaches (Chapter 2, 
3 and 6) were co-crystallized with the CA domain of T. maritima CheA HK as a model 
system (data not shown) 
87
. In some cases, such as A5, B13, B14, F1, F2, F2.3, H30 
the CheA-inhibitor structures, solved by X-ray crystallography, revealed electron 
density in the binding site, although the structures of the HK inhibitors could not be 
fully resolved, probably due to partial occupancy and/or multiple conformations. 
Unfortunately, these structures could not be used to guide rational design of more 
potent inhibitors following structure-based drug design approach. Therefore, the 
putative binding mode of the HK inhibitors was predicted by molecular docking to the 
structure of the CA domain of T. maritima HK853 
88
 or B. subtilis WalK 
89
. The 
predicted binding modes of the HKAIs (Chapter 2 and 3) resembled the binding mode 
of the natural substrate ATP/ADP. The most potent inhibitors, e.g. B13, were 
predicted to form contacts with conserved residues in the N-, G1- and G2-boxes in the 
ATP-binding site. Some inhibitors, such as B7, were predicted to interact with the 
variable ATP-lid and showed significant differences in the autophosphorylation 
inhibitory capacity for different HKs. Other inhibitors predicted to interact with the 
ATP-lid, e.g. F1.8 (Chapter 3), showed broad spectrum HK inhibitory activity and 
antibacterial action. Although the ATP-lid is more variable compared to the remaining 
parts of the ATP-binding site of the CA domains (Figure 2), it contains conserved 
residues, such as Arg, Ile or Leu, and Tyr (Figure 2B). These residues are conserved 
among HKs from different species or different HKs from the same bacteria (Figure 2C 
and 2D). The binding modes predicted by molecular modeling can serve as starting 
point for the structure-based design of more potent and specific or broad-spectrum 
inhibitors with lower off-target effects by exploring the features of the ATP-lid. 
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ANTIMICROBIAL PEPTIDES AND TWO-COMPONENT SYSTEMS 
INHIBITION  
 
Eukaryotic cationic antimicrobial peptides (AMPs) are produced at sites of 
infection or inflammation in many different organisms 
90, 91, 92
. Usually, AMPs 
increase the permeability of the bacterial membrane, leading to loss of pH gradient and 
cell death. Some AMPs have been shown to interact with intracellular targets 
93, 94
 but 
in most cases the exact mechanism of action of intracellular AMPs remains unclear.  
 
INHIBITION OF T. MARITIMA HK853-RR468 BY LACTOFERRICIN B-
DERIVED PEPTIDES IS NOT SUITABLE FOR STRUCTURAL STUDIES ON 
TCS INHIBITION BY AMPS 
LactoferricinB (LfcinB) is an AMP with broad-spectrum antibacterial activity 
95
, 
96
. It has been shown by in vitro and in vivo experiments and bioinformatics methods 
that LfcinB inhibits the phosphorylation of the RRs (BasR and CreB) by their cognate 
histidine kinases (HKs), BasS and CreC 
97
. We showed that LfcinB-derived peptides 
inhibit the phosphotransfer and phosphatase activity of T. maritima HK853-RR468 
(Chapter 6). However, the LfcinB-derived peptides seemed to induce aggregation of T. 
maritima HK853 and E. coli PhoB. Therefore, T. maritima HK853-RR468 and E. coli 
PhoRB might not be suitable for structural studies of TCS inhibition by LfcinB-
derived peptides. Furthermore, the described results taken together with the broad-
spectrum of antibacterial activity of LfcinB point to the possibility that the 
antibacterial effect caused by LfcinB and LfcinB-derived peptides might be attributed 
to non-specific protein aggregation and might act on multiple cellular targets after 
entering into the cell. On this basis further work on LfcinB-derived peptide inhibitors 
was abandoned.  
 
SYNERGY EFFECT BETWEEN ANTIMICROBIAL PEPTIDES AND TCS 
INHIBITORS  
Antimicrobial peptides have been proposed as a way to overcome the lower 
permeability of Gram-negatives cell envelope 
98, 99
. Therefore, we tested the 
synergistic effect of three frog AMPs with antibacterial effect against Gram-negative 
bacteria and B13, as the most potent HK inhibitor described in this thesis. The AMPs 
tested were [E4k]alyteserin-1c, [E6K]hymenochirin-1B and [K20K27]esculentin-2Cha 
100, 101
. Unfortunately, no synergistic antibacterial effect against E. coli CFT 073 was 
observed (data not shown). ε-Poly-L-lysine (ePLL) is a homo-polypeptide with 
demonstrated antibacterial effect 
102
. Similar to the frog AMPs, ePLL showed no 
synergistic effect with HK inhibitors on antibacterial activity against E. coli CFT073 
(Chapter 4). The MICs against E. coli CFT073 of the tested frog AMPs and ePLL 
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were ≥ 63 µg/ml. Combinations of more potent AMPs and/or more potent HKAIs 
might be required to achieve synergistic effect and ultimately to observe antibacterial 
effect against Gram-negative pathogens.  
 
HK INHIBITOR SPECTRUM CAN BE BROADENED AND THE 
CYTOTOXICITY REDUCED VIA THE USE OF NANOTECHNOLOGY 
 
Although the best hits described in Chapter 2 and 3 have weak or no activity 
(MICs in the range of 125-500 µg/ml) against Gram-negative pathogens, they do 
inhibit autophosphorylation of HKs from Gram-negative bacteria suggesting 
permeability of the Gram-negative cell envelope is limiting their anti-bacterial effects. 
This assumption was shown to be correct using histidine kinase autophosphorylation 
inhibitors (HKAIs) loaded mesoporous silica-based nanoparticles capped with ε-poly-
L-lysine as a strategy for effective drug delivery (Chapter 4) 
68
. Whereas the 
nanoparticles themselves had no antibacterial activity, the MICs of HKAIs combined 
with nanoparticles was decreased more than 10-fold (Chapter 4). The free HKAIs 
showed relatively low toxicity to human cells and even lower toxicity when combined 
with nanoparticles. Taken together these data indicate high potential for developing a 
new structural class of antibacterial lead compounds with activity against multiple 
targets in several MDR Gram-positive and Gram-negative pathogens.  
 
COMPARISON OF THE NOVEL HK INHIBITORS WITH OTHER 
PUBLISHED TCS INHIBITORS 
 
Structure-based virtual screenings for S. epidermidis WalK ligands yielded 
inhibitors which have been subsequently further optimized by rational design 
43, 46, 47
. 
The last generation of S. epidirimids WalK inhibitors had MICs for S. epidermidis and 
S. aureus lower than 3.1 µM, corresponding to lower than 1.66 µg/ml 
47
. B13, the most 
potent hit described in this thesis (Chapter 2), possess MICs for S. epidermidis 
laboratory strains and clinical isolates in the range of 1 to 8 µg/ml. B13 MICs for 
reference strains of S. aureus and clinical isolates of MRSA are in the range of from 8 
to 16 µg/ml (Chapter 2). Therefore, in terms of antibacterial activity B13 is 
comparable to the last generation of published S. epidermidis WalK inhibitors. S. 
epidermidis WalK inhibitors inhibited S. epidermidis WalK autophosphorylation with 
IC50 values in the range of 24.2 to 71.2 µM 
47
. B13 has not been tested for its 
autophosphorylation inhibitory capacity for any WalK, however, it inhibits E. coli 
PhoR and S. aureus PhoR with IC50 of 16 and 212 µM, respectively (Chapter 2). 
Considering the differences in the experiments used to determine the IC50s of the S. 
epidermidis WalK inhibitors and B13 and the fact that different HKs Km differ in the 
range 2 and 200 µM 
103
, it is difficult to conclude how B13 compares to the last 
generation of published S. epidermidis WalK inhibitors. The cytotoxicity of the S. 
Discovery of Inhibitors of Bacterial Histidine Kinases 
 
199 
epidermidis WalK inhibitors was evaluated with Vero Cells using the MTT assay and 
the IC50 were higher than 100 µg/ml 
47
 corresponding to > 60 selectivity index 
(IC50viability/MIC). B13 cytotoxicty was evaluated with Caco-2 cells using the 
neutral-red uptake assay (Chapter 2) and with macrophages in cell culture (Raw cells) 
using the XTT assay (Chapter 4) and the IC50 were 29 µg/ml and ≤ 20 µg/ml, 
respectively, corresponding to selectivity index ≥ 1.25 for the different S. epidermidis 
and S. aureus strains tested (Chapter 2). Even though the cell viability was evaluated 
using different cell lines and methods, it is clear that B13 selectivity is worse than the 
selectivity of the last generation published S. epidermidis WalK inhibitors and needs to 
be improved. However, B13 (MW 272.4) is a relatively smaller compound compared 
to the last generation S. epidermidis WalK inhibitors (MW between 498.02 and 
534.02) implying that it possesses higher ligand efficiency and more possibilities for 
further improvements using an iterative structure-based drug design approach.  
 
FUTURE CHALLENGES AND PERSPECTIVES OF THE DISCOVERY OF TCS 
INHIBITORS 
 
Both SBVS and FBS seem to be promising tools for the discovery of TCS 
inhibitors. The application of multidisciplinary screening approach (including SBVS, 
FBD, and LBSS) allowed us to identify HK inhibitors with activity against multiple 
HKs and a broad-spectrum antibacterial effect. Furthermore, the identified inhibitors 
are predicted to interact with different parts of the ATP-binding sites. The latter 
together with the relatively small size of the identified HK inhibitors (MW < 300) 
provides the possibility to design improved inhibitors by combining chemical moieties 
from the different hits to generate inhibitors with stronger affinity and higher 
specificity to bacterial HKs.  
Although a very promising starting point for development of novel antibacterials, 
the identified HKAIs have a number of shortcomings that need to be addressed in the 
hit-to-lead optimisation process: 
- The affinity to model HKs such as T. maritima CheA is most likely not high 
enough and/ or multiple conformations of the inhibitors are possible and therefore, the 
CheA-inhibitors structures cannot be resolved and used for structure-based drug 
design. This liability can be addressed by discovering more potent HK 
autophosphorylation inhibitors and/ or by solving the structures of the discovered 
inhibitors with other putative target HKs, such as the recently published B. subtilis and 
S. mutans WalK (PDB: 3SL2 and 4I5S) or E. coli/T. maritima EnvZ (PDB: 4KP4) 
89, 
104
. 
- The identified HKs inhibitors are not sufficiently permeable to Gram-
negative bacteria. This can be overcome by using nanoparticles (Chapter 4). The latter 
however, raises additional issues related to the following steps of the drug discovery 
process related to the safety of such complex therapeutic agents. Therefore, it is 
desirable to apply medicinal chemistry approaches to design inhibitors with improved 
permeability for Gram-negatives 
69
. Addition of functional groups to the identified 
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HKAIs, given their small size, could increases the permeability in Gram-negatives. 
Nevertheless, increasing the specificity of the identified inhibitors to Gram-positive 
targets such as the obligatory essential WalKR can be a promising strategy to develop 
narrow-spectrum antibacterials against Gram-positive bacterial infections. 
- The identified HKAIs showed some cytotoxicity to Caco-2 cells evaluated by 
neutral-red uptake assays (Chapter 2 and 3) and B13 showed cytotoxic effect to 
macrophages (Raw cells) evaluated by the XTT assay (Chapter 4). The most 
promising and most potent HK inhibitor B13 possesses a selectivity index for Gram 
positives (IC50 viability/ MICs) ≥ 1.25. Increasing the potency and the selectivity of 
the HK inhibitors will most likely lead to decrease in their cytotoxicity. To facilitate 
the discovery of more selective HK inhibitors, the next generation of HK inhibitors 
should be tested also for their inhibitory activity on the structurally closely related 
mammalian members of the GHKL superfamily 
15, 105
.  
In summary, following structure-based and ligand-based virtual screenings and 
fragment-based in vitro screenings, we have successfully identified HK 
autophosphorylation inhibitors (HKAIs) that can serve as a starting point for the 
design of HKAIs with improved target affinity and selectivity, which would lead to 
stronger antibacterial effect and lower toxicity.  
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The growing problem of bacterial multi-drug resistance requires the urgent 
establishment of pipelines for discovery of novel antibacterials. Two-component 
systems (TCS) have been proposed for years as promising novel antibacterial targets. 
Inhibitors of TCS, especially autophosphorylation inhibitors targeted at the CA 
domains of multiple histidine kinases (HKs) are expected to show broad-spectrum of 
antibacterial activity and low toxicity to host cells.  
Using structure-based virtual screenings (SBVS) for putative ligands of three 
different HKs followed by ligand–based similarity search with the most promising 
SBVS hits (Chapter 2) we identified HK autophosphorylation inhibitors of multiple 
HKs from both Gram-positive and Gram-negative bacteria. The inhibitors showed 
broad-spectrum antibacterial activity for Gram-positive bacteria, including clinical 
isolates of MRSA strains resistant to a wide range of β-lactam and non-β-lactam 
antibiotics. The most promising hit, B13, showed relatively low cytotoxicity and 
hemolytic activity and therefore presents a promising starting point for hit-to-lead 
optimisation using a structure-based drug design approach. The predicted binding 
modes of the other less potent hits, B7 and B14, point to possibilities to design more 
potent and selective inhibitors by combining chemical moieties belonging to the 
different hits.  
In Chapter 3 fragment-based in vitro screenings (FBS) by differential scanning 
fluorimetry (DSF) were performed for ligands of two different HKs followed by 
ligand-based similarity searches with the two identified hits. Weak HK 
autophosphorylation inhibitors with broad spectrum of antibacterial activity were 
identified. Compounds F1.8 and F2.3 showed antibacterial effect for both Gram-
positive and Gram-negative strains, including clinical isolates of MRSA and multi-
drug resistant Acinetobacter baumannii and Stenotrophomonas maltophilia. The 
identified hits present a promising starting point for the design of HK 
autophosphorylation inhibitors with improved permeability. 
In Chapter 5 a computer-aided approach was used in an attempt to identify more 
promising hits for HK autophosphorylation inhibitors using  
Nanoparticles delivery was employed to show that the most potent HK inhibitors, 
e.g. B13, possess antibacterial effect against Gram-negative bacteria (Chapter 4). 
Mesoporous silica-based nanoparticles loaded with HK autophosphorylation inhibitors 
showed 10-fold lower MICs compared to the free HK autophosphorylation inhibitors 
for UPEC E. coli CFT 073 and Serratia marcescens. Despite the lower MICs of HK 
autophosphorylation inhibitors loaded in nanoparticles for bacteria they were less 
cytotoxic than the free inhibitors at equivalent concentrations  
Lactoferricin (LfcinB) has been shown to inhibit TCS from E. coli. We 
demonstrated that LfcinB-derived peptides interact with T. maritima HK853-RR468 
and E. coli PhoRB however, the mechanism of interaction was most likely non-
specific and due to protein aggregation. (Chapter 6). Therefore efforts to co-crystalize 
these peptides with TCS for the rational structure-based drug design of improved 
inhibitors was not pursued further.  
Co-crystallization of the HK autophosphorylation inhibitors with T. maritima 
CheA is described in Chapter 7.1. Furthermore, the purification, crystallization and 
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preliminary X-ray analysis of the periplasmic domain of CopM, a protein suggested to 
be involved in copper resistance, is presented in Chapter 7.2.  
Chapter 8 is a discussion on the possibility to develop novel antibacterials with 
low potential for resistance development by targeting TCS signalling in general and 
the essential WalKR in particular.  
Chapter 9 is a discussion of the main results of this thesis in the context of 
current literature on antibacterial drug discovery and published research on discovery 
of TCS inhibitors. 
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Het toenemende probleem van bacteriële multidrug resistentie vereist het vlotte 
opzetten van onderzoeks-structuren om nieuwe antibiotica te ontdekken. Enkele jaren 
geleden werd voorgesteld dat twee-component systemen (TCSen) veelbelovende 
nieuwe antibacteriële doelwitten zouden kunnen vormen. Het is de verwachting dat 
remmers van TCSen, vooral autofosforylatie remmers gericht op de zogenoemde "CA" 
domeinen van histidine kinases (HKs), een breed spectrum van antibacteriële activiteit 
en lage toxiciteit voor gastheercellen zullen vertonen.  
Met behulp van structuur-gebaseerde virtuele screenings (SBVS) voor vermeende 
liganden van drie verschillende HKs, gevolgd door zoeken naar liganden die het 
sterkst lijken op de meest veelbelovende SBVS treffers (Hoofdstuk 2) identificeerden 
we HK autofosforylatie remmers van HKs van zowel Gram-positieve als Gram-
negatieve bacteriën. De remmers toonden breed-spectrum antibacteriële activiteit ten 
aanzien van Gram-positieve bacteriën, inclusief klinische isolaten van MRSA-
stammen met resistentie tegen diverse β-lactam en niet-β-lactam antibiotica. De meest 
veelbelovende treffer, B13, liet een relatief lage cytotoxiciteit en hemolytische 
activiteit zien en lijkt daarom een veelbelovend uitgangspunt voor de zogenoemde 
"hit-to-lead" optimalisatie waarbij een structuur-gebaseerde drug ontwerp aanpak 
wordt gevolgd. De voorspelde bindingscapaciteit van twee minder krachtige treffers, 
B7 en B14, biedt mogelijkheden om krachtiger en selectievere remmers te ontwerpen, 
door het combineren van chemische groepen die behoren tot de verschillende treffers.  
In hoofdstuk 3 is beschreven hoe fragment-gebaseerde in vitro screenings (FBS) 
door differentiële scanning fluorimetrie (DSF) werden uitgevoerd om liganden van 
twee verschillende HKs te zoeken, gevolgd door het zoeken naar chemische 
verbindingen die een ligand-gebaseerde gelijkenis vertonen, met als uitgangspunt de 
twee in hoofdstuk 2 geïdentificeerde treffers. Zwakke HK autofosforylatie remmers 
met een breed spectrum van antibacteriële activiteit werden gevonden. De 
verbindingen F1.8 en F2.3 toonden antibacteriële werking tegen zowel Gram-positieve 
als Gram-negatieve stammen, met inbegrip van klinische isolaten van MRSA en 
multiresistente Acinetobacter baumannii en Stenotrophomonas maltophilia. De 
geïdentificeerde treffers bieden een veelbelovend uitgangspunt voor het ontwerp van 
HK autofosforylatie remmers met verbeterde doorlaatbaarheid voor bacterie 
membranen.  
In hoofdstuk 5 werd een computer-gebaseerde benadering gebruikt in een poging 
om meer veelbelovende treffers van HK autofosforylatie remmers te vinden.  
Nanodeeltjes werden gebruikt om te laten zien dat de meest potente HK-remmers, 
bijvoorbeeld B13, een antibacteriële werking hebben tegen Gram-negatieve bacteriën 
(Hoofdstuk 4). Mesoporeuze silica-gebaseerde nanodeeltje gevuld met HK 
autofosforylatie remmers toonden 10-voudig lagere MICs in vergelijking met de MIC 
van de pure HK autofosforylatie remmers; deze remmers hadden aantoonbare activiteit 
tegen UPEC E. coli CFT 073 en Serratia marcescens. Ondanks het feit dat de in 
nanodeeltjes verpakte HK autofosforylatie remmers een lagere MIC hadden wanneer 
toegepast om bacteriën te bestrijden, waren deze verpakte remmers minder cytotoxisch 
dan de pure remmers bij dezelfde concentraties.  
Het is aangetoond dat Lactoferricine (LfcinB) TCSen uit E. coli kan remmen. We 
toonden aan dat van LfcinB afgeleide peptides activiteit bezitten tegen T. maritima 
HK853-RR468 en E. coli PhoRB, en dat het mechanisme van interactie 
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hoogstwaarschijnlijk niet specifiek was maar werd bepaald door eiwit aggregatie 
(Hoofdstuk 6). Pogingen om deze peptiden samen te kristalliseren met TCSen om 
betere remmers te vinden via een rationele structuur-gebaseerde drug ontwerp 
benadering werden daarom niet doorgezet.  
Het tegelijk kristalliseren van HK autofosforylatie remmers met het T. maritima 
CheA TCS wordt beschreven in hoofdstuk 7.1. In hoofdstuk 7.2 worden eveneens de 
zuivering, kristallisatie en voorlopige röntgenanalyse van het periplasmatische domein 
van CopM, een eiwit dat gedacht wordt betrokken te zijn bij koper resistentie, 
beschreven.  
Hoofdstuk 8 presenteert een discussie over de mogelijkheid om nieuwe 
antibacteriële middelen met een lage kans op ontwikkeling van resistentie te 
ontwikkelen, door middelen te ontwikkelen die het doorgeven van cellulaire signalen 
via TCSen in het algemeen, en in het bijzonder de essentiële WalKR, blokkeren. 
In hoofdstuk 9 worden de belangrijkste resultaten van dit proefschrift en hun 
inbedding in de huidige literatuur over antibacteriële drug ontdekking in het algemeen, 
en de specifiekere literatuur over de ontdekking van TCS-remmers, bediscussiëerd. 
 
Translated from English to Dutch by Peter van Baarlen 
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